<!DOCTYPE html>
 <!--[if lt IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]--> <!--[if IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8"> <![endif]--> <!--[if IE 8]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9"> <![endif]--> <!--[if gt IE 8]><!--> <html class="aui ltr" dir="ltr" lang="en-US" prefix="og: http://ogp.me/ns#"> <!--<![endif]--> <head> <title>Interventions for tophi in gout - Sriranganathan, MK - 2021 | Cochrane Library</title> <meta content="Interventions for tophi in gout - Sriranganathan, MK - 2021 | Cochrane Library" property="og:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010069.pub3/full" property="og:url"/> <meta content="article" property="og:type"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" property="og:image"/> <meta content="summary_large_image" name="twitter:card"/> <meta content="Interventions for tophi in gout - Sriranganathan, MK - 2021 | Cochrane Library" name="twitter:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010069.pub3/full" name="twitter:url"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" name="twitter:image"/> <meta content="initial-scale=1.0, width=device-width" name="viewport"/> <meta content="10.1002/14651858.CD010069.pub3" name="dc.identifier" scheme="DOI"/> <meta content="Interventions for tophi in gout" name="citation_title"/> <meta content="Melonie K Sriranganathan" name="citation_author"/> <meta content="Changi General Hospital" name="citation_author_institution"/> <meta content="melonie@doctors.org.uk" name="citation_author_email"/> <meta content="Ophir Vinik" name="citation_author"/> <meta content="St Michael's Hospital" name="citation_author_institution"/> <meta content="Jordi Pardo Pardo" name="citation_author"/> <meta content="Ottawa Hospital Research Institute, The Ottawa Hospital - General Campus" name="citation_author_institution"/> <meta content="Claire Bombardier" name="citation_author"/> <meta content="University Health Network" name="citation_author_institution"/> <meta content="Christopher J Edwards" name="citation_author"/> <meta content="University Hospital Southampton NHS Foundation Trust" name="citation_author_institution"/> <meta content="Cochrane Database of Systematic Reviews" name="citation_journal_title"/> <meta content="John Wiley &amp; Sons, Ltd" name="citation_publisher"/> <meta content="8" name="citation_issue"/> <meta content="10.1002/14651858.CD010069.pub3" name="citation_doi"/> <meta content="2021" name="citation_date"/> <meta content="2021/08/11" name="citation_online_date"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010069.pub3/abstract" name="citation_abstract_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010069.pub3/full" name="citation_fulltext_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010069.pub3/pdf/full" name="citation_pdf_url"/> <meta content="1465-1858" name="citation_issn"/> <meta content="en" name="citation_language"/> <meta content="Allopurinol [therapeutic use]; Febuxostat [therapeutic use]; Gout [*drug therapy]; Gout Suppressants [*therapeutic use]; Polyethylene Glycols [*therapeutic use]; Randomized Controlled Trials as Topic; Thioglycolates [therapeutic use]; Triazoles [therapeutic use]; Urate Oxidase [*therapeutic use]" name="citation_keywords"/> <link href="https://fonts.googleapis.com/css?family=Source+Sans+Pro:400,700,600,900" rel="stylesheet"/> <script src="https://cmp.osano.com/AzZdRbSORDOOzF9W/d594efc1-9663-477d-9528-6576640e64fd/osano.js"></script> <style> .osano-cm-widget{display: none;} </style> <script src="https://static.addtoany.com/menu/page.js"></script> <script async="" charset="utf-8" src="https://platform.twitter.com/widgets.js"></script> <script async="async" src="//script.crazyegg.com/pages/scripts/0056/6375.js" type="text/javascript"></script> <script type="text/javascript">window.dataLayer={};var xtend=function(){var a={};var b=false;var c=0;var d=arguments.length;if(Object.prototype.toString.call(arguments[0])==="[object Boolean]"){b=arguments[0];c++}var f=function(g){for(var h in g){if(Object.prototype.hasOwnProperty.call(g,h)){if(b&&Object.prototype.toString.call(g[h])==="[object Object]"){a[h]=xtend(true,a[h],g[h])}else{a[h]=g[h]}}}};for(;c<d;c++){var e=arguments[c];f(e)}return a};</script> <!-- Global site tag (gtag.js) - Google Analytics --> <script src="https://www.googletagmanager.com/gtag/js?id=UA-189672-63&amp;l=gDataLayer"></script> <script>window.gDataLayer=window.gDataLayer||[];function gtag(){gDataLayer.push(arguments)}gtag("js",new Date());gtag("config","UA-189672-63");</script> <script type="text/javascript">var o={auth:{customerIds:[],individualId:null,brandedCustomer:null,roles:["Guest"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <script type="text/javascript">var o={page:{siteSection:"Content",languageCode:"en",cms:{pageTitle:"Content"}}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <meta content="text/html; charset=utf-8" http-equiv="content-type"/> <link href="https://www.cochranelibrary.com/cochrane-theme/images/favicon.ico" rel="Shortcut Icon"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010069.pub3&amp;doi=10.1002/14651858.CD010069.pub3&amp;type=cdsr&amp;contentLanguage=" rel="canonical"/> <link href="https://www.cochranelibrary.com/zh/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010069.pub3&amp;doi=10.1002/14651858.CD010069.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANS" rel="alternate"/> <link href="https://www.cochranelibrary.com/zh_HANT/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010069.pub3&amp;doi=10.1002/14651858.CD010069.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANT" rel="alternate"/> <link href="https://www.cochranelibrary.com/hr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010069.pub3&amp;doi=10.1002/14651858.CD010069.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="hr-HR" rel="alternate"/> <link href="https://www.cochranelibrary.com/nl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010069.pub3&amp;doi=10.1002/14651858.CD010069.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="nl-NL" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010069.pub3&amp;doi=10.1002/14651858.CD010069.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="x-default" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010069.pub3&amp;doi=10.1002/14651858.CD010069.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="en-US" rel="alternate"/> <link href="https://www.cochranelibrary.com/fr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010069.pub3&amp;doi=10.1002/14651858.CD010069.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="fr-FR" rel="alternate"/> <link href="https://www.cochranelibrary.com/de/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010069.pub3&amp;doi=10.1002/14651858.CD010069.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="de-DE" rel="alternate"/> <link href="https://www.cochranelibrary.com/hi/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010069.pub3&amp;doi=10.1002/14651858.CD010069.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="hi-HI" rel="alternate"/> <link href="https://www.cochranelibrary.com/hu/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010069.pub3&amp;doi=10.1002/14651858.CD010069.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="hu-HU" rel="alternate"/> <link href="https://www.cochranelibrary.com/in/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010069.pub3&amp;doi=10.1002/14651858.CD010069.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="in-ID" rel="alternate"/> <link href="https://www.cochranelibrary.com/ja/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010069.pub3&amp;doi=10.1002/14651858.CD010069.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ja-JP" rel="alternate"/> <link href="https://www.cochranelibrary.com/ko/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010069.pub3&amp;doi=10.1002/14651858.CD010069.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ko-KR" rel="alternate"/> <link href="https://www.cochranelibrary.com/ms/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010069.pub3&amp;doi=10.1002/14651858.CD010069.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ms-MY" rel="alternate"/> <link href="https://www.cochranelibrary.com/fa/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010069.pub3&amp;doi=10.1002/14651858.CD010069.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="fa-IR" rel="alternate"/> <link href="https://www.cochranelibrary.com/pl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010069.pub3&amp;doi=10.1002/14651858.CD010069.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="pl-PL" rel="alternate"/> <link href="https://www.cochranelibrary.com/pt/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010069.pub3&amp;doi=10.1002/14651858.CD010069.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="pt-PT" rel="alternate"/> <link href="https://www.cochranelibrary.com/ro/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010069.pub3&amp;doi=10.1002/14651858.CD010069.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ro-RO" rel="alternate"/> <link href="https://www.cochranelibrary.com/ru/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010069.pub3&amp;doi=10.1002/14651858.CD010069.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ru-RU" rel="alternate"/> <link href="https://www.cochranelibrary.com/es/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010069.pub3&amp;doi=10.1002/14651858.CD010069.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="es-ES" rel="alternate"/> <link href="https://www.cochranelibrary.com/ta/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010069.pub3&amp;doi=10.1002/14651858.CD010069.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ta-IN" rel="alternate"/> <link href="https://www.cochranelibrary.com/th/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010069.pub3&amp;doi=10.1002/14651858.CD010069.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="th-TH" rel="alternate"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" rel="stylesheet" type="text/css"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/aui.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" rel="stylesheet" type="text/css"/> <link href="/html/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773519000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/scolaris-content-display/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/notifications-portlet/notifications/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/html/portlet/login/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773548000" rel="stylesheet" type="text/css"/> <script type="text/javascript">var Liferay={Browser:{acceptsGzip:function(){return false},getMajorVersion:function(){return 80},getRevision:function(){return"537.36"},getVersion:function(){return"80.0"},isAir:function(){return false},isChrome:function(){return true},isFirefox:function(){return false},isGecko:function(){return true},isIe:function(){return false},isIphone:function(){return false},isLinux:function(){return true},isMac:function(){return false},isMobile:function(){return false},isMozilla:function(){return false},isOpera:function(){return false},isRtf:function(){return true},isSafari:function(){return true},isSun:function(){return false},isWap:function(){return false},isWapXhtml:function(){return false},isWebKit:function(){return true},isWindows:function(){return false},isWml:function(){return false}},Data:{NAV_SELECTOR:"#navigation",isCustomizationView:function(){return false},notices:[null]},ThemeDisplay:{getLayoutId:function(){return"7"},getLayoutURL:function(){return"https://www.cochranelibrary.com/en/content"},getParentLayoutId:function(){return"0"},isPrivateLayout:function(){return"false"},isVirtualLayout:function(){return false},getBCP47LanguageId:function(){return"en-US"},getCDNBaseURL:function(){return"https://www.cochranelibrary.com"},getCDNDynamicResourcesHost:function(){return""},getCDNHost:function(){return""},getCompanyId:function(){return"20155"},getCompanyGroupId:function(){return"20195"},getDefaultLanguageId:function(){return"en_US"},getDoAsUserIdEncoded:function(){return""},getLanguageId:function(){return"en_US"},getParentGroupId:function(){return"20182"},getPathContext:function(){return""},getPathImage:function(){return"/image"},getPathJavaScript:function(){return"/html/js"},getPathMain:function(){return"/en/c"},getPathThemeImages:function(){return"https://www.cochranelibrary.com/cochrane-theme/images"},getPathThemeRoot:function(){return"/cochrane-theme"},getPlid:function(){return"20757"},getPortalURL:function(){return"https://www.cochranelibrary.com"},getPortletSetupShowBordersDefault:function(){return true},getScopeGroupId:function(){return"20182"},getScopeGroupIdOrLiveGroupId:function(){return"20182"},getSessionId:function(){return""},getSiteGroupId:function(){return"20182"},getURLControlPanel:function(){return"/group/control_panel?refererPlid=20757"},getURLHome:function(){return"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane"},getUserId:function(){return"20159"},getUserName:function(){return""},isAddSessionIdToURL:function(){return false},isFreeformLayout:function(){return false},isImpersonated:function(){return false},isSignedIn:function(){return false},isStateExclusive:function(){return false},isStateMaximized:function(){return false},isStatePopUp:function(){return false}},PropsValues:{NTLM_AUTH_ENABLED:false}};var themeDisplay=Liferay.ThemeDisplay;Liferay.AUI={getAvailableLangPath:function(){return"available_languages.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513680837000"},getCombine:function(){return true},getComboPath:function(){return"/combo/?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513680837000&"},getFilter:function(){return"min"},getJavaScriptRootPath:function(){return"/html/js"},getLangPath:function(){return"aui_lang.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513680837000"},getStaticResourceURLParams:function(){return"?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513680837000"}};Liferay.authToken="9mpoajSI";Liferay.currentURL="\x2fweb\x2fcochrane\x2fcontent\x3ftemplateType\x3dfull\x26urlTitle\x3d\x2fcdsr\x2fdoi\x2f10\x2e1002\x2f14651858\x2eCD010069\x2epub3\x26doi\x3d10\x2e1002\x2f14651858\x2eCD010069\x2epub3\x26type\x3dcdsr\x26contentLanguage\x3d";Liferay.currentURLEncoded="\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD010069\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD010069\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D";</script> <script src="/html/js/barebone.jsp?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;colorSchemeId=01&amp;minifierType=js&amp;minifierBundleId=javascript.barebone.files&amp;languageId=en_US&amp;b=6210&amp;t=1513680837000" type="text/javascript"></script> <script type="text/javascript"></script> <script type="text/javascript">var o={database:"CDSR",page:{pageType:"Article Full Text HTML"},article:{availableLanguage:["en","es","zh_HANS","zh_HANT","ru","ms","hr","fa"],languageCode:"en",accessStatus:"delayed-free",doi:"10.1002/14651858.CD010069.pub3",title:"Interventions for tophi in gout",firstPublishedDate:"Aug 11, 2021 12:00:00 AM",isCurrentVersion:true,editorialGroup:"Cochrane Musculoskeletal Group",availableParts:["PDF Full","PDF Standard","PDF Abstract","HTML","Comments","Information","References","Stats","Related Content"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/custom.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" rel="stylesheet" type="text/css"/> <style type="text/css"></style> <script async="" src="https://assets.adobedtm.com/59640f9fa510/7cad07cf7779/launch-a215d9c51521.min.js"></script> <!--[if lt IE 9]> <script src="/cochrane-theme/vendor/respond/dest/respond.min.js?t=1738734739000" type="text/javascript"></script> <![endif]--> </head> <body class="yui3-skin-sam controls-visible guest-site signed-out public-page site"> <div class="site-container"> <a href="#main-content" id="skip-to-content">Skip to Content</a> <div class="cookie-message cookie-message--hidden system-message-container" id="js-cookie-message"> <div class="container"> <a aria-label="Close cookies message" class="fa fa-times js-cookie-close pull-right" href="#"></a> <div class="system-message-wrapper container"> <i aria-hidden="true" class="fa fa-exclamation-triangle"></i> <div class="system-message-title">Cookies</div> <div class="system-message-description"> <p> Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in <a href="http://olabout.wiley.com/WileyCDA/Section/id-813473.html">About Cookies</a>. </p> <a class="btn secondary js-cookie-close js-cookie-accept" href="#">I accept</a> </div> </div> </div> </div> <script>document.body.className=document.body.className+" js_enabled";</script><header> <div class="container"> <div class="branding"> <h1 class="brand-container"> <a href="https://www.cochranelibrary.com/en/"> <span class="brand-name">The Cochrane Library</span> <img alt="Cochrane Library logo" class="brand-logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_logo.png" title="Cochrane Library"/> </a> </h1> <span class="additional-branding"> <p class="brand-message"> <em>Trusted evidence.</em> <em>Informed decisions.</em> <em>Better health.</em> </p> </span> </div> <div class="desktop-search basic-search-container"> <div class="desktop-search-form"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="owel__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=9mpoajSI&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"/> <input name="facetDisplayName" type="hidden" value=""/> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD010069.pub3&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD010069.pub3';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<div class="search-tools-nav">
<a class="btn secondary" href="/en/browse-by-topic">Browse</a>
<a class="btn primary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
</div>
<a class="toggle-menu-switch" href="#"><i aria-hidden="true" class="fa fa-bars"></i> <div class="toggle-menu-text">Open menu</div></a>
</div>
<div class="auxiliary-container">
<div class="container">
<div class="header-auxiliary-menu">
<div class="auxiliary-menu-item language-selector">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="bvrs__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> Review language : English </a> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> Website language : English </a> </div> <div class="language-selector-modal-content" data-modal-title="Language selection" data-size="large" style="display: none;"> <div class="form-content language-selector-modal"> <div class="row-fluid"> <div> <table class="mytable" style="border: 1px solid #f0f0f0" width="90%"> <tbody> <tr class="row-box"> <td><i class="fa fa-file-text icon-size"></i></td> <td><h3>Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> </td> <td> <div> <select id="contentLanguageSelector" onchange="updateLang(this.value)"> <option class="content-language-option" data-languagecode="de" value="de"> Deutsch </option> <option class="content-language-option" data-languagecode="en" selected="" value="en"> English </option> <option class="content-language-option" data-languagecode="es" value="es"> Español </option> <option class="content-language-option" data-languagecode="fa" value="fa"> فارسی </option> <option class="content-language-option" data-languagecode="fr" value="fr"> Français </option> <option class="content-language-option" data-languagecode="hi" value="hi"> हिन्दी </option> <option class="content-language-option" data-languagecode="hr" value="hr"> Hrvatski </option> <option class="content-language-option" data-languagecode="id" value="id"> Bahasa Indonesia </option> <option class="content-language-option" data-languagecode="ja" value="ja"> 日本語 </option> <option class="content-language-option" data-languagecode="ko" value="ko"> 한국어 </option> <option class="content-language-option" data-languagecode="hu" value="hu"> Magyar </option> <option class="content-language-option" data-languagecode="ms" value="ms"> Bahasa Malaysia </option> <option class="content-language-option" data-languagecode="nl" value="nl"> Nederlands </option> <option class="content-language-option" data-languagecode="pl" value="pl"> Polski </option> <option class="content-language-option" data-languagecode="pt" value="pt"> Português </option> <option class="content-language-option" data-languagecode="ru" value="ru"> Русский </option> <option class="content-language-option" data-languagecode="ro" value="ro"> Română </option> <option class="content-language-option" data-languagecode="ta" value="ta"> தமிழ் </option> <option class="content-language-option" data-languagecode="th" value="th"> ภาษาไทย </option> <option class="content-language-option" data-languagecode="zh_HANT" value="zh_HANT"> 繁體中文 </option> <option class="content-language-option" data-languagecode="zh_HANS" value="zh_HANS"> 简体中文 </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> <tr class="row-box"> <td><i class="fa fa-globe icon-size"></i></td> <td> <div class="language-info"> <h3>Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> </div> </td> <td> <div class="language-dropdown"> <select id="portalLanguageSelector"> <option class="portal-language-selector" data-portallanguage="en" selected="" value="/en/cdsr/doi/10.1002/14651858.CD010069.pub3/full/en"> English </option> <option class="portal-language-selector" data-portallanguage="es" value="/es/cdsr/doi/10.1002/14651858.CD010069.pub3/full/es"> Español </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> </tbody> </table> </div> </div> <div style="text-align: right;"> <button class="btn primary btn-cancel" style="margin-left: 10px;" type="button">Cancel</button> <a class="btn secondary ok-btn" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<a class="auxiliary-menu-item signin last" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD010069.pub3%2Ffull" rel="nofollow">
<i class="icon fa fa-user"></i> Sign In
    </a>
<span class="auxiliary-container-extended"></span>
</div>
</div>
</div>
</header>
<div class="main-nav-wrapper">
<span class="main-nav-left-extended"></span>
<nav class="main container">
<ul>
<li class="nav-root-item parent">
<a href="#">Cochrane reviews<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_14" role="presentation">
<a aria-labelledby="layout_14" href="https://www.cochranelibrary.com/en/cdsr/reviews" role="menuitem">
            Search reviews (CDSR)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_15" role="presentation">
<a aria-labelledby="layout_15" href="https://www.cochranelibrary.com/en/cdsr/reviews/topics" role="menuitem">
            Browse reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_18" role="presentation">
<a aria-labelledby="layout_18" href="https://www.cochranelibrary.com/en/cdsr/table-of-contents" role="menuitem">
            Issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_17" role="presentation">
<a aria-labelledby="layout_17" href="https://www.cochranelibrary.com/en/cdsr/editorials" role="menuitem">
            Editorials
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_19" role="presentation">
<a aria-labelledby="layout_19" href="https://www.cochranelibrary.com/en/special-collections" role="menuitem">
            Special Collections
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_20" role="presentation">
<a aria-labelledby="layout_20" href="https://www.cochranelibrary.com/en/cdsr/supplements" role="menuitem">
            Supplements
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_121" role="presentation">
<a aria-labelledby="layout_121" href="https://www.cochranelibrary.com/en/about/about-cochrane-reviews" role="menuitem">
            About Cochrane reviews
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Searching for trials<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_254" role="presentation">
<a aria-labelledby="layout_254" href="https://www.cochranelibrary.com/en/search/releases" role="menuitem">
            What's new (search and CENTRAL)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_266" role="presentation">
<a aria-labelledby="layout_266" href="https://www.cochranelibrary.com/en/search-help" role="menuitem">
            Search help
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_252" role="presentation">
<a aria-labelledby="layout_252" href="https://www.cochranelibrary.com/en/search-help-quick-guides" role="menuitem">
            Search help quick guides
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_251" role="presentation">
<a aria-labelledby="layout_251" href="https://www.cochranelibrary.com/en/search-faqs" role="menuitem">
            Search FAQs
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_114" role="presentation">
<a aria-labelledby="layout_114" href="https://www.cochranelibrary.com/en/central/about-central" role="menuitem">
            About CENTRAL
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_115" role="presentation">
<a aria-labelledby="layout_115" href="https://www.cochranelibrary.com/en/central/central-creation" role="menuitem">
            How CENTRAL is created
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_241" role="presentation">
<a aria-labelledby="layout_241" href="https://www.cochranelibrary.com/en/retracted-trials" role="menuitem">
            Retracted publications in CENTRAL
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Clinical Answers<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_29" role="presentation">
<a aria-labelledby="layout_29" href="https://www.cochranelibrary.com/en/cca" role="menuitem">
            Browse Clinical Answers
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_91" role="presentation">
<a aria-labelledby="layout_91" href="https://www.cochranelibrary.com/en/cca/about" role="menuitem">
            About Clinical Answers
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">About<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_116" role="presentation">
<a aria-labelledby="layout_116" href="https://www.cochranelibrary.com/en/about/about-cochrane-library" role="menuitem">
            About the Cochrane Library
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_13" role="presentation">
<a aria-labelledby="layout_13" href="https://www.cochranelibrary.com/en/cdsr/about-cdsr" role="menuitem">
            Cochrane Database of Systematic reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_198" role="presentation">
<a aria-labelledby="layout_198" href="https://www.cochranelibrary.com/en/cdsr/editorial-policies" role="menuitem">
            Editorial policies
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_92" role="presentation">
<a aria-labelledby="layout_92" href="https://www.cochranelibrary.com/en/about/author-information" role="menuitem">
            Information for authors
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_212" role="presentation">
<a aria-labelledby="layout_212" href="https://www.cochranelibrary.com/en/about-pico" role="menuitem">
            About PICO
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_207" role="presentation">
<a aria-labelledby="layout_207" href="https://www.cochranelibrary.com/en/about/about-translations" role="menuitem">
            About translations
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_188" role="presentation">
<a aria-labelledby="layout_188" href="https://www.cochranelibrary.com/en/about/releases" role="menuitem">
            What's new
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_216" role="presentation">
<a aria-labelledby="layout_216" href="https://www.cochranelibrary.com/en/data" role="menuitem">
            Data reuse
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_235" role="presentation">
<a aria-labelledby="layout_235" href="https://www.cochranelibrary.com/en/about/about-cochrane-library/editorial-board" role="menuitem">
            Cochrane Library Editorial Board
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Help<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_259" role="presentation">
<a aria-labelledby="layout_259" href="https://m.info.wiley.com/webApp/cochranenewsletter?id=0" role="menuitem">
            Newsletter
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_177" role="presentation">
<a aria-labelledby="layout_177" href="https://www.wiley.com/en-us/customer-success/cochrane-library-training-hub" role="menuitem">
            Cochrane Library Training
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_44" role="presentation">
<a aria-labelledby="layout_44" href="https://www.cochranelibrary.com/en/help/access" role="menuitem">
            Access
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_150" role="presentation">
<a aria-labelledby="layout_150" href="https://www.cochranelibrary.com/en/help/permissions" role="menuitem">
            Permissions and reprints
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_93" role="presentation">
<a aria-labelledby="layout_93" href="https://www.cochranelibrary.com/en/help/media" role="menuitem">
            Media information
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_97" role="presentation">
<a aria-labelledby="layout_97" href="https://www.cochranelibrary.com/en/help/contact-us" role="menuitem">
            Contact us
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_125" role="presentation">
<a aria-labelledby="layout_125" href="https://www.cochranelibrary.com/en/about/terms-and-conditions" role="menuitem">
            Terms and conditions
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_176" role="presentation">
<a aria-labelledby="layout_176" href="https://cochranesupport.wiley.com/s/article/cochrane-library-known-issues" role="menuitem">
            Known issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_270" role="presentation">
<a aria-labelledby="layout_270" href="https://www.cochranelibrary.com/search-help" role="menuitem">
            Search help
        </a>
</li>
</ul>
</li>
<li class="about-link"><a href="https://www.cochrane.org/about-us" target="_blank"><span>About Cochrane</span><i class="fa fa-caret-right"></i></a></li>
</ul>
</nav>
</div>
<div class="portlet-boundary portlet-boundary_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_">
<span id="p_scolariscontentlanguagebanner_WAR_scolarislanguageportlet"></span>
<section class="portlet" id="portlet_scolariscontentlanguagebanner_WAR_scolarislanguageportlet">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Language\x20Banner\x20Portlet')">
<img alt="" id="etlj__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Language Banner Portlet</span> </span> <span class="portlet-title-text">Scolaris Content Language Banner Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentlanguagebanner_WAR_scolarislanguageportlet" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="" id="content">
<div class="columns-1" id="main-content" role="main">
<div class="portlet-layout row-fluid">
<div class="portlet-column portlet-column-only span12" id="column-1">
<div class="portlet-dropzone portlet-column-content portlet-column-content-only" id="layout-column_column-1">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="rjus__column1__0" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="publication cdsr container"> <div class="article-navigation-container" id="cdsr-nav"> <nav class="article-navigation"> <ul class="tools-row"> <li> <li class="tools pdf pulldown-menu readcube-menu closed en_US"> <a class="pulldown-menu-trigger" href="#0"> <span class="pdf-icon"> <i class="icon fa fa-file-pdf-o"></i> <span>Download PDF</span> </span> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> <ul class="pulldown-menu-items"> <li class=""> <a class="download media pdf-link-full pdf-link" href="/cdsr/doi/10.1002/14651858.CD010069.pub3/pdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> <a class="download media pdf-link-full readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD010069.pub3/epdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> </li> <li class=""> <a class="download media pdf-link-abstract pdf-link" href="/cdsr/doi/10.1002/14651858.CD010069.pub3/pdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> <a class="download media pdf-link-abstract readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD010069.pub3/epdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> </li> </ul> </li> <li class="tools cite cite-article-link" data-article-id="CD010069.PUB3" data-modal-title="Cite this review"> <span><i aria-hidden="true" class="icon fa fa-share"></i></span> <span>Cite this review</span> </li> </li> </ul> <ul class="tools-row tools-secondary"> <li> <li class="tools print print-cdsr-link" data-content-language="en" data-indicator-tooltip="scolaris.print.modal.language.tooltip.en" data-print-options="[{&quot;param&quot;: &quot;abstract&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Abstract&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;چکیده&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;摘要&quot;}]},{&quot;param&quot;: &quot;pls&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen en términos sencillos&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;خلاصه به زبان ساده&quot;},{&quot;language&quot;:&quot;hr&quot;,&quot;title&quot;:&quot;Laički sažetak&quot;},{&quot;language&quot;:&quot;ms&quot;,&quot;title&quot;:&quot;Ringkasan bahasa mudah&quot;},{&quot;language&quot;:&quot;ru&quot;,&quot;title&quot;:&quot;Резюме на простом языке&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;简语概要&quot;},{&quot;language&quot;:&quot;zh_HANT&quot;,&quot;title&quot;:&quot;淺顯易懂的口語結論&quot;}]},{&quot;param&quot;: &quot;conclusions&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors' conclusions&quot;}]},{&quot;param&quot;: &quot;summaryOfFindings&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Summary of findings&quot;}]},{&quot;param&quot;: &quot;background&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Background&quot;}]},{&quot;param&quot;: &quot;objectives&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Objectives&quot;}]},{&quot;param&quot;: &quot;methods&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Methods&quot;}]},{&quot;param&quot;: &quot;results&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Results&quot;}]},{&quot;param&quot;: &quot;discussion&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Discussion&quot;}]},{&quot;param&quot;: &quot;references&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;References&quot;}]},{&quot;param&quot;: &quot;appendices&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Appendices&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Search strategies&quot;}]},{&quot;param&quot;: &quot;characteristics&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Characteristics of studies&quot;}]},{&quot;param&quot;: &quot;data&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Analyses&quot;}]},{&quot;param&quot;: &quot;information&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Information&quot;}]},{&quot;param&quot;: &quot;authors&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors&quot;}]},{&quot;param&quot;: &quot;history&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;}]}]" data-print-urlbase="/cdsr/doi/10.1002/14651858.CD010069.pub3/print"> <span><i class="icon fa fa-print"></i></span> <span>Print</span> </li> <li class="js-old-version-modal-trigger tools comments comment-on-review" data-article-id="CD010069.PUB3" data-english-only-message="Please note, that commenting is available in English only. Apologies for any inconvenience." data-href="/cdsr/doi/10.1002/14651858.CD010069.pub3/read-comments" data-new-version="" id="comment-on-review"> <span class="comment-icon"><i class="icon fa fa-comment"></i></span> <span class="comments-count">0</span> <span>Comment</span> </li> <li class="tools share-cdsr-link" data-share-url="/cdsr/doi/10.1002/14651858.CD010069.pub3/full"> <span><i class="icon fa fa-share-alt"></i></span> <span>Share</span> </li> <li class="tools follow"> <span class="article-not-followed cochrane-link signin follow-wrapper"> <span> <i class="icon fa fa-plus"></i> </span> <span> Follow </span> </span> </li> </li> </ul> <div class="metrics-wrapper"> <div class="metrics-count"> <span>Full text views: </span> <span>2642 <i class="icon fa fa-info-circle custom-tooltip" style="padding-left: 2px;color: #962d91;" title="Usage represents full text views on Cochrane Library since January 2022 or 2023. For articles published after this date, the usage represents views since the article was first published on Cochrane Library."> </i> </span> </div> </div> <div class="metrics-wrapper nav-link-section"> <div class="altmetric-embed" data-badge-type="1" data-condensed="true" data-doi="10.1002/14651858.CD010069.pub3" data-link-target="_blank"></div> <div class="inline-status-wrapper guidelines-count" data-count-plural="Cited in $1 guidelines" data-count-single="Cited in 1 guideline"> <a href="related-content#guidelines_data" title="Guidelines"></a> </div> </div> <ul class="nav-section-header"> <li> <h3>Contents</h3> </li> </ul> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010069.pub3/full"> Abstract </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010069.pub3/full#pico"> PICOs </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010069.pub3/full#CD010069-abs-0002"> Plain language summary </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010069.pub3/full#CD010069-sec-0092"> Authors' conclusions </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010069.pub3/full#CD010069-sec-0008"> Summary of findings </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010069.pub3/full#CD010069-sec-0009"> Background </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010069.pub3/full#CD010069-sec-0014"> Objectives </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010069.pub3/full#CD010069-sec-0015"> Methods </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010069.pub3/full#CD010069-sec-0039"> Results </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010069.pub3/full#CD010069-sec-0082"> Discussion </a> </li> <li class="cdsr-nav-link"> <a class="figures-and-tables-link" href="/cdsr/doi/10.1002/14651858.CD010069.pub3/#"> Figures and tables </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010069.pub3/references"> References </a> </li> </ul> <div class="nav-section-header"> <h3>Supplementary materials</h3> </div> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010069.pub3/appendices#CD010069-sec-0097"> Search strategies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010069.pub3/references#characteristicStudies"> Characteristics of studies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010069.pub3/references#dataAndAnalyses"> Analyses </a> </li> <li class="cdsr-nav-link download-stats-data-link" data-download-href="/cdsr/doi/10.1002/14651858.CD010069.pub3/media/CDSR/CD010069/table_n/CD010069StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> <a href="/cdsr/doi/10.1002/14651858.CD010069.pub3/media/CDSR/CD010069/table_n/CD010069StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> Download data </a> </li> </ul> <ul class="tools-row"> <li> </li> </ul> <ul class="nav-section-header"> <li><h3>Related</h3></li> </ul> <ul class="linked-content linked-content-dropdown" id="linked-content-articles" tabindex="0"> <li class="linked-cca" data-type="cca"> <div class="linked-content-section"> <span class="linked-type">Cochrane Clinical Answers<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-editorials" data-type="editorial"> <div class="linked-content-section"> <span class="linked-type">Editorials<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-podcasts" data-type="podcast"> <div class="linked-content-section"> <span class="linked-type">Podcasts<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-sc" data-type="sc"> <div class="linked-content-section"> <span class="linked-type">Special Collections<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> </ul> <div class="nav-section-header"> <h3>About this review</h3> </div> <ul class="nav-long-form nav-info nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010069.pub3/information"> <i> <svg viewbox="0 0 24 24"> <path d="M11,9H13V7H11M12,20C7.59,20 4,16.41 4,12C4,7.59 7.59,4 12,4C16.41,4 20,7.59 20,12C20,16.41 16.41,20 12,20M12,2A10,10 0 0,0 2,12A10,10 0 0,0 12,22A10,10 0 0,0 22,12A10,10 0 0,0 12,2M11,17H13V11H11V17Z"></path> </svg> </i> Information </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010069.pub3/information#authors"> <i> <svg viewbox="0 0 24 24"> <path d="M12,5.5A3.5,3.5 0 0,1 15.5,9A3.5,3.5 0 0,1 12,12.5A3.5,3.5 0 0,1 8.5,9A3.5,3.5 0 0,1 12,5.5M5,8C5.56,8 6.08,8.15 6.53,8.42C6.38,9.85 6.8,11.27 7.66,12.38C7.16,13.34 6.16,14 5,14A3,3 0 0,1 2,11A3,3 0 0,1 5,8M19,8A3,3 0 0,1 22,11A3,3 0 0,1 19,14C17.84,14 16.84,13.34 16.34,12.38C17.2,11.27 17.62,9.85 17.47,8.42C17.92,8.15 18.44,8 19,8M5.5,18.25C5.5,16.18 8.41,14.5 12,14.5C15.59,14.5 18.5,16.18 18.5,18.25V20H5.5V18.25M0,20V18.5C0,17.11 1.89,15.94 4.45,15.6C3.86,16.28 3.5,17.22 3.5,18.25V20H0M24,20H20.5V18.25C20.5,17.22 20.14,16.28 19.55,15.6C22.11,15.94 24,17.11 24,18.5V20Z"></path> </svg> </i> Authors </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010069.pub3/information#history"> <i> <svg viewbox="0 0 24 24"> <path d="M13.5,8H12V13L16.28,15.54L17,14.33L13.5,12.25V8M13,3A9,9 0 0,0 4,12H1L4.96,16.03L9,12H6A7,7 0 0,1 13,5A7,7 0 0,1 20,12A7,7 0 0,1 13,19C11.07,19 9.32,18.21 8.06,16.94L6.64,18.36C8.27,20 10.5,21 13,21A9,9 0 0,0 22,12A9,9 0 0,0 13,3"></path> </svg> </i> Version history </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD010069.pub3/information#keywords"> <i> <svg viewbox="0 0 24 24"> <path d="M11 3C10.18 3 9.44 3.5 9.14 4.27L3.64 18.27C3.12 19.58 4.09 21 5.5 21H7.75C8.59 21 9.33 20.5 9.62 19.7L10.26 18H13.74L14.38 19.7C14.67 20.5 15.42 21 16.25 21H18.5C19.91 21 20.88 19.58 20.36 18.27L14.86 4.27C14.56 3.5 13.82 3 13 3M11 5H13L18.5 19H16.25L15.12 16H8.87L7.75 19H5.5M12 7.67L9.62 14H14.37Z"></path> </svg> </i> Keywords (MeSH, PICOs) </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD010069.pub3/related-content"> <i class="icon fa fa-sitemap fa-rotate-270"></i> Related content </a> </li> <li class="cdsr-nav-link translation-notes-link"> <a href="/cdsr/doi/10.1002/14651858.CD010069.pub3/#"> <i> <svg viewbox="0 0 24 24"> <path d="M12.87,15.07L10.33,12.56L10.36,12.53C12.1,10.59 13.34,8.36 14.07,6H17V4H10V2H8V4H1V6H12.17C11.5,7.92 10.44,9.75 9,11.35C8.07,10.32 7.3,9.19 6.69,8H4.69C5.42,9.63 6.42,11.17 7.67,12.56L2.58,17.58L4,19L9,14L12.11,17.11L12.87,15.07M18.5,10H16.5L12,22H14L15.12,19H19.87L21,22H23L18.5,10M15.88,17L17.5,12.67L19.12,17H15.88Z"></path> </svg> </i> Translation notes </a> </li> <li class="cdsr-nav-link"> <a class="request-permissions" data-copyright="Copyright © 2021 The Cochrane Collaboration. Published by John Wiley &amp; Sons, Ltd." data-creative-commons="false" href="/cdsr/doi/10.1002/14651858.CD010069.pub3/#"> <span class="request-permissions-icon"></span> Request permissions </a> </li> <li class="cdsr-nav-link"> <a href="/data"> <i class="icon fa fa-database"></i> Request data reuse </a> </li> </ul> </nav> </div> <article> <div class="cdsr-header-top"> <div class="cdsr-header-left"> <a class="publish-database" href="/">Cochrane Database of Systematic reviews</a> <span class="publish-type">Review - Intervention</span> </div> <div class="cdsr-header-right"> </div> </div> <header class="publication-header"> <h1 class="publication-title" lang="en">Interventions for tophi in gout</h1> <div class="publication-metadata-block"> <div class="publication-authors"> <div class="publish-meta-wrapper"> <ul class="authors"> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD010069.pub3/information#CD010069-cr-0004"><i class="icon corresponding-author fa fa-envelope"></i>Melonie K Sriranganathan</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD010069.pub3/information#CD010069-cr-0005">Ophir Vinik</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD010069.pub3/information#CD010069-cr-0006">Jordi Pardo Pardo</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD010069.pub3/information#CD010069-cr-0007">Claire Bombardier</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD010069.pub3/information#CD010069-cr-0008">Christopher J Edwards</a></li> </ul> <span class="author declaration"> <a class="declarationsOfInterestLink" href="/cdsr/doi/10.1002/14651858.CD010069.pub3/information/en#CD010069-sec-0105">Authors' declarations of interest</a> </span> </div> </div> </div> <div class="publication-metadata-block"> <p> <span class="publish-date">Version published: 11 August 2021 </span> <a class="whatsNewLink" href="/cdsr/doi/10.1002/14651858.CD010069.pub3/information/en#versionTable">Version history</a> </p> <div class="doi-header"> <a href="https://doi.org/10.1002/14651858.CD010069.pub3">https://doi.org/10.1002/14651858.CD010069.pub3</a> </div> </div> </header> <div class="publication-control-bar"> <span class="publication-control-button publication-control-collapse"> Collapse all </span> <span class="publication-control-button publication-control-expand"> Expand all </span> </div> <section class="abstract"> <div class="section-header section-collapse-header" id="CD010069-abs-0001" lang="en"> <h2 class="title section-collapse-title"> Abstract <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD010069-abs-0001">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD010069-abs-0011">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD010069-abs-0009">فارسی</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD010069-abs-0003">简体中文</a> </li> </nav> </div> </div> <div class="abstract full_abstract" id="CD010069-abs-0001" lang="en"> <section id="CD010069-sec-0001"> <h3 class="title" id="CD010069-sec-0001">Background</h3> <p>Tophi develop in untreated or uncontrolled gout. This is an update of a Cochrane Review first published in 2014.  </p> </section> <section id="CD010069-sec-0002"> <h3 class="title" id="CD010069-sec-0002">Objectives</h3> <p>To assess the benefits and harms of non‐surgical and surgical treatments for the management of tophi in gout. </p> </section> <section id="CD010069-sec-0003"> <h3 class="title" id="CD010069-sec-0003">Search methods</h3> <p>We updated the search of Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE and Embase databases to 28 August 2020. </p> </section> <section id="CD010069-sec-0004"> <h3 class="title" id="CD010069-sec-0004">Selection criteria</h3> <p>We included all published randomised controlled trials (RCTs) or controlled clinical trials examining interventions for tophi in gout in adults. </p> </section> <section id="CD010069-sec-0005"> <h3 class="title" id="CD010069-sec-0005">Data collection and analysis</h3> <p>We used standard methodological procedures expected by Cochrane.</p> </section> <section id="CD010069-sec-0006"> <h3 class="title" id="CD010069-sec-0006">Main results</h3> <p>We included one trial in our original review. We added four more trials (1796 participants) in this update. One had three arms; pegloticase infusion every two weeks (biweekly), monthly pegloticase infusion (pegloticase infusion alternating with placebo infusion every two weeks) and placebo. Two studies looked at lesinurad 200 mg or 400 mg in combination with allopurinol. One trial studied lesinurad 200 mg or 400 mg in combination with febuxostat. One trial compared febuxostat 80 mg and 120 mg to allopurinol. </p> <p>Two trials were at unclear risk of performance and detection bias due to lack of information on blinding of participants and personnel. All other trials were at low risk of bias. </p> <p>Moderate‐certainty evidence (downgraded for imprecision; one study; 79 participants) showed that biweekly pegloticase resolved tophi in 21/52 participants compared with 2/27 on placebo (risk ratio (RR) 5.45, 95% confidence interval (CI) 1.38 to 21.54; number needed to treat for a benefit (NNTB) 3, 95% CI 2 to 6). Similar proportions of participants receiving biweekly pegloticase (80/85) had an adverse event compared to placebo (41/43) (RR 0.99, 95% CI 0.91 to 1.07). However, more participants on biweekly pegloticase (15/85) withdrew due to an adverse event compared to placebo (1/43) (RR 7.59, 95% CI 1.04 to 55.55; number needed to treat for a harm (NNTH) 7, 95% CI 4 to 16). </p> <p>More participants on monthly pegloticase (11/52) showed complete resolution of tophi compared with placebo (2/27) (RR 2.86, 95% CI 0.68 to 11.97; NNTB 8, 95% CI 4 to 91). Similar numbers of participants on monthly pegloticase (84/84) had an adverse event compared to placebo (41/43) (RR 1.05, 95% CI 0.98 to 1.14). More participants on monthly pegloticase (16/84) withdrew due to adverse events compared to placebo (1/43) (RR 8.19, 95% CI 1.12 to 59.71; NNTH 6, 95% CI 4 to 14). Infusion reaction was the most common reason for withdrawal. </p> <p>Moderate‐certainty evidence (2 studies; 103 participants; downgraded for imprecision) showed no clinically significant difference for complete resolution of target tophus in the lesinurad 200 mg plus allopurinol arm (11/53) compared to the placebo plus allopurinol arm (16/50) (RR 0.40, 95% CI 0.04 to 4.57), or in the lesinurad 400 mg plus allopurinol arm (12/48) compared to the placebo plus allopurinol arm (16/50) (RR 0.79, 95% CI 0.42 to 1.49). </p> <p>An extension study examined lesinurad 200 mg or 400 mg in combination with febuxostat, or placebo (low‐certainty evidence, downgraded for indirectness and imprecision). Participants on lesinurad in the original study continued (CONT) on the same dose. Lesinurad 400 mg plus febuxostat may be beneficial for tophi resolution; 43/65 in the lesinurad 400 mg CONT arm compared to 38/64 in the lesinurad 200 mg CONT arm had tophi resolution (RR 1.11, 95% CI 0.85 to 1.46). Lesinurad 400 mg plus febuxostat may result in no difference in adverse events; 57/65 in the lesinurad 400 mg CONT arm had an adverse event compared to 50/64 in lesinurad 200 mg CONT arm (RR 1.12, 95% CI 0.96 to 1.32). Lesinurad 400 mg plus febuxostat may result in no difference in withdrawals due to adverse events; 10/65 participants in the lesinurad 400 mg CONT arm withdrew due to an adverse event compared to 10/64 participants in the lesinurad 200 mg CONT arm (RR 0.98, 95% CI 0.44 to 2.20). Lesinurad 400 mg plus febuxostat may result in no difference in mean serum uric acid (sUA), which was 3 mg/dl in the lesinurad 400 mg CONT group compared to 3.9 mg/dl in the lesinurad 200 mg CONT group (mean difference ‐0.90, 95% CI ‐1.51 to ‐0.29). </p> <p>Participants who were not on lesinurad in the original study were randomised (CROSS) to lesinurad 200 mg or 400 mg, both in combination with febuxostat. Low‐certainty evidence downgraded for indirectness and imprecision showed that lesinurad 400 mg (CROSS) may result in tophi resolution (17/34) compared to lesinurad 200 mg (CROSS) (14/33) (RR 1.18, 95% CI 0.70 to 1.98). Lesinurad 400 mg in combination with febuxostat may result in no difference in adverse events (33/34 in the lesinurad 400 mg CROSS arm compared to 27/33 in the lesinurad 200 mg (CROSS); RR 1.19, 95% CI 1.00 to 1.41). Lesinurad 400 mg plus febuxostat may result in no difference in withdrawals due to adverse events, 5/34 in the lesinurad 400 mg CROSS arm withdrew compared to 2/33 in the lesinurad 200 mg CROSS arm (RR 2.43, 95% CI 0.51 to 11.64). Lesinurad 400 mg plus febuxostat results in no difference in sUA (4.2 mg/dl in lesinurad 400 mg CROSS) compared to lesinurad 200 mg (3.8 mg/dl in lesinurad 200 mg CROSS), mean difference 0.40 mg/dl, 95% CI ‐0.75 to 1.55. </p> </section> <section id="CD010069-sec-0007"> <h3 class="title" id="CD010069-sec-0007">Authors' conclusions</h3> <p>Moderate‐certainty evidence showed that pegloticase is probably beneficial for resolution of tophi in gout. Although there was little difference in adverse events when compared to placebo, participants on pegloticase had more withdrawals due to adverse events. Lesinurad 400 mg plus febuxostat may be beneficial for tophi resolution compared with lesinurad 200 mg plus febuxostat; there was no difference in adverse events between these groups. We were unable to determine whether lesinurad plus febuxostat is more effective than placebo. Lesinurad (400 mg or 200 mg) plus allopurinol is probably not beneficial for tophi resolution, and there was no difference in adverse events between these groups. RCTs on interventions for managing tophi in gout are needed, and the lack of trial data is surprising given that allopurinol is a well‐established treatment for gout. </p> </section> </div> </section> <section class="pico-section" id="pico"> <h2 class="title section-collapse-title">PICOs <i class="icon fa fa-info-circle" title="The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome."></i> <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-content" style="display: block;"> <h3 class="keyword-heading">PICOs</h3> <div class="pico-table"> <div class="pico-column Population"> <h6>Population<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Intervention"> <h6>Intervention<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Comparison"> <h6>Comparison<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Outcome"> <h6>Outcome<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> </div> <div class="pico-information"> <p><i class="icon fa fa-info-circle"></i> The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome.</p> <p>See more on using PICO in the <a href="https://training.cochrane.org/handbook/current/chapter-02#section-2-3">Cochrane Handbook</a>.</p> </div> </div> </section> <section class="pls"> <div class="section-header section-collapse-header" id="CD010069-abs-0002" lang="en"> <h2 class="title section-collapse-title"> Plain language summary <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD010069-abs-0002">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD010069-abs-0012">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD010069-abs-0010">فارسی</a> </li> <li class="section-language"> <a class="" href="full/hr#CD010069-abs-0008">Hrvatski</a> </li> <li class="section-language"> <a class="" href="full/ms#CD010069-abs-0007">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="full/ru#CD010069-abs-0006">Русский</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD010069-abs-0004">简体中文</a> </li> <li class="section-language"> <a class="" href="full/zh_HANT#CD010069-abs-0005">繁體中文</a> </li> </nav> </div> </div> <div class="abstract abstract_plainLanguageSummary" id="CD010069-abs-0002" lang="en"> <h3>Interventions for tophi in gout</h3> <p><b>Background</b> </p> <p>Gout is caused by urate crystals forming within or around joints.</p> <p>Inflammation can lead to pain, redness, warmth and swelling of the affected joints, making it difficult to touch or move. Some of the reasons why people develop gout include their genetic makeup, being overweight, ingesting certain medications (e.g. cyclosporine), impaired kidney function and lifestyle habits such as drinking excessive amounts of alcohol and sugar sweetened drinks. </p> <p>Tophi are nodules that develop in people with uncontrolled chronic gout. Tophi can become infected, cause pain and lead to reduced function. Tophi can be treated with urate‐lowering drugs (e.g. benzbromarone, probenecid, allopurinol, febuxostat, pegloticase, lesinurad), surgical removal or other interventions. </p> <p><b>Study characteristics</b> </p> <p>This is a summary of a Cochrane Review on interventions for the management of tophi. The literature was searched up to 28 August 2020. We reported five studies on pharmacological interventions. Participants were from a wide range of countries, including the USA, Canada, Mexico, South Africa, Australia, New Zealand, and locations in Europe. All studies were funded by pharmaceutical companies. </p> <p><b>Key results</b> </p> <p><b>Comparing biweekly pegloticase to placebo (fake treatment) (1 study; 79 participants)</b> </p> <p><i>Resolution of tophi</i> </p> <p>33 more people out of 100 had resolution of one or more tophi after six months' treatment with pegloticase biweekly (every 2 weeks) compared with placebo (16% better to 50% better). </p> <p>40 out of 100 people had tophi resolution with pegloticase.</p> <p>7 out of 100 people had tophi resolution with placebo.</p> <p><i>Total adverse events:</i> </p> <p>1 more person out of 100 had an adverse event with pegloticase compared with placebo (9% fewer to 7% more). </p> <p>95 out of 100 people had an adverse event with pegloticase.</p> <p>94 out of 100 people had an adverse event with placebo.</p> <p><b>Comparing monthly pegloticase to placebo (1 study; 79 participants)</b> </p> <p><i>Resolution of tophi</i> </p> <p>14 more people out of 100 had resolution of one or more tophi after six months' treatment with pegloticase monthly compared with placebo (1% worse to 29% better). </p> <p>21 out of 100 people had tophi resolution with pegloticase.</p> <p>7 out of 100 people had tophi resolution with placebo.</p> <p><i>Total adverse events</i> </p> <p>5 more people out of 100 had an adverse event with pegloticase compared with placebo (20% fewer to 12% more). </p> <p>100 out of 100 people had an adverse event with pegloticase.</p> <p>95 out of 100 people had an adverse event with placebo.</p> <p><b>Comparing lesinurad plus allopurinol to allopurinol (2 studies; 103 participants)</b> </p> <p><i>Resolution of tophi</i> </p> <p>11 fewer people out of 100 had complete resolution of target tophus after 12 month's treatment with lesinurad 200 mg plus allopurinol versus alopurinol alone (28% worse to 6% better). </p> <p>21 out of 100 people had tophi resolution with lesinurad 200 mg plus allopurinol.</p> <p>32 out of 100 people had tophi resolution with allopurinol.</p> <p>7 fewer people out of 100 had complete resolution of target tophus after 12 month's treatment with lesinurad 400 mg combination versus allopurinol alone (25% worse to 11% better). </p> <p>25 out of 100 people had tophi resolution with lesinurad 400 mg plus allopurinol.</p> <p>32 out of 100 people had tophi resolution with allopurinol.</p> <p><b>Comparing lesinurad 400 mg plus febuxostat to lesinurad 200 mg plus febuxostat (1 study; 129 participants)</b> </p> <p><i>Resolution of tophi</i> </p> <p>7 more people out of 100 had complete resolution of target tophus after 12 month's treatment with lesinurad 400 mg versus lesinurad 200 mg, both in combination with febuxostat (10% fewer to 23% more). </p> <p>66 out of 100 people had tophi resolution with lesinurad 400 mg plus febuxostat.</p> <p>59 out of 100 people had tophi resolution with lesinurad 200 mg plus febuxostat.</p> <p><i>Number of participant withdrawals due to adverse events</i> </p> <p>Only one study reported on adverse events separately in participants with tophi. </p> <p>9 more people out of 100 withdrew due to adverse events after 12 month's treatment with lesinurad 400 mg versus lesinurad 200 mg, both in combination with febuxostat (3% less to 43% better). </p> <p>70 out of 100 people with lesinurad 400 mg plus febuxostat withdrew from the study.</p> <p>61 out of 100 people with lesinurad 200 mg plus febuxostat withdrew from the study.</p> <p><i>Total adverse events</i> </p> <p>15 more people out of 100 had one or more adverse event after 12 month's treatment with lesinurad 400 mg versus lesinurad 200 mg, both in combination with febuxostat (3% less to 18% better). </p> <p>97 out of 100 people had an adverse event with lesinurad 400 mg plus febuxostat.</p> <p>82 out of 100 people had an adverse event with lesinurad 200 mg plus febuxostat.</p> <p><b>Certainty of evidence</b> </p> <p>Moderate‐certainty evidence indicated that pegloticase biweekly or monthly probably resolves one or more tophi. Moderate‐certainty evidence showed that lesinurad (400 mg or 200 mg) in combination with allopurinol is probably not beneficial for resolution of tophi in gout. Low‐certainty evidence indicated that lesinurad 400 mg compared to lesinurad 200 mg (both in combination with febuxostat) may resolve tophi and may result in no difference in adverse events or withdrawals due to adverse events. However, this study did not have a placebo arm.  </p> </div> </section> <section id="vls" style="display: none"> <div class="section-header section-collapse-header"> <h2 class="title section-collapse-title">Visual summary<i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i></h2> </div> <a href="" target="_blank"><img alt="visual summary" src=""/></a> </section> <section class="conclusions"> <div class="section-header section-collapse-header" id="CD010069-sec-0092" lang="en"> <h2 class="title section-collapse-title"> Authors' conclusions <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="authorsConclusions" lang="en"> <div class="section-header" id="CD010069-sec-0092"></div> <h3 class="title" id="CD010069-sec-0093">Implications for practice</h3> <section id="CD010069-sec-0093"> <p>One study from this review showed that pegloticase is probably beneficial in the management of tophi in gout. The main reason for withdrawal from its treatment was infusion reactions. Two studies that examined lesinurad in combination with allopurinol failed to show that lesinurad plus allopurinol was superior to allopurinol alone for resolution of tophi. However, the number of participants with tophi was small. </p> <p>One study from this review showed that lesinurad 400 mg in combination with febuxostat may be beneficial compared to lesinurad 200 mg plus febuxostat in the management of tophi in gout. However, we note that the study lacked a placebo arm, thus we could not determine whether lesinurad 400 mg in combination with febuxostat is more effective than placebo. </p> <p>Further randomised controlled trial (RCT) evidence is needed for all other urate‐lowering therapies as well as non‐pharmacological management. Analyses of lowering serum uric acid and its effect on the rate of reduction of tophi would also be useful. </p> <p>We found several case series and reports describing non‐pharmacological therapies for the management of tophi. These included surgical interventions such as decompression and debridement, and other interventions such as haemodialysis. However, there was no RCT evidence for this. Thus, we are unable to draw conclusions about the benefit of these treatments against pharmacological treatments. </p> </section> <h3 class="title" id="CD010069-sec-0094">Implications for research</h3> <section id="CD010069-sec-0094"> <p>Currently, there is insufficient RCT evidence to show which intervention is preferable for treating tophi in gout. Future research could include RCTs examining non‐pharmacological interventions for tophi. Outcomes such as withdrawal due to adverse events, quality of life and function could be included specifically for people with tophi (<a href="./references#CD010069-bbs2-0018" title="AndersonA , SinghJA . Pegloticase for chronic gout. Cochrane Database of Systematic Reviews2010, Issue 3. Art. No: CD008335. [DOI: 10.1002/14651858.CD008335.pub2]">Anderson 2010</a>). </p> <p><a href="./references#CD010069-bbs2-0005" title="SundyJS , BarafHS , YoodRA , EdwardsNL , Gutierrez-UrenaSR , TreadwellEL , et al. Efficacy and tolerability of pegloticase for the treatment of chronic gout in patients refractory to conventional treatment; two randomized controlled trials. Journal of the American Medical Association2011;306:711-20. [ClinicalTrials.gov Identifier NCT00325195]">Sundy 2011</a> has suggested that measurement of serum uric acid prior to infusion may identify people likely to have developed antibodies and, therefore, be at risk of reaction. Future research could also examine this in people with tophi. </p> <p>Results from <a href="./references#CD010069-bbs2-0001" title="BardinT , KeenanRT , KhannaPP , KopickoJ , FungM , BhaktaN , et al. Lesinurad in combination with allopurinol: a randomised, double-blind, placebo-controlled study in patients with gout with inadequate response to standard of care (the multinational CLEAR 2 study). Annals of the Rheumatic Diseases2017;76(5):811-20. [DOI: 10.1136/annrheumdis-2016-209213]">Bardin 2017</a> and <a href="./references#CD010069-bbs2-0004" title="SaagKG , Fitz-PatrickD , KopickoJ , FungM , BhaktaN , AdlerS , et al. Lesinurad combined with allopurinol: a randomized, double-blind, placebo-controlled study in gout patients with an inadequate response to standard-of-care allopurinol (a US-based study). Arthritis &amp; Rheumatology2017;69(1):203-12. [DOI: 10.1002/art.39840]">Saag 2017</a> for lesinurad in combination with allopurinol were not expected. Further RCTs with a larger cohort of participants with tophi at baseline would be useful. </p> <p>The 2012 American College of Rheumatology (ACR) guidelines on management of gout advocated a‐treat‐to‐target strategy for management of gout (<a href="./references#CD010069-bbs2-0025" title="KhannaD , FitzgeraldJD , KhannaPP , BaeS , SinghMK , NeogiT , et al, American College of Rheumatology. 2012 American College of Rheumatology guidelines for management of gout. Part 1: systematic nonpharmacologic and pharmacologic therapeutic approaches to hyperuricemia. Arthritis Care &amp; Research2012;64(10):1431-46.">Khanna 2012</a>), with a lower serum uric acid target for people with tophi. However, our review update has not revealed high‐certainty trial data to support this lower target. This is in line with the more recent 2020 ACR guidelines on management of gout (<a href="./references#CD010069-bbs2-0022" title="FitzGeraldJD , DalbethN , MikulsT , Brignardello-PetersenR , GuyattG , AbelesAM , et al. 2020 American College of Rheumatology Guideline for the Management of Gout. Arthritis Care &amp; Research2020;72(6):744-60.">FitzGerald 2020</a>), which has removed advice for the lower target due to lack of supporting data. </p> </section> </section> </section> <section class="summaryOfFindings"> <div class="section-header section-collapse-header" id="CD010069-sec-0008" lang="en"> <h2 class="title section-collapse-title"> Summary of findings <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="summaryOfFindings" lang="en"> <div class="section-header" id="CD010069-sec-0008"></div> <div class="table" id="CD010069-tbl-0001"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Pegloticase every two weeks (biweekly) compared with placebo for tophi in gout</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Pegloticase every two weeks (biweekly) compared with placebo for tophi in gout</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> participants with tophi in gout<br/><b>Settings:</b> clinic<br/><b>Intervention:</b> pegloticase every two weeks (biweekly)<br/><b>Comparison:</b> placebo </p> </td> </tr> <tr class="separated"> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="center" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>No of participants<br/>(studies)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with placebo</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p>Risk difference with b<b>iweekly pegloticase</b> </p> </th> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Proportion with complete resolution of tophi<br/>Follow‐up: median 6 months </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>74 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>404 per 1000<br/>(104 to 1000) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 5.45<br/>(1.38 to 21.54) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>79<br/>(1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/>MODERATE<sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Biweekly pegloticase probably improves resolution of tophi.</p> <p>Absolute improvement with pegloticase 33% (16% better to 50% better)</p> <p>Relative change 445% (40% better to 2060% better)</p> <p>NNTB 3 (2 to 6)</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Joint pain reduction ‐ not reported</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Reported for all participants but not separately for people with tophi</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Quality of life ‐ not reported</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Reported for all participants but not separately for people with tophi</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Serum urate normalisation ‐ not reported</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Reported for all participants but not separately for people with tophi</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Function ‐ not reported</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Reported for all participants but not separately for people with tophi</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Number of participant withdrawals due to adverse events</p> <p>Follow‐up: median 6 months</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>23 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>177 per 1000<br/>(24 to 1000) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 7.59<br/>(1.04 to 55.55) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>128<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/>MODERATE<sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Biweekly pegloticase probably increases withdrawals due to adverse events.</p> <p>Absolute increase in withdrawals with pegloticase 16% (8% more to 28% more)</p> <p>Relative increase in withdrawals 660% (4% more to 5455% more)</p> <p>NNTH 7 (4 to 16)</p> <p>(Reported for all participants but not separately for those with tophi)</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Total adverse events</p> <p>Follow‐up: 25 weeks</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>953 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>941 per 1000</p> <p>(851 to 1000)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.99 (0.91</p> <p>to 1.07)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>128 (1 RCT)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/>MODERATE<sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Biweekly pegloticase probably results in little or no difference in adverse events.</p> <p>Absolute decrease in adverse events with pegloticase 1% (9% decrease to 7% increase)</p> <p>Relative decrease 1% (10% decrease to 7% increase)</p> <p>NNTH ‐ not applicable</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><b>CI:</b> confidence interval; <b>NNTB:</b> number needed to treat for an additional beneficial outcome; <b>NNTH:</b> number needed to treat for an additional harmful outcome; <b>RR:</b> risk ratio. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/><b>High certainty:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/><b>Moderate certainty:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/><b>Low certainty:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/><b>Very low certainty:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Estimates are from a single study, and wide confidence intervals indicate imprecision. Downgraded by one level. </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD010069-tbl-0002"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Monthly pegloticase compared with placebo for tophi in gout</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Monthly pegloticase compared with placebo for tophi in gout</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> participants with tophi in gout<br/><b>Settings:</b> clinic<br/><b>Intervention:</b> monthly pegloticase<br/><b>Comparison:</b> placebo </p> </td> </tr> <tr class="separated"> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="center" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>No of participants<br/>(studies)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with placebo</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p>Risk difference with m<b>onthly pegloticase</b> </p> </th> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Proportion with complete resolution of tophi<br/>Follow‐up: mean 6 months </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>74 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>212 per 1000<br/>(52 to 889) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 2.86<br/>(0.68, 11.97) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>79<br/>(1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/>MODERATE<sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Monthly pegloticase probably improves resolution of tophi. Absolute improvement with pegloticase: 14% (1% worse to 29% better) </p> <p>Relative change: 190% improvement (30% worse to 1100% better)</p> <p>NNTB 8 (95% CI 4 to 91)</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Joint pain reduction ‐ not reported</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Reported for all participants but not separately for people with tophi</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Quality of life ‐ not reported</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not estimable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Reported for all participants but not separately for people with tophi</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Serum urate normalisation ‐ not reported</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Reported for all participants but not separately for people with tophi</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Function ‐ not reported</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not estimable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Reported for all participants but not separately for people with tophi</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Number of participant withdrawals due to adverse events</p> <p>Follow‐up: mean 6 months</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>23 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>190 per 1000<br/>(166 to 1000) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RR 8.19 <br/>(1.12 to 59.71) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>127<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊕⊝<br/>MODERATE<sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Monthly pegloticase probably increases withdrawals due to adverse events. Absolute increase in withdrawals with pegloticase: 17% (7% to 26%), which was clinically significant. </p> <p>Relative change: 719% more withdrawals (12% more to 5870% more)</p> <p>NNTH 6 (4 to 14)</p> <p>(Reported for all participants but not separately for people with tophi)</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Total adverse events</p> <p>Follow‐up: mean 6 months</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>953 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>1000 per 1000</p> <p>(980 to 1000)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 1.05</p> <p>(0.98 to 1.14)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>127 (1 RCT)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/>MODERATE<sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Monthly pegloticase probably results in little or no difference in adverse events. Absolute increase with pegloticase: 5% (20% decrease to 12% increase) </p> <p>Relative increase 5% (2% decrease to 14% increase)</p> <p>NNTH ‐ not applicable</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><b>CI:</b> confidence interval; <b>NNTB:</b> number needed to treat for an additional beneficial outcome; <b>NNTH:</b> number needed to treat for an additional harmful outcome; <b>RR:</b> risk ratio. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/><b>High certainty:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/><b>Moderate certainty:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/><b>Low certainty:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/><b>Very low certainty:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Estimates are from a single study, and wide confidence intervals indicate imprecision. Downgraded by one level. </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD010069-tbl-0003"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">Lesinurad 200 mg plus allopurinol compared to placebo plus allopurinol for tophi in gout</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Lesinurad 200 mg plus allopurinol compared to placebo plus allopurinol for tophi in gout</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> participants with tophi in gout<br/><b>Setting:</b> clinic<br/><b>Intervention:</b> lesinurad 200 mg plus allopurinol<br/><b>Comparison:</b> placebo plus allopurinol </p> </td> </tr> <tr class="separated"> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="center" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect</b> <br/><b>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>No of participants</b> <br/><b>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence</b> <br/><b>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with allopurinol alone</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk difference with lesinurad 200 mg plus allopurinol</b> </p> </th> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Proportion with complete resolution of a target tophus</p> <p>Follow up: 12 months</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>320 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>128 fewer per 1000<br/>(13 fewer to 1000 more) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RR 0.40 (0.04, 4.57)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>103<br/>(2 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊕⊝<br/>MODERATE<sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Lesinurad 200 mg plus allopurinol is probably not beneficial for the resolution of tophi in gout. Absolute reduction 19% (31% less to 114% more) </p> <p>Relative reduction 60% (96% less to 357% more)</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><br/><b>CI:</b> Confidence interval; <b>RR:</b> Risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> We are very confident that the true effect lies close to that of the estimate of the effect<br/><b>Moderate certainty:</b> We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/><b>Low certainty:</b> Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect<br/><b>Very low certainty:</b> We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Downgraded for imprecision as low number of participants. </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD010069-tbl-0004"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 4.</span> <span class="table-title">Lesinurad 400 mg plus allopurinol compared to placebo plus allopurinol for tophi in gout</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Lesinurad 400 mg plus allopurinol compared to placebo plus allopurinol for tophi in gout</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> participants with tophi in gout<br/><b>Setting:</b> clinic<br/><b>Intervention:</b> lesinurad 400 mg plus allopurinol<br/><b>Comparison:</b> placebo plus allopurinol </p> </td> </tr> <tr class="separated"> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="center" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect</b> <br/><b>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>№ of participants</b> <br/><b>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence</b> <br/><b>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with allopurinol alone</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk difference with lesinurad 400 mg plus allopurinol</b> </p> </th> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Proportion with complete resolution of a target tophus</p> <p>Follow up:12 months</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>320 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>253 per 1000<br/>(134 fewer to 477 more) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.79<br/>(0.42 to 1.49) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>98<br/>(2 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/>MODERATE<sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Lesinurad 400 mg plus allopurinol is probably not beneficial for the resolution of tophi in gout. Absolute reduction 6.7% fewer (18.6% fewer to 15.7% more) </p> <p>Relative reduction 21% fewer (58% fewer to 49% more)</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><br/><b>CI:</b> Confidence interval; <b>RR:</b> Risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> We are very confident that the true effect lies close to that of the estimate of the effect<br/><b>Moderate certainty:</b> We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/><b>Low certainty:</b> Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect<br/><b>Very low certainty:</b> We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>The number of participants with tophi from both studies was small; downgraded by one level for imprecision. </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD010069-tbl-0005"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 5.</span> <span class="table-title">Lesinurad 400 mg plus febuxostat CONTINUED compared to lesinurad 200 mg plus febuxostat CONTINUED for tophi in gout</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Lesinurad 400 mg plus febuxostat CONTINUED compared to lesinurad 200 mg plus febuxostat CONTINUED for tophi in gout</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> participants with tophi in gout<br/><b>Setting:</b> clinic<br/><b>Intervention:</b> lesinurad 400 mg plus febuxostat CONTINUED<br/><b>Comparison:</b> lesinurad 200 mg plus febuxostat CONTINUED </p> </td> </tr> <tr class="separated"> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="center" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect</b> <br/><b>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>№ of participants</b> <br/><b>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence</b> <br/><b>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with lesinurad 200 mg plus febuxostat CONTINUED</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk difference with lesinurad 400 mg plus febuxostat CONTINUED</b> </p> </th> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Proportion with complete resolution of a target tophus</p> <p>Follow up: 12 months</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>594 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>65 more per 1000<br/>(89 fewer to 273 more) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RR 1.11<br/>(0.85 to 1.46) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>129<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊝⊝<br/>LOW<sup>a,b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Lesinurad 400 mg in combination with febuxostat may be beneficial for resolution of tophi in gout. Absolute improvement 7% (10% less to 23% more) </p> <p>Relative improvement 12% (3% less to 19% more)</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Total adverse events</p> <p>Follow up: 12 months</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>781 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>94 more per 1000<br/>(31 fewer to 250 more) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 1.12<br/>(0.96 to 1.32) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>129<br/>(1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/>LOW<sup>a,b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Lesinurad 400 mg in combination with febuxostat may result in little to no difference in adverse events. Absolute increase 9% (3% less to 25% more) </p> <p>Relative increase 12% (8% less to 17% more)</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Number of participant withdrawals due to adverse events</p> <p>Follow up: 12 months</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>156 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>3 fewer per 1000<br/>(88 fewer to 188 more) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.98<br/>(0.44 to 2.20) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>129<br/>(1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/>LOW<sup>a,b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Lesinurad 400 mg in combination with febuxostat may result in little to no difference in withdrawals due to adverse events. Absolute reduction 0.3% (9% less to 188% more) </p> <p>Relative reduction 1.92% (20% less to 20% more)</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean sUA at end of 12 months</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean sUA at end of 12 months was 3.9 mg/dl</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>MD 0.9 mg/dl lower<br/>(1.51 lower to 0.29 lower) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>129<br/>(1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/>LOW<sup>a,b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Lesinurad 400 mg in combination with febuxostat may result in little to no difference in mean serum uric acid. Absolute reduction 0.9% (1.5% lower to 0.3% lower) relative reduction 2.2% (3.75% lower to 0.7% lower)<sup>c</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><br/><b>CI:</b> Confidence interval; <b>RR:</b> Risk ratio;<b>sUA</b>: serum uric acid </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> We are very confident that the true effect lies close to that of the estimate of the effect<br/><b>Moderate certainty:</b> We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/><b>Low certainty:</b> Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect<br/><b>Very low certainty:</b> We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Downgraded for indirectness. Study is an extension trial. There is no placebo arm. Thus unable to assess if interventions are better than placebo.<br/><sup>b</sup>Downgraded for imprecision as low number of participants.<br/><sup>c</sup>Relative change calculated based on mean (SD) sUA in control group (lesinurad 200 mg CONT) at baseline 4 mg/dl (2.2) (<a href="./references#CD010069-bbs2-0003" title="Dalbeth, N, Jones, G, Terkeltaub, R, Khanna, D, Kopicko, J, Bhakta, N et al. Lesinurad, a Selective Uric Acid Reabsorption Inhibitor, in Combination With Febuxostat in Patients With Tophaceous Gout: Findings of a Phase III Clinical Trial. Arthritis &amp; Rheumatology2017;69:1903-13. DalbethN , JonesG , TerkeltaubR , KhannaD , FungM , BaumgartnerS , et al. Efficacy and safety during extended treatment of lesinurad in combination with febuxostat in patients with tophaceous gout: CRYSTAL extension study. Arthritis Research &amp; Therapy2019;21(1):8. [DOI: https://dx.doi.org/10.1186/s13075-018-1788-4]">Dalbeth 2019</a>). ‘CONT’ = patients who continued with the same treatment as given during original CRYSTAL study i.e. febuxostat plus lesinurad or placebo </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD010069-tbl-0006"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 6.</span> <span class="table-title">Lesinurad 400 mg plus febuxostat CROSS compared to lesinurad 200 mg plus febuxostat CROSS for tophi in gout</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Lesinurad 400 mg plus febuxostat CROSS compared to lesinurad 200 mg plus febuxostat CROSS for tophi in gout</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> participants with tophi in gout<br/><b>Setting:</b> clinic<br/><b>Intervention:</b> lesinurad 400 mg plus febuxostat CROSS<br/><b>Comparison:</b> lesinurad 200 mg plus febuxostat CROSS </p> </td> </tr> <tr class="separated"> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="center" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect</b> <br/><b>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>№ of participants</b> <br/><b>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence</b> <br/><b>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with lesinurad 200 mg plus febuxostat CROSS</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk difference with lesinurad 400 mg plus febuxostat CROSS</b> </p> </th> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Proportion with complete resolution of a target tophus</p> <p>Follow up: 12 months</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>424 per 1,000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>76 more per 1,000<br/>(127 fewer to 416 more) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 1.18<br/>(0.70 to 1.98) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>67<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/>LOW<sup>a,b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Lesinurad 400 mg plus febuxostat may be beneficial for resolution of tophi in gout. Absolute improvement 8% (16% less to 31% more) </p> <p>Relative improvement 19% (7% less to 30% more)</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Total adverse events</p> <p>Follow up: 12 months</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>818 per 1,000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>152 more per 1,000<br/>(29 fewer to 178 more) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 1.19 (1.00 to 1.41)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>67<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/>LOW<sup>a,b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Lesinurad 400 mg in combination with febuxostat may result in no difference in adverse events. Absolute increase 15% (2.9% less to 18% better) </p> <p>Relative increase 18.6% (15% less to 23% more)</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Number of participant withdrawals due to adverse events</p> <p>Follow up: 12 months</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>61 per 1,000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>86 more per 1,000<br/>(31 fewer to 429 more)  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 2.43 (0.51 to 11.64)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>67<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/>LOW<sup>a,b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Lesinurad 400 mg plus febuxostat may result in little to no difference in withdrawals due to adverse events. Absolute increase 8.6% (3% less to 43% more) </p> <p>Relative increase 142% (81% less to 221% more)</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean sUA at end of 12 months</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean sUA at end of 12 months was 3.8 mg/dl</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>MD 0.4 mg/dl higher<br/>(0.75 lower to 1.55 higher) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>67<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/>LOW<sup>a,b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Lesinurad 400 mg plus febuxostat may result in no difference in serum uric acid. Absolute difference 0.4% higher (0.75% lower to 1.55% higher) relative difference 0.7% higher (1.4% lower to 2.9% higher)<sup>c</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><br/><b>CI:</b> Confidence interval; <b>RR:</b> Risk ratio; <b>sUA</b>: serum uric acid </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> We are very confident that the true effect lies close to that of the estimate of the effect<br/><b>Moderate certainty:</b> We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/><b>Low certainty:</b> Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect<br/><b>Very low certainty:</b> We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Downgraded for indirectness. This is an extension study with no placebo arm. Therefore we have only been able to compare different interventions against each other.<br/><sup>b</sup>Downgraded for imprecision; number of participants/events was small<br/><sup>c</sup>Relative change calculated based on mean (SD) sUA in control group (lesinurad 200 mg CROSS) at baseline 5.2 mg/dl (1.7) <a href="./references#CD010069-bbs2-0003" title="Dalbeth, N, Jones, G, Terkeltaub, R, Khanna, D, Kopicko, J, Bhakta, N et al. Lesinurad, a Selective Uric Acid Reabsorption Inhibitor, in Combination With Febuxostat in Patients With Tophaceous Gout: Findings of a Phase III Clinical Trial. Arthritis &amp; Rheumatology2017;69:1903-13. DalbethN , JonesG , TerkeltaubR , KhannaD , FungM , BaumgartnerS , et al. Efficacy and safety during extended treatment of lesinurad in combination with febuxostat in patients with tophaceous gout: CRYSTAL extension study. Arthritis Research &amp; Therapy2019;21(1):8. [DOI: https://dx.doi.org/10.1186/s13075-018-1788-4]">Dalbeth 2019</a>. ‘CROSS’ = patients who crossed into different treatment arm, i.e. randomised to receive lesinurad instead of placebo in combination with febuxostat </p> </div> </td> </tr> </tfoot> </table> </div> </section> </section> <section class="background"> <div class="section-header section-collapse-header" id="CD010069-sec-0009" lang="en"> <h2 class="title section-collapse-title"> Background <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="background" lang="en"> <div class="section-header" id="CD010069-sec-0009"></div> <p>This is an update of our original review (<a href="./references#CD010069-bbs2-0031" title="Sriranganathan MK, VinikO , BombardierC , EdwardsCJ . Interventions for tophi in gout. Cochrane Database of Systematic Reviews2014, Issue 10. Art. No: CD010069. [DOI: 10.1002/14651858.CD010069.pub2]">Sriranganathan 2014</a>), which only included one trial. Updated search revealed five new studies for inclusion. </p> <section id="CD010069-sec-0010"> <h3 class="title" id="CD010069-sec-0010">Description of the condition</h3> <p>Gout is the most common type of inflammatory arthritis in men; it affects at least 1% of the population in western countries (<a href="./references#CD010069-bbs2-0030" title="TerkeltaubRA . Gout. New England Journal of Medicine2003;349:1647-55.">Terkeltaub 2003</a>). It is characterised by the formation of monosodium urate crystals in joints and other tissues. The crystals trigger release of pro‐inflammatory cytokines leading to inflammation that causes gouty arthritis. Gouty arthritis can progress to chronic, deforming and physically disabling disease through the development of disfiguring tophi, joint destruction and persistent pain (<a href="./references#CD010069-bbs2-0027" title="SchlesingerN . Difficult-to-treat gouty arthritis: a disease warranting better management. Drugs2011;71(11):1413-39.">Schlesinger 2011</a>). </p> <p>Tophi are nodular masses of monosodium urate. The presence of tophi is common in people with untreated or inadequately controlled gout. Tophi can become infected, cause pain and lead to a decrease in function. Complications may also occur when tophi develop in unusual sites, such as the heart valves, carpal tunnel, larynx and spine. </p> </section> <section id="CD010069-sec-0011"> <h3 class="title" id="CD010069-sec-0011">Description of the intervention</h3> <p>The mainstay of management of tophi is through pharmacological interventions (i.e. urate‐lowering therapy, including purine and non‐purine xanthine oxidase inhibitors (such as allopurinol and febuxostat), uricosuric agents (e.g. probenecid and benzbromarone) and uricases (e.g. pegloticase). However, other interventions such as surgical management are also used in practice. </p> </section> <section id="CD010069-sec-0012"> <h3 class="title" id="CD010069-sec-0012">How the intervention might work</h3> <p>Tophi develop in people with poorly treated or uncontrolled gout. This is postulated to be due to persistently raised serum uric acid levels. Pharmacotherapy aims to reduce serum uric acid levels and thus leads to a reduction in tophi. </p> <p>Surgical therapy may be used for direct removal of tophi, for example, where the presence of tophi have led to a decrease in function, or where there is urgent need for removal, for example, as a cause of spinal cord compression. </p> <p>Other interventions may also work by reducing serum uric acid (e.g. haemodialysis).</p> </section> <section id="CD010069-sec-0013"> <h3 class="title" id="CD010069-sec-0013">Why it is important to do this review</h3> <p>The presence of tophi can lead to significant morbidity, and even mortality through potential complications. Despite this, there have been few systematic reviews to date determining the management of tophi separately from the management of gout. Our original review only included one study looking at a single drug intervention (<a href="./references#CD010069-bbs2-0031" title="Sriranganathan MK, VinikO , BombardierC , EdwardsCJ . Interventions for tophi in gout. Cochrane Database of Systematic Reviews2014, Issue 10. Art. No: CD010069. [DOI: 10.1002/14651858.CD010069.pub2]">Sriranganathan 2014</a>). It is important to update this review for recent evidence on the available interventions for the management of tophi in gout. </p> </section> </section> </section> <section class="objectives"> <div class="section-header section-collapse-header" id="CD010069-sec-0014" lang="en"> <h2 class="title section-collapse-title"> Objectives <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="objectives" lang="en"> <div class="section-header" id="CD010069-sec-0014"></div> <p>To assess the benefits and harms of non‐surgical and surgical treatments for the management of tophi in gout. </p> </section> </section> <section class="methods"> <div class="section-header section-collapse-header" id="CD010069-sec-0015" lang="en"> <h2 class="title section-collapse-title"> Methods <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="methods" lang="en"> <div class="section-header" id="CD010069-sec-0015"></div> <section id="CD010069-sec-0016"> <h3 class="title">Criteria for considering studies for this review</h3> <section id="CD010069-sec-0017"> <h4 class="title">Types of studies</h4> <p>We included all published, randomised controlled trials (RCTs) or controlled clinical trials (CCTs) with pseudo‐randomised methods of allocating people to treatment that considered the management of tophi in gout. Although our original search included other types of studies, for the purpose of this review we only included trials and pseudo‐RCTs for assessment of treatment benefit. </p> </section> <section id="CD010069-sec-0018"> <h4 class="title">Types of participants</h4> <p>Eligible participants were all adults (aged 18 years or older) with a diagnosis of gout and the presence of one or more tophi. Where trials included gout with a subset of people with tophi, we reported on the people with tophi only. </p> </section> <section id="CD010069-sec-0019"> <h4 class="title">Types of interventions</h4> <p> <ul id="CD010069-list-0001"> <li> <p>Pharmacotherapy (i.e. urate‐lowering therapy including purine and non‐purine xanthine oxidase inhibitors, uricosuric agents and uricases). </p> </li> <li> <p>Any form of surgical removal (e.g. debridement, shaving, arthroscopic removal).</p> </li> </ul> </p> <p>Comparators were:</p> <p> <ul id="CD010069-list-0002"> <li> <p>placebo;</p> </li> <li> <p>one pharmacological or surgical intervention versus another;</p> </li> <li> <p>combination versus single intervention or another combination therapy. </p> </li> </ul> </p> </section> <section id="CD010069-sec-0020"> <h4 class="title">Types of outcome measures</h4> <section id="CD010069-sec-0021"> <h5 class="title">Major outcomes</h5> <p> <ul id="CD010069-list-0003"> <li> <p>Proportion of people with complete resolution of tophi</p> </li> <li> <p>Pain reduction </p> </li> <li> <p>Health‐related quality of life </p> </li> <li> <p>Serum urate normalisation </p> </li> <li> <p>Function (i.e. activity limitation)</p> </li> <li> <p>Study participant withdrawal due to adverse events (e.g. wound infection, failure to close or surgical complications, infusion reactions) </p> </li> <li> <p>Total adverse events </p> </li> </ul> </p> </section> <section id="CD010069-sec-0022"> <h5 class="title">Minor outcomes</h5> <p> <ul id="CD010069-list-0004"> <li> <p>Proportion of people with recurrence</p> </li> <li> <p>Time to recurrence</p> </li> </ul> </p> </section> </section> </section> <section id="CD010069-sec-0023"> <h3 class="title">Search methods for identification of studies</h3> <section id="CD010069-sec-0024"> <h4 class="title">Electronic searches</h4> <p>We searched a registry of all randomised controlled trials in gout, established by Cochrane Musculoskeletal to facilitate the updates of a series of reviews of interventions for gout, including this review update. </p> <p>The search for the gout registry was designed not to include terms for any interventions, in order to establish a registry of all randomised trials in this condition, regardless of the intervention. </p> <p>The following electronic databases were searched to establish the registry. The search strategy combined standard Cochrane search filters for 'gout' and 'randomised trial', with no language restrictions. </p> <p>Details of our original search can be found in <a href="./appendices#CD010069-sec-0098">Appendix 1</a>. The new search was limited to 1 July 2011 to 28 August 2020. </p> <p> <ol id="CD010069-list-0005"> <li> <p>Cochrane Central Register of Controlled Trials (CENTRAL, via the Cochrane Library) (<a href="./appendices#CD010069-sec-0099">Appendix 2</a>) </p> </li> <li> <p>Ovid MEDLINE (<a href="./appendices#CD010069-sec-0100">Appendix 3</a>) </p> </li> <li> <p>Embase (<a href="./appendices#CD010069-sec-0101">Appendix 4</a>) </p> </li> </ol> </p> <p>We searched the Clinicaltrials.gov trial registry (<a href="https://clinicaltrials.gov/" target="_blank">clinicaltrials.gov/</a>) to 28 August 2020. We did not exclude studies based on language. </p> </section> <section id="CD010069-sec-0025"> <h4 class="title">Searching other resources</h4> <p>We also conducted handsearches of references from included articles and relevant reviews to identify any additional studies not retrieved by the search strategies. </p> </section> </section> <section id="CD010069-sec-0026"> <h3 class="title" id="CD010069-sec-0026">Data collection and analysis</h3> <section id="CD010069-sec-0027"> <h4 class="title">Selection of studies</h4> <p>Editorial staff from Cochrane Musculoskeletal initially screened titles and abstracts in gout registry and retrieved the full text for all records they identified as randomised controlled trials of an intervention for people with gout, and retrieved the full texts. Editorial staff annotated the population, intervention and comparator for each full text article, and assigned it to the appropriate gout review in Covidence (<a href="http://www.covidence.org/" target="_blank">www.covidence.org</a>). Two independent review authors (MS, OV) retrieved all relevant articles in full text for closer examination. We resolved disagreements about study inclusion or exclusion by consensus or by discussion with a third review author (CE) if needed. We did not need to translate any studies into English. </p> </section> <section id="CD010069-sec-0028"> <h4 class="title">Data extraction and management</h4> <p>Two independent review authors (MS, OV) extracted the following information from included trials using <a href="./references#CD010069-bbs2-0020" title="Veritas Health InnovationCovidence. Version accessed September 2020. Melbourne, Australia: Veritas Health Innovation. Available at covidence.org.">Covidence</a>: </p> <p> <ul id="CD010069-list-0006"> <li> <p>study design;</p> </li> <li> <p>characteristics of the study population (age, gender, number and distribution of tophi);</p> </li> <li> <p>intervention used;</p> </li> <li> <p>control interventions;</p> </li> <li> <p>outcome measures;</p> </li> <li> <p>timing of outcome assessment; and</p> </li> <li> <p>methodological domains relevant to risk of bias assessment.</p> </li> </ul> </p> <p>We resolved any differences in data extraction by referring back to the original articles and establishing consensus. We consulted a third review author (CE) to help resolve differences if necessary. </p> </section> <section id="CD010069-sec-0029"> <h4 class="title">Assessment of risk of bias in included studies</h4> <p>We assessed the potential for bias in included studies using a risk of bias table (<a href="./references#CD010069-bbs2-0024" title="HigginsJP , GreenS , editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration. Available from training.cochrane.org/handbook/archive/v5.1/.">Higgins 2011</a>). Two review authors (MS, OV) independently assessed the risk of bias for all included trials, and resolved any disagreements by consensus. We consulted a third review author (CE) to help resolve differences if necessary. We assessed the following methodological domains in conformity with Cochrane's recommendations (<a href="./references#CD010069-bbs2-0024" title="HigginsJP , GreenS , editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration. Available from training.cochrane.org/handbook/archive/v5.1/.">Higgins 2011</a>). </p> <p> <ol id="CD010069-list-0007"> <li> <p>Random sequence generation: to determine if the method of generating the randomisation sequence was adequate to prevent biased allocation to interventions. </p> </li> <li> <p>Allocation concealment: to determine if adequate methods were used to conceal allocation to interventions. </p> </li> <li> <p>Blinding of participants, personnel and outcome assessors for each outcome measure.</p> </li> <li> <p>Incomplete outcome data.</p> </li> <li> <p>Selective outcome reporting.</p> </li> <li> <p>Other potential sources of bias, such as inappropriate administration of an intervention or insensitive instrument to measure outcome. </p> </li> </ol> </p> <p>To determine the risk of bias of an included study, for each criterion we evaluated the presence of sufficient information and the likelihood of potential bias. We rated each criterion as 'low risk' of bias, 'high risk' of bias or 'unclear risk' of bias (either lack of information or uncertainty over the potential for bias). </p> </section> <section id="CD010069-sec-0030"> <h4 class="title">Measures of treatment effect</h4> <p>For dichotomous outcomes, we calculated the risk ratio (RR) with corresponding 95% confidence intervals (CIs) and numbers needed to treat for an additional beneficial (NNTB) or harmful (NNTH) outcome. We calculated the absolute per cent change from the difference in risks between the intervention and control group using GRADEpro (<a href="./references#CD010069-bbs2-0023" title="McMaster University (developed by EvidencePrime)GRADEpro GDT. Version accessed January 2021. Hamilton (ON): McMaster University (developed by EvidencePrime). Available at gradepro.org.">GRADEpro GDT</a>), and expressed this as a percentage. We calculated the relative per cent change as the risk ratio − 1, and expressed this as a percentage. </p> <p>For continuous outcomes, we calculated the mean difference (MD) and 95% CI if trials measured the outcome on the same scale, and planned to use the standardised mean difference (SMD) and 95% CI for continuous outcomes reported on different scales. We planned to back‐translate the SMDs to a typical scale (e.g. 0 to 10 for pain) by multiplying the SMD by a typical among‐person standard deviation (e.g. the standard deviation of the control group at baseline from the most representative trial). We calculated the absolute benefit as the improvement in the intervention group minus the improvement in the control group, in the original units, expressed as a percentage. We calculated the relative difference in the change from baseline as the absolute benefit divided by the baseline mean of the control group, expressed as a percentage. </p> <p>In the <a href="#CD010069-sec-0053">Effects of interventions</a> results section and the comments column of the summary of findings table, we provided the absolute per cent difference, the relative per cent change from baseline, and the NNTB or NNTH if the outcome showed a clinically significant difference. For dichotomous outcomes, we calculated the NNTB or NNTH from the control group event rate and the relative risk using the Visual Rx NNT calculator (<a href="./references#CD010069-bbs2-0019" title="Cates 2008. Visual Rx [Computer program]. Version 3; 2008. Available at: www.nntonline.net.">Cates 2008</a>). </p> </section> <section id="CD010069-sec-0031"> <h4 class="title">Unit of analysis issues</h4> <p>We compared each treatment arm against placebo in separate analyses. Where a single trial reported multiple arms, we included only the relevant arms. If two comparisons were to be combined in the same meta‐analysis, we planned to halve the control group to avoid double‐counting. Where there were multiple interventions we also compared one intervention versus another. </p> </section> <section id="CD010069-sec-0032"> <h4 class="title">Dealing with missing data</h4> <p>We did not need to deal with missing data.</p> </section> <section id="CD010069-sec-0033"> <h4 class="title">Assessment of heterogeneity</h4> <p>We planned to assess clinical and methodological diversity in terms of participants, interventions, outcomes and study characteristics for the included studies, to determine whether a meta‐analysis was appropriate. We assessed statistical heterogeneity by visual inspection of the forest plot to assess for obvious differences in results between the studies, and used the I<sup>2</sup> and Chi<sup>2</sup> statistical tests.<br/>As recommended in the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD010069-bbs2-0021" title="Deeks JJ, Higgins JP, Altman DG, editor(s). Chapter 10: Analysing data and undertaking meta-analyses. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA, editor(s). Cochrane Handbook for Systematic Reviews of Interventions version 6.1 (updated September 2020). Cochrane, 2020. Available from www.training.cochrane.org/handbook.">Deeks 2020</a>), we used the interpretation of an I<sup>2</sup> value of 0% to 40% to indicate that heterogeneity 'might not be important'; 30% to 60% may represent 'moderate' heterogeneity; 50% to 90% may represent 'substantial' heterogeneity; and 75% to 100% represents 'considerable' heterogeneity. The importance of I<sup>2</sup> depends on: (i) the magnitude and direction of effects and (ii) the strength of evidence for heterogeneity. We used the Chi<sup>2</sup> test, where a P value of 0.10 or less indicated evidence of statistical heterogeneity. </p> </section> <section id="CD010069-sec-0034"> <h4 class="title">Assessment of reporting biases</h4> <p>In order to determine whether reporting bias was present, we searched trial registries for trial protocols to determine whether the protocol of the RCT was published before the trial started recruitment of participants. We evaluated whether selective reporting of outcomes was present (outcome reporting bias). We planned to compare the fixed‐effect estimate against the random‐effects model. In the event of the possible presence of small sample bias in the published literature (i.e. in which the intervention effect was more beneficial in smaller studies), the random‐effects estimate of the intervention is more beneficial than the fixed‐effect estimate (<a href="./references#CD010069-bbs2-0026" title="PageMJ , HigginsJP , SterneJA . Chapter 13: Assessing risk of bias due to missing results in a synthesis. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA, editor(s). Cochrane Handbook for Systematic Reviews of Interventions version 6.1 (updated September 2020). Cochrane, 2020. Available from www.training.cochrane.org/handbook.">Page 2020</a>). </p> <p>We were unable to explore the potential for reporting bias by funnel plots further due to lack of data. </p> </section> <section id="CD010069-sec-0035"> <h4 class="title">Data synthesis</h4> <p>We planned to perform meta‐analyses using a random‐effects model, regardless of the results of the I<sup>2</sup> statistic. We were able to include two studies for meta‐analysis. We presented analyses of all outcomes (<a href="#CD010069-sec-0020">Types of outcome measures</a>) for people with tophi from all studies in forest plots. </p> </section> <section id="CD010069-sec-0036"> <h4 class="title">Subgroup analysis and investigation of heterogeneity</h4> <p>We planned subgroup analyses to study the effect of serum urate levels on tophus regression, or rate of tophi recurrence following surgical treatment. Two studies had similar interventions. However, tophus regression was the only outcome reported for people with tophi in these studies, and there were insufficient studies to do the planned subgroup analyses. </p> </section> <section id="CD010069-sec-0037"> <h4 class="title">Sensitivity analysis</h4> <p>There were insufficient studies to conduct sensitivity analysis.</p> </section> <section id="CD010069-sec-0038"> <h4 class="title">Summary of findings and assessment of the certainty of the evidence</h4> <p>We produced summary of findings tables using GRADEpro software (<a href="./references#CD010069-bbs2-0023" title="McMaster University (developed by EvidencePrime)GRADEpro GDT. Version accessed January 2021. Hamilton (ON): McMaster University (developed by EvidencePrime). Available at gradepro.org.">GRADEpro GDT</a>). As recommended by Cochrane (<a href="./references#CD010069-bbs2-0028" title="SchünemannHJ , HigginsJP , VistGE , GlasziouP , AklEA , SkoetzN , et al. Chapter 14: Completing ‘Summary of findings’ tables and grading the certainty of the evidence. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA, editor(s). Cochrane Handbook for Systematic Reviews of Interventions version 6.1 (updated September 2020). Cochrane, 2020. Available from www.training.cochrane.org/handbook.">Schünemann 2020a</a>), the tables provide key information concerning the certainty of evidence, the magnitude of effect of the interventions examined, and the sum of available data on the most important participant‐relevant outcomes (number of participants with complete resolution of tophi, joint pain reduction, number of study participant withdrawals due to adverse events, total adverse events, health‐related quality of life, serum urate normalisation and function). </p> <p>The summary of findings tables include an overall grading of the evidence related to each of the main outcomes using the GRADE approach (<a href="./references#CD010069-bbs2-0029" title="SchünemannHJ , VistGE , HigginsJP , SantessoN , DeeksJJ , GlasziouP , et al. Chapter 15: Interpreting results and drawing conclusions. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA, editor(s). Cochrane Handbook for Systematic Reviews of Interventions version 6.1 (updated September 2020). Cochrane, 2020. Available from www.training.cochrane.org/handbook..">Schünemann 2020b</a>). Two people (MS, OV) independently assessed the certainty of the evidence. We used the five GRADE considerations (study limitations, consistency of effect, imprecision, indirectness and publication bias) to assess the certainty of the body of evidence as it relates to the studies which contribute data to the meta‐analyses for the prespecified outcomes. We reported the certainty of evidence as high, moderate, low, or very low. We used methods and recommendations described in the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD010069-bbs2-0028" title="SchünemannHJ , HigginsJP , VistGE , GlasziouP , AklEA , SkoetzN , et al. Chapter 14: Completing ‘Summary of findings’ tables and grading the certainty of the evidence. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA, editor(s). Cochrane Handbook for Systematic Reviews of Interventions version 6.1 (updated September 2020). Cochrane, 2020. Available from www.training.cochrane.org/handbook.">Schünemann 2020a</a>). We justified all decisions to downgrade the certainty of studies using footnotes to aid the reader's understanding of the review where necessary. We provided the NNTB or NNTH and the absolute and relative per cent change in the comments column of the summary of findings tables, as described in the <a href="#CD010069-sec-0030">Measures of treatment effect</a> section above. </p> </section> </section> </section> </section> <section class="results"> <div class="section-header section-collapse-header" id="CD010069-sec-0039" lang="en"> <h2 class="title section-collapse-title"> Results <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="results" lang="en"> <div class="section-header" id="CD010069-sec-0039"></div> <section id="CD010069-sec-0040"> <h3 class="title">Description of studies</h3> <section id="CD010069-sec-0041"> <h4 class="title">Results of the search</h4> <p>Cochrane Musculoskeletal updated the search for all gout review updates on 28 August 2020, searching for studies from July 2011 to August 2020 (<a href="#CD010069-fig-0001">Figure 1</a>). The new search identified 4511 studies from Cochrane Central (849), MEDLINE (2125) and Embase (1537) databases. We screened 3181 records after duplicates were removed and assessed 531 potentially eligible full texts, of which we included four studies and excluded 523 articles (326 because the intervention was ineligible, 189 because the study design was not of interest, six because the population was not eligible, and two studies which used an ineligible comparator). There are four ongoing studies (<a href="./references#CD010069-bbs2-0014" title="A long-term extension study of lesinurad in combination with allopurinol for subjects completing an efficacy and safety study of lesinurad and allopurinol. Ongoing study. February 2013. Contact author for more information.">CLEAR I and II Extension</a>; <a href="./references#CD010069-bbs2-0015" title="A study of SEL-212 in patients with gout refractory to conventional therapy (DISSOLVE I). Ongoing study. 18 August 2020. Contact author for more information.">DISSOLVE I</a>; <a href="./references#CD010069-bbs2-0016" title="A study of SEL-212 in patients with gout refractory to conventional therapy II (DISSOLVE II). Ongoing study. October 2020. Contact author for more information.">DISSOLVE II</a>; <a href="./references#CD010069-bbs2-0017" title="A randomized, double-Blind, placebo-controlled, multicenter, efficacy and safety study of methotrexate to increase response rates in patients with uncontrolled gout receiving KRYSTEXXA® (Pegloticase) (MIRROR Randomized Controlled Trial (RCT)). Ongoing study. 13 June 2019. Contact author for more information.">MIRROR RCT</a>), which we have described in the <a href="./references#CD010069-sec-0113" title="">Characteristics of ongoing studies</a> table. </p> <div class="figure" id="CD010069-fig-0001"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 1</div> </div> <hr class="top"/><img alt="PRISMA Flow diagram for updated search 2020" data-id="CD010069-fig-0001" src="/cdsr/doi/10.1002/14651858.CD010069.pub3/media/CDSR/CD010069/image_n/nCD010069-FIG-01.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>PRISMA Flow diagram for updated search 2020</p> </div> </div> </div> <p>One study was included in the original review by <a href="./references#CD010069-bbs2-0031" title="Sriranganathan MK, VinikO , BombardierC , EdwardsCJ . Interventions for tophi in gout. Cochrane Database of Systematic Reviews2014, Issue 10. Art. No: CD010069. [DOI: 10.1002/14651858.CD010069.pub2]">Sriranganathan 2014</a>. We included four more trials in this update, so there are five included studies overall in this review update. Details of the search for the original review are given in <a href="./appendices#CD010069-sec-0098">Appendix 1</a>. </p> </section> <section id="CD010069-sec-0042"> <h4 class="title">Included studies</h4> <section id="CD010069-sec-0043"> <h5 class="title">Design</h5> <p>We included five trials (1796 participants) in this review update. All five studies were randomised controlled trials (RCTs). <a href="./references#CD010069-bbs2-0003" title="Dalbeth, N, Jones, G, Terkeltaub, R, Khanna, D, Kopicko, J, Bhakta, N et al. Lesinurad, a Selective Uric Acid Reabsorption Inhibitor, in Combination With Febuxostat in Patients With Tophaceous Gout: Findings of a Phase III Clinical Trial. Arthritis &amp; Rheumatology2017;69:1903-13. DalbethN , JonesG , TerkeltaubR , KhannaD , FungM , BaumgartnerS , et al. Efficacy and safety during extended treatment of lesinurad in combination with febuxostat in patients with tophaceous gout: CRYSTAL extension study. Arthritis Research &amp; Therapy2019;21(1):8. [DOI: https://dx.doi.org/10.1186/s13075-018-1788-4]">Dalbeth 2019</a> was an extension of an RCT (Combination Treatment Study in Subjects with Subcutaneous Tophaceous Gout with Lesinurad and Febuxostat (CRYSTAL study). <a href="./references#CD010069-bbs2-0005" title="SundyJS , BarafHS , YoodRA , EdwardsNL , Gutierrez-UrenaSR , TreadwellEL , et al. Efficacy and tolerability of pegloticase for the treatment of chronic gout in patients refractory to conventional treatment; two randomized controlled trials. Journal of the American Medical Association2011;306:711-20. [ClinicalTrials.gov Identifier NCT00325195]">Sundy 2011</a> reported on the pooled results of two replicate randomised, double‐blind placebo‐controlled trials. <a href="./references#CD010069-bbs2-0001" title="BardinT , KeenanRT , KhannaPP , KopickoJ , FungM , BhaktaN , et al. Lesinurad in combination with allopurinol: a randomised, double-blind, placebo-controlled study in patients with gout with inadequate response to standard of care (the multinational CLEAR 2 study). Annals of the Rheumatic Diseases2017;76(5):811-20. [DOI: 10.1136/annrheumdis-2016-209213]">Bardin 2017</a> and <a href="./references#CD010069-bbs2-0004" title="SaagKG , Fitz-PatrickD , KopickoJ , FungM , BhaktaN , AdlerS , et al. Lesinurad combined with allopurinol: a randomized, double-blind, placebo-controlled study in gout patients with an inadequate response to standard-of-care allopurinol (a US-based study). Arthritis &amp; Rheumatology2017;69(1):203-12. [DOI: 10.1002/art.39840]">Saag 2017</a> were both RCTs with similar interventions. <a href="./references#CD010069-bbs2-0002" title="BeckerMA , Schumacher HR Jr, WortmannRL , MacDonaldPA , EustaceD , PaloWA , StreitJ , Joseph-RidgeN . Febuxostat compared with allopurinol in patients with hyperuricemia and gout. New England Journal of Medicine December 8, 2005;353(23):2450-61. ">Becker 2005</a> reported on the FACT (Febuxostat versus Allopurinol Controlled Trial) study, another RCT.  </p> </section> <section id="CD010069-sec-0044"> <h5 class="title">Interventions</h5> <p>Details of interventions for each trial are presented in the <a href="./references#CD010069-sec-0111" title="">Characteristics of included studies</a> table. </p> <p><a href="./references#CD010069-bbs2-0005" title="SundyJS , BarafHS , YoodRA , EdwardsNL , Gutierrez-UrenaSR , TreadwellEL , et al. Efficacy and tolerability of pegloticase for the treatment of chronic gout in patients refractory to conventional treatment; two randomized controlled trials. Journal of the American Medical Association2011;306:711-20. [ClinicalTrials.gov Identifier NCT00325195]">Sundy 2011</a> reported on the efficacy and tolerability of pegloticase in people with chronic gout that was refractory to traditional urate‐lowering therapy. A subset of these participants had one or more tophi at baseline. </p> <p><a href="./references#CD010069-bbs2-0001" title="BardinT , KeenanRT , KhannaPP , KopickoJ , FungM , BhaktaN , et al. Lesinurad in combination with allopurinol: a randomised, double-blind, placebo-controlled study in patients with gout with inadequate response to standard of care (the multinational CLEAR 2 study). Annals of the Rheumatic Diseases2017;76(5):811-20. [DOI: 10.1136/annrheumdis-2016-209213]">Bardin 2017</a> and <a href="./references#CD010069-bbs2-0004" title="SaagKG , Fitz-PatrickD , KopickoJ , FungM , BhaktaN , AdlerS , et al. Lesinurad combined with allopurinol: a randomized, double-blind, placebo-controlled study in gout patients with an inadequate response to standard-of-care allopurinol (a US-based study). Arthritis &amp; Rheumatology2017;69(1):203-12. [DOI: 10.1002/art.39840]">Saag 2017</a> both reported on the efficacy of lesinurad in combination with allopurinol versus allopurinol alone in people with chronic gout. A subset of these participants had one or more tophi at baseline. </p> <p><a href="./references#CD010069-bbs2-0003" title="Dalbeth, N, Jones, G, Terkeltaub, R, Khanna, D, Kopicko, J, Bhakta, N et al. Lesinurad, a Selective Uric Acid Reabsorption Inhibitor, in Combination With Febuxostat in Patients With Tophaceous Gout: Findings of a Phase III Clinical Trial. Arthritis &amp; Rheumatology2017;69:1903-13. DalbethN , JonesG , TerkeltaubR , KhannaD , FungM , BaumgartnerS , et al. Efficacy and safety during extended treatment of lesinurad in combination with febuxostat in patients with tophaceous gout: CRYSTAL extension study. Arthritis Research &amp; Therapy2019;21(1):8. [DOI: https://dx.doi.org/10.1186/s13075-018-1788-4]">Dalbeth 2019</a> was an extension study looking at the efficacy of lesinurad in combination with febuxostat in people with tophaceous gout. </p> <p><a href="./references#CD010069-bbs2-0002" title="BeckerMA , Schumacher HR Jr, WortmannRL , MacDonaldPA , EustaceD , PaloWA , StreitJ , Joseph-RidgeN . Febuxostat compared with allopurinol in patients with hyperuricemia and gout. New England Journal of Medicine December 8, 2005;353(23):2450-61. ">Becker 2005</a> studied Febuxostat in comparison to allopurinol in participants with gout. A subset of these participants had history or presence of tophi.  </p> </section> <section id="CD010069-sec-0045"> <h5 class="title">Participants</h5> <p>All participants in the included studies were aged 18 years or older. <a href="./references#CD010069-bbs2-0005" title="SundyJS , BarafHS , YoodRA , EdwardsNL , Gutierrez-UrenaSR , TreadwellEL , et al. Efficacy and tolerability of pegloticase for the treatment of chronic gout in patients refractory to conventional treatment; two randomized controlled trials. Journal of the American Medical Association2011;306:711-20. [ClinicalTrials.gov Identifier NCT00325195]">Sundy 2011</a> included a total of 262 participants in the study, of whom 225 participants were randomised. The primary efficacy endpoint was normalisation of plasma uric acid, and secondary efficacy endpoints included reduction in tophi, gout flares, and improvement in physical function and quality of life. One hundred and thirty‐one participants had tophi at baseline; 52 in the pegloticase every two weeks (biweekly) group, 52 in the monthly pegloticase group and 27 in the placebo group. <a href="./references#CD010069-bbs2-0001" title="BardinT , KeenanRT , KhannaPP , KopickoJ , FungM , BhaktaN , et al. Lesinurad in combination with allopurinol: a randomised, double-blind, placebo-controlled study in patients with gout with inadequate response to standard of care (the multinational CLEAR 2 study). Annals of the Rheumatic Diseases2017;76(5):811-20. [DOI: 10.1136/annrheumdis-2016-209213]">Bardin 2017</a> had a total of 610 participants; 77 of these had one or more tophi at baseline. <a href="./references#CD010069-bbs2-0004" title="SaagKG , Fitz-PatrickD , KopickoJ , FungM , BhaktaN , AdlerS , et al. Lesinurad combined with allopurinol: a randomized, double-blind, placebo-controlled study in gout patients with an inadequate response to standard-of-care allopurinol (a US-based study). Arthritis &amp; Rheumatology2017;69(1):203-12. [DOI: 10.1002/art.39840]">Saag 2017</a> had a similar number of participants at 603; 54 of these had one or more tophi at baseline. 193 participants enrolled for the <a href="./references#CD010069-bbs2-0003" title="Dalbeth, N, Jones, G, Terkeltaub, R, Khanna, D, Kopicko, J, Bhakta, N et al. Lesinurad, a Selective Uric Acid Reabsorption Inhibitor, in Combination With Febuxostat in Patients With Tophaceous Gout: Findings of a Phase III Clinical Trial. Arthritis &amp; Rheumatology2017;69:1903-13. DalbethN , JonesG , TerkeltaubR , KhannaD , FungM , BaumgartnerS , et al. Efficacy and safety during extended treatment of lesinurad in combination with febuxostat in patients with tophaceous gout: CRYSTAL extension study. Arthritis Research &amp; Therapy2019;21(1):8. [DOI: https://dx.doi.org/10.1186/s13075-018-1788-4]">Dalbeth 2019</a> extension study.  In <a href="./references#CD010069-bbs2-0002" title="BeckerMA , Schumacher HR Jr, WortmannRL , MacDonaldPA , EustaceD , PaloWA , StreitJ , Joseph-RidgeN . Febuxostat compared with allopurinol in patients with hyperuricemia and gout. New England Journal of Medicine December 8, 2005;353(23):2450-61. ">Becker 2005</a>, 762 participants were randomised to treatment. 183 participants had history or presence of tophi at baseline. 156 participants were assessed for tophus outcomes.  </p> <p>In <a href="./references#CD010069-bbs2-0005" title="SundyJS , BarafHS , YoodRA , EdwardsNL , Gutierrez-UrenaSR , TreadwellEL , et al. Efficacy and tolerability of pegloticase for the treatment of chronic gout in patients refractory to conventional treatment; two randomized controlled trials. Journal of the American Medical Association2011;306:711-20. [ClinicalTrials.gov Identifier NCT00325195]">Sundy 2011</a>, participants were recruited from rheumatology practices across the USA, Canada and Mexico between June 2006 and October 2007. They met the following criteria for refractory gout: baseline serum uric acid (sUA) 8.0 mg/dL or greater; contraindication to treatment with allopurinol or history of failure to normalise uric acid despite three months or more with maximal medically appropriate allopurinol dose (determined by the participant's physician); at least one of the following: a) three or more self‐reported gout flares during previous 12 to 18 months; b) one or more tophi; c) gouty arthropathy defined clinically or radiographically as joint damage due to gout. Participants who were on urate‐lowering therapy at the time of screening underwent a one‐week washout period prior to entering study. </p> <p><a href="./references#CD010069-bbs2-0004" title="SaagKG , Fitz-PatrickD , KopickoJ , FungM , BhaktaN , AdlerS , et al. Lesinurad combined with allopurinol: a randomized, double-blind, placebo-controlled study in gout patients with an inadequate response to standard-of-care allopurinol (a US-based study). Arthritis &amp; Rheumatology2017;69(1):203-12. [DOI: 10.1002/art.39840]">Saag 2017</a> and <a href="./references#CD010069-bbs2-0001" title="BardinT , KeenanRT , KhannaPP , KopickoJ , FungM , BhaktaN , et al. Lesinurad in combination with allopurinol: a randomised, double-blind, placebo-controlled study in patients with gout with inadequate response to standard of care (the multinational CLEAR 2 study). Annals of the Rheumatic Diseases2017;76(5):811-20. [DOI: 10.1136/annrheumdis-2016-209213]">Bardin 2017</a> included participants who were currently on a stable dose of allopurinol deemed suitable by the treating physician. An sUA level of 6.5 mg/dl at screening and 6.0 mg/dl seven days prior to the start of treatment on day one was required. Participants must have reported two or more gout flares during the previous 12 months. </p> <p><a href="./references#CD010069-bbs2-0003" title="Dalbeth, N, Jones, G, Terkeltaub, R, Khanna, D, Kopicko, J, Bhakta, N et al. Lesinurad, a Selective Uric Acid Reabsorption Inhibitor, in Combination With Febuxostat in Patients With Tophaceous Gout: Findings of a Phase III Clinical Trial. Arthritis &amp; Rheumatology2017;69:1903-13. DalbethN , JonesG , TerkeltaubR , KhannaD , FungM , BaumgartnerS , et al. Efficacy and safety during extended treatment of lesinurad in combination with febuxostat in patients with tophaceous gout: CRYSTAL extension study. Arthritis Research &amp; Therapy2019;21(1):8. [DOI: https://dx.doi.org/10.1186/s13075-018-1788-4]">Dalbeth 2019</a> included participants who had completed the original CRYSTAL study which was a phase III randomised, double‐blind, placebo‐controlled combination trial evaluating the efficacy and safety of Lesinurad in combination with Febuxostat. Participants who successfully completed the original phase III study either continued on the same treatment as the original study (CONT arm) or were randomised to receive Lesinurad instead of placebo in combination with Febuxostat (CROSS arm) in the CRYSTAL extension study. Criteria required sUA to be ≥ 8.0 mg/dl for participants not receiving urate‐lowering therapy (ULT) and ≥ 6.0 mg/dl for those receiving ULT prior to the original study. Participants were also required to have at least one measurable tophus on the hands/wrists or feet/ankles between 5mm and 20mm in length. </p> <p><a href="./references#CD010069-bbs2-0002" title="BeckerMA , Schumacher HR Jr, WortmannRL , MacDonaldPA , EustaceD , PaloWA , StreitJ , Joseph-RidgeN . Febuxostat compared with allopurinol in patients with hyperuricemia and gout. New England Journal of Medicine December 8, 2005;353(23):2450-61. ">Becker 2005</a> recruited participants from 112 centres across United States and Canada. Participants were required meet preliminary criteria of American College of Rheumatology for acute arthritis of gout and to have serum uric acid of at least 8.0mg/dL. Participants already receiving urate lowering therapy underwent a two week washout period prior to randomisation.  </p> </section> </section> <section id="CD010069-sec-0046"> <h4 class="title">Excluded studies</h4> <p>We have provided a description of excluded studies in the <a href="./references#CD010069-sec-0112" title="">Characteristics of excluded studies</a> table. These are studies that a reader might reasonably expect to find in this review, rather than a comprehensive list of all the studies we excluded. Six studies did not include participants with tophi (<a href="./references#CD010069-bbs2-0007" title="FleischmannR , WinkleP , MinerJN , YanX , HicksL , ValdezS , et al. Pharmacodynamic and pharmacokinetic effects and safety of verinurad in combination with allopurinol in adults with gout: a phase IIa, open-label study. Rheumatic &amp; Musculoskeletal Diseases Open2018;4(1):e000584. ">Fleischmann 2018</a>; <a href="./references#CD010069-bbs2-0008" title="HaberSL , FenteG , FentonSN , WalkerEP , WeaverBM , CanoAJ , et al. Lesinurad: a novel agent for management of chronic gout. Annals of Pharmacotherapy2018;52(7):690-6. ">Haber 2018</a>; <a href="./references#CD010069-bbs2-0009" title="HaoG , DuanW , SunJ , LiuJ , PengB . Effects of febuxostat on serum cytokines IL-1, IL-4, IL-6, IL-8, TNF-α and COX-2. Experimental and Therapeutic Medicine2019;17(1):812-6. ">Hao 2019</a>; <a href="./references#CD010069-bbs2-0011" title="KankamM , HallJ , GillenM , YangX , ShenZ , LeeC , et al. Pharmacokinetics, pharmacodynamics, and tolerability of concomitant multiple dose administration of verinurad (RDEA3170) and allopurinol in adult male subjects with gout. Journal of Clinical Pharmacology2018;58(9):1214-22. ">Kankam 2018</a>; <a href="./references#CD010069-bbs2-0012" title="TimilsinaS , BrittanK , O'DellJR , BrophyM , Davis-KarimA , HenrieAM , et al. Design and rationale for the Veterans Affairs &quot;Cooperative study program 594 comparative effectiveness in gout: allopurinol vs. febuxostat&quot; trial. Contemporary Clinical Trials2018;68:102-8. ">Timilsina 2018</a>; <a href="./references#CD010069-bbs2-0013" title="WhiteWB , SaagKG , BeckerMA , BorerJS , GorelickPB , WheltonA , et al, CARES Investigators. Cardiovascular safety of febuxostat or allopurinol in patients with gout. New England Journal of Medicine2018;378(13):1200-10. ">White 2018</a>), and two studies had the wrong comparator (<a href="./references#CD010069-bbs2-0006" title="DohertyM , JenkinsW , RichardsonH , SarmanovaA , AbhishekA , AshtonD , et al. Efficacy and cost-effectiveness of nurse-led care involving education and engagement of patients and a treat-to-target urate-lowering strategy versus usual care for gout: a randomised controlled trial. Lancet2018;392(10156):1403-12. ">Doherty 2018</a>; <a href="./references#CD010069-bbs2-0010" title="HosoyaT , IshikawaT , OgawaY , SakamotoR , OhashiT . Multicenter, open-label study of long-term topiroxostat (FYX-051) administration in Japanese hyperuricemic patients with or without gout. Clinical Drug Investigation2018;38(45):1135-43. ">Hosoya 2018</a>). </p> </section> </section> <section id="CD010069-sec-0047"> <h3 class="title">Risk of bias in included studies</h3> <p>We assessed risk of bias for all included studies, summarised in <a href="#CD010069-fig-0002">Figure 2</a> and <a href="#CD010069-fig-0003">Figure 3</a>. </p> <div class="figure" id="CD010069-fig-0002"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 2</div> </div> <hr class="top"/><img alt="Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies." data-id="CD010069-fig-0002" src="/cdsr/doi/10.1002/14651858.CD010069.pub3/media/CDSR/CD010069/image_n/nCD010069-FIG-02.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies. </p> </div> </div> </div> <div class="figure" id="CD010069-fig-0003"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 3</div> </div> <hr class="top"/><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study." data-id="CD010069-fig-0003" src="/cdsr/doi/10.1002/14651858.CD010069.pub3/media/CDSR/CD010069/image_n/nCD010069-FIG-03.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> </div> <section id="CD010069-sec-0048"> <h4 class="title">Allocation</h4> <p>There was no selection bias in any of the included studies.</p> </section> <section id="CD010069-sec-0049"> <h4 class="title">Blinding</h4> <p>There was adequate blinding of outcome data (e.g. the use of a blinded central reader for tophi outcomes), and thus a low risk of detection bias for all studies. except <a href="./references#CD010069-bbs2-0002" title="BeckerMA , Schumacher HR Jr, WortmannRL , MacDonaldPA , EustaceD , PaloWA , StreitJ , Joseph-RidgeN . Febuxostat compared with allopurinol in patients with hyperuricemia and gout. New England Journal of Medicine December 8, 2005;353(23):2450-61. ">Becker 2005</a> where blinding of staff during outcomes was unclear. There was also blinding in terms of treatment (ensuring the same number of infusions for all participants). However, the blinding of staff during treatment, and thus the risk of performance bias, was unclear in the study by <a href="./references#CD010069-bbs2-0005" title="SundyJS , BarafHS , YoodRA , EdwardsNL , Gutierrez-UrenaSR , TreadwellEL , et al. Efficacy and tolerability of pegloticase for the treatment of chronic gout in patients refractory to conventional treatment; two randomized controlled trials. Journal of the American Medical Association2011;306:711-20. [ClinicalTrials.gov Identifier NCT00325195]">Sundy 2011</a>. </p> </section> <section id="CD010069-sec-0050"> <h4 class="title">Incomplete outcome data</h4> <p>All four studies had a low risk of attrition bias.</p> </section> <section id="CD010069-sec-0051"> <h4 class="title">Selective reporting</h4> <p>We have no evidence to suggest there was selective reporting of data in any of the included studies. </p> </section> <section id="CD010069-sec-0052"> <h4 class="title">Other potential sources of bias</h4> <p>We did not find any other potential sources of bias.</p> <p>We noted potential conflict of interest bias for three of the included studies. <a href="./references#CD010069-bbs2-0001" title="BardinT , KeenanRT , KhannaPP , KopickoJ , FungM , BhaktaN , et al. Lesinurad in combination with allopurinol: a randomised, double-blind, placebo-controlled study in patients with gout with inadequate response to standard of care (the multinational CLEAR 2 study). Annals of the Rheumatic Diseases2017;76(5):811-20. [DOI: 10.1136/annrheumdis-2016-209213]">Bardin 2017</a> and <a href="./references#CD010069-bbs2-0004" title="SaagKG , Fitz-PatrickD , KopickoJ , FungM , BhaktaN , AdlerS , et al. Lesinurad combined with allopurinol: a randomized, double-blind, placebo-controlled study in gout patients with an inadequate response to standard-of-care allopurinol (a US-based study). Arthritis &amp; Rheumatology2017;69(1):203-12. [DOI: 10.1002/art.39840]">Saag 2017</a> were sponsored by Ardea Biosciences, who produce lesinurad. Ardea Biosciences played a role in the design and conduct of the study; collection, management, analysis and interpretation of the data; and the review. </p> <p>For <a href="./references#CD010069-bbs2-0003" title="Dalbeth, N, Jones, G, Terkeltaub, R, Khanna, D, Kopicko, J, Bhakta, N et al. Lesinurad, a Selective Uric Acid Reabsorption Inhibitor, in Combination With Febuxostat in Patients With Tophaceous Gout: Findings of a Phase III Clinical Trial. Arthritis &amp; Rheumatology2017;69:1903-13. DalbethN , JonesG , TerkeltaubR , KhannaD , FungM , BaumgartnerS , et al. Efficacy and safety during extended treatment of lesinurad in combination with febuxostat in patients with tophaceous gout: CRYSTAL extension study. Arthritis Research &amp; Therapy2019;21(1):8. [DOI: https://dx.doi.org/10.1186/s13075-018-1788-4]">Dalbeth 2019</a>, the core and extension studies were funded by Ardea Biosciences/AstraZeneca. The study sponsor had a role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; and review and approval of the manuscript. </p> <p><a href="./references#CD010069-bbs2-0002" title="BeckerMA , Schumacher HR Jr, WortmannRL , MacDonaldPA , EustaceD , PaloWA , StreitJ , Joseph-RidgeN . Febuxostat compared with allopurinol in patients with hyperuricemia and gout. New England Journal of Medicine December 8, 2005;353(23):2450-61. ">Becker 2005</a> study was sponsored by TAP Pharmaceutical Products. Representatives had a role on data collection and statistical analyses.  </p> </section> </section> <section id="CD010069-sec-0053"> <h3 class="title" id="CD010069-sec-0053">Effects of interventions</h3> <p>See: <a href="./full#CD010069-tbl-0001"><b>Summary of findings 1</b> Pegloticase every two weeks (biweekly) compared with placebo for tophi in gout</a>; <a href="./full#CD010069-tbl-0002"><b>Summary of findings 2</b> Monthly pegloticase compared with placebo for tophi in gout</a>; <a href="./full#CD010069-tbl-0003"><b>Summary of findings 3</b> Lesinurad 200 mg plus allopurinol compared to placebo plus allopurinol for tophi in gout</a>; <a href="./full#CD010069-tbl-0004"><b>Summary of findings 4</b> Lesinurad 400 mg plus allopurinol compared to placebo plus allopurinol for tophi in gout</a>; <a href="./full#CD010069-tbl-0005"><b>Summary of findings 5</b> Lesinurad 400 mg plus febuxostat CONTINUED compared to lesinurad 200 mg plus febuxostat CONTINUED for tophi in gout</a>; <a href="./full#CD010069-tbl-0006"><b>Summary of findings 6</b> Lesinurad 400 mg plus febuxostat CROSS compared to lesinurad 200 mg plus febuxostat CROSS for tophi in gout</a> </p> <p>We present the outcomes that were reported separately for the subgroup of participants with tophi at baseline. Four of the studies reported on resolution of tophi alone for these participants (<a href="./references#CD010069-bbs2-0001" title="BardinT , KeenanRT , KhannaPP , KopickoJ , FungM , BhaktaN , et al. Lesinurad in combination with allopurinol: a randomised, double-blind, placebo-controlled study in patients with gout with inadequate response to standard of care (the multinational CLEAR 2 study). Annals of the Rheumatic Diseases2017;76(5):811-20. [DOI: 10.1136/annrheumdis-2016-209213]">Bardin 2017</a>; <a href="./references#CD010069-bbs2-0004" title="SaagKG , Fitz-PatrickD , KopickoJ , FungM , BhaktaN , AdlerS , et al. Lesinurad combined with allopurinol: a randomized, double-blind, placebo-controlled study in gout patients with an inadequate response to standard-of-care allopurinol (a US-based study). Arthritis &amp; Rheumatology2017;69(1):203-12. [DOI: 10.1002/art.39840]">Saag 2017</a>; <a href="./references#CD010069-bbs2-0005" title="SundyJS , BarafHS , YoodRA , EdwardsNL , Gutierrez-UrenaSR , TreadwellEL , et al. Efficacy and tolerability of pegloticase for the treatment of chronic gout in patients refractory to conventional treatment; two randomized controlled trials. Journal of the American Medical Association2011;306:711-20. [ClinicalTrials.gov Identifier NCT00325195]">Sundy 2011</a>, <a href="./references#CD010069-bbs2-0002" title="BeckerMA , Schumacher HR Jr, WortmannRL , MacDonaldPA , EustaceD , PaloWA , StreitJ , Joseph-RidgeN . Febuxostat compared with allopurinol in patients with hyperuricemia and gout. New England Journal of Medicine December 8, 2005;353(23):2450-61. ">Becker 2005</a>).   </p> <section id="CD010069-sec-0054"> <h4 class="title">1. Pegloticase every two weeks (biweekly) compared with placebo for participants with tophi </h4> <p>One study with 79 participants (<a href="./references#CD010069-bbs2-0005" title="SundyJS , BarafHS , YoodRA , EdwardsNL , Gutierrez-UrenaSR , TreadwellEL , et al. Efficacy and tolerability of pegloticase for the treatment of chronic gout in patients refractory to conventional treatment; two randomized controlled trials. Journal of the American Medical Association2011;306:711-20. [ClinicalTrials.gov Identifier NCT00325195]">Sundy 2011</a>), which was from the original Cochrane Review, compared biweekly pegloticase versus placebo. Results are shown in <a href="./full#CD010069-tbl-0001">summary of findings Table 1</a> </p> <section id="CD010069-sec-0055"> <h5 class="title">Proportion with complete resolution of tophi</h5> <p>Biweekly pegloticase probably improves resolution of tophi. Moderate‐certainty evidence from one study (downgraded for imprecision) showed a clinically significant benefit where more participants in the pegloticase every two weeks (biweekly) group had complete resolution of one or more tophi compared with participants in the placebo group (21/52 with biweekly pegloticase versus 2/27 with placebo (RR 5.45, 95% CI 1.38 to 21.54; NNTB 3, 95% CI 2 to 6; <a href="./references#CD010069-fig-0004" title="">Analysis 1.1</a>) The absolute improvement was 33% (16% better to 50% better) and the relative improvement was 445% (40% better to 2060% better). </p> </section> <section id="CD010069-sec-0056"> <h5 class="title">Withdrawal due to adverse event </h5> <p>We reported on withdrawals due to adverse events for all participants, with or without tophi at baseline, as this study (<a href="./references#CD010069-bbs2-0005" title="SundyJS , BarafHS , YoodRA , EdwardsNL , Gutierrez-UrenaSR , TreadwellEL , et al. Efficacy and tolerability of pegloticase for the treatment of chronic gout in patients refractory to conventional treatment; two randomized controlled trials. Journal of the American Medical Association2011;306:711-20. [ClinicalTrials.gov Identifier NCT00325195]">Sundy 2011</a>) only reported on adverse events across all participants. Biweekly pegloticase probably increases withdrawals due to adverse events. More participants in the pegloticase group (15/85) withdrew due to an adverse event compared to those in the placebo group (1/43) (RR 7.59, 95% CI 1.04 to 55.55; NNTH 7, 95% CI 4 to 16; <a href="./references#CD010069-fig-0005" title="">Analysis 1.2</a>), which was clinically significant. The absolute increase in withdrawals with pegloticase was 16% (8% more to 28% more), and the relative increase in withdrawals was 660% (4% more to 5455% more). </p> <p>Infusion reactions were the most common reason for study discontinuation.</p> <p><a href="./references#CD010069-bbs2-0005" title="SundyJS , BarafHS , YoodRA , EdwardsNL , Gutierrez-UrenaSR , TreadwellEL , et al. Efficacy and tolerability of pegloticase for the treatment of chronic gout in patients refractory to conventional treatment; two randomized controlled trials. Journal of the American Medical Association2011;306:711-20. [ClinicalTrials.gov Identifier NCT00325195]">Sundy 2011</a> did not report on pain reduction, health‐related quality of life, serum urate normalisation, and function (i.e. activity limitation) for participants with tophi at baseline. </p> </section> <section id="CD010069-sec-0057"> <h5 class="title">Proportion with an adverse event</h5> <p>We reported on total adverse events for all participants, with or without tophi at baseline, as <a href="./references#CD010069-bbs2-0005" title="SundyJS , BarafHS , YoodRA , EdwardsNL , Gutierrez-UrenaSR , TreadwellEL , et al. Efficacy and tolerability of pegloticase for the treatment of chronic gout in patients refractory to conventional treatment; two randomized controlled trials. Journal of the American Medical Association2011;306:711-20. [ClinicalTrials.gov Identifier NCT00325195]">Sundy 2011</a> only reported this outcome across all participants. Biweekly pegloticase probably results in little or no difference in adverse events. Moderate‐certainty evidence (downgraded for imprecision) showed similar number of participants in the pegloticase biweekly group (80/85) had an adverse event compared to those in the placebo group (41/43) (RR 0.99, 95% CI 0.91 to 1.07; <a href="./references#CD010069-fig-0006" title="">Analysis 1.3</a>). The absolute decrease in adverse events with pegloticase was 1% (9% decrease to 7% increase), and the relative decrease was 1% (10% decrease to 7% increase). </p> <p>The three most common adverse events were gout flares, infusion reactions and headaches; 80% of adverse events were due to flares of gout. Placebo groups did not receive urate lowering therapy, hence were at risk of ongoing gout flares. </p> </section> </section> <section id="CD010069-sec-0058"> <h4 class="title">2. Monthly pegloticase compared with placebo for participants with tophi</h4> <p>One study (79 participants), which was from the original review, compared monthly pegloticase versus placebo (<a href="./references#CD010069-bbs2-0005" title="SundyJS , BarafHS , YoodRA , EdwardsNL , Gutierrez-UrenaSR , TreadwellEL , et al. Efficacy and tolerability of pegloticase for the treatment of chronic gout in patients refractory to conventional treatment; two randomized controlled trials. Journal of the American Medical Association2011;306:711-20. [ClinicalTrials.gov Identifier NCT00325195]">Sundy 2011</a>). Results for this comparison are shown in <a href="./full#CD010069-tbl-0002">summary of findings Table 2</a>. </p> <section id="CD010069-sec-0059"> <h5 class="title">Proportion with complete resolution of tophi</h5> <p>Monthly pegloticase probably improves resolution of tophi. Moderate‐certainty evidence (downgraded for imprecision) showed a clinically significant benefit, where more participants in the monthly pegloticase group had complete resolution of one or more tophi compared with participants in the placebo group (11/52 with monthly pegloticase versus 2/27 with placebo (RR 2.86, 95% CI 0.68 to 11.97; NNTB 8, 95% CI 4 to 91; <a href="./references#CD010069-fig-0007" title="">Analysis 2.1</a>). This corresponds to an absolute improvement of 14% (1% worse to 29% better) and a relative improvement of 190% (30% worse to 1100% better). </p> <p>In addition, comparison of the two pegloticase groups (biweekly versus monthly) found that more participants in the biweekly pegloticase arm had complete resolution of one or more tophi compared with participants in the monthly pegloticase group (RR 1.91, 95% CI 1.03 to 3.55; <a href="./references#CD010069-fig-0010" title="">Analysis 3.1</a>). </p> </section> <section id="CD010069-sec-0060"> <h5 class="title">Withdrawal due to adverse event</h5> <p>Monthly pegloticase probably increases withdrawals due to adverse events. Moderate‐certainty evidence (downgraded for imprecision) showed that more participants in the pegloticase monthly arm (16/84) withdrew due to adverse events compared to placebo (1/43) (RR 8.19, 95% CI 1.12 to 59.71; NNTH 6, 95% CI 4 to 14; <a href="./references#CD010069-fig-0008" title="">Analysis 2.2</a>), which was clinically significant. The absolute increase in withdrawals with pegloticase was 17% (7% to 26%); the relative increase was 719% more withdrawals (12% more to 5870% more). Infusion reactions were the most common reason for study discontinuation. </p> </section> <section id="CD010069-sec-0061"> <h5 class="title">Proportion with an adverse event </h5> <p>Monthly pegloticase probably results in little or no difference in adverse events. Moderate‐certainty evidence (downgraded for imprecision) showed that similar number of participants in the pegloticase monthly arm (84/84) had an adverse event compared to placebo (41/43) (RR 1.05, 95% CI 0.98 to 1.14; <a href="./references#CD010069-fig-0009" title="">Analysis 2.3</a>). The absolute increase with pegloticase was 5% (20% decrease to 12% increase), and the relative increase was 5% (2% decrease to 14% increase).  </p> </section> </section> <section id="CD010069-sec-0062"> <h4 class="title">3. Lesinurad 200 mg in combination with allopurinol compared with placebo plus allopurinol for participants with tophi </h4> <p>Two studies (103 participants) (<a href="./references#CD010069-bbs2-0001" title="BardinT , KeenanRT , KhannaPP , KopickoJ , FungM , BhaktaN , et al. Lesinurad in combination with allopurinol: a randomised, double-blind, placebo-controlled study in patients with gout with inadequate response to standard of care (the multinational CLEAR 2 study). Annals of the Rheumatic Diseases2017;76(5):811-20. [DOI: 10.1136/annrheumdis-2016-209213]">Bardin 2017</a>; <a href="./references#CD010069-bbs2-0004" title="SaagKG , Fitz-PatrickD , KopickoJ , FungM , BhaktaN , AdlerS , et al. Lesinurad combined with allopurinol: a randomized, double-blind, placebo-controlled study in gout patients with an inadequate response to standard-of-care allopurinol (a US-based study). Arthritis &amp; Rheumatology2017;69(1):203-12. [DOI: 10.1002/art.39840]">Saag 2017</a>) had similar interventions: lesinurad 200 mg or 400 mg in combination with allopurinol versus placebo plus allopurinol. Thus, we pooled the results. </p> <section id="CD010069-sec-0063"> <h5 class="title">Proportion with complete resolution of a target tophus</h5> <p>Lesinurad 200 mg plus allopurinol is probably not beneficial for the resolution of tophi in gout. Moderate‐certainty evidence (downgraded for imprecision) showed that more participants in the placebo plus allopurinol arm (16/50) had complete resolution of target tophus compared to 11/53 in the lesinurad 200 mg plus allopurinol arm (RR 0.40, 95% CI 0.04 to 4.57; <a href="./references#CD010069-fig-0011" title="">Analysis 4.1</a>). This corresponds to an absolute reduction 19% (31% less to 114% more) relative reduction 60% (96% less to 357% more). This comparison is shown in <a href="./full#CD010069-tbl-0003">summary of findings Table 3</a>. </p> <p>The studies did not measure any of the other outcomes.</p> </section> </section> <section id="CD010069-sec-0064"> <h4 class="title">4. Lesinurad 400 mg in combination with allopurinol compared with placebo plus allopurinol for participants with tophi </h4> <section id="CD010069-sec-0065"> <h5 class="title">Proportion with complete resolution of a target tophus</h5> <p>Lesinurad 400 mg plus allopurinol is probably not beneficial for the resolution of tophi in gout. Moderate‐certainty evidence (downgraded for imprecision) showed that more participants in the placebo plus allopurinol arm (16/50) had complete resolution of target tophus compared to 12/48 in the lesinurad 400 mg plus allopurinol group (RR 0.79, 95% CI 0.42 to 1.49; <a href="./references#CD010069-fig-0012" title="">Analysis 5.1</a>). The absolute reduction was 6.7% fewer (18.6% fewer to 15.7% more) relative reduction 21% fewer (58% fewer to 49% more). This comparison is shown in <a href="./full#CD010069-tbl-0004">summary of findings Table 4</a>. </p> <p>Neither of the studies measured any of the other outcomes.</p> </section> </section> <section id="CD010069-sec-0066"> <h4 class="title">5. Lesinurad 400 mg plus febuxostat CONTINUED compared to lesinurad 200 mg plus febuxostat CONTINUED for participants with tophi </h4> <p>As an extension study (129 participants), <a href="./references#CD010069-bbs2-0003" title="Dalbeth, N, Jones, G, Terkeltaub, R, Khanna, D, Kopicko, J, Bhakta, N et al. Lesinurad, a Selective Uric Acid Reabsorption Inhibitor, in Combination With Febuxostat in Patients With Tophaceous Gout: Findings of a Phase III Clinical Trial. Arthritis &amp; Rheumatology2017;69:1903-13. DalbethN , JonesG , TerkeltaubR , KhannaD , FungM , BaumgartnerS , et al. Efficacy and safety during extended treatment of lesinurad in combination with febuxostat in patients with tophaceous gout: CRYSTAL extension study. Arthritis Research &amp; Therapy2019;21(1):8. [DOI: https://dx.doi.org/10.1186/s13075-018-1788-4]">Dalbeth 2019</a> did not have a placebo arm. We therefore made comparisons with the following intervention arms: </p> <p> <ul id="CD010069-list-0008"> <li> <p>Lesinurad 400 mg plus febuxostat 80 mg (CONTinued) versus lesinurad 200 mg plus febuxostat 80 mg (CONTinued). Results for this comparison are shown in <a href="./full#CD010069-tbl-0005">summary of findings Table 5</a> and presented in the text below. </p> </li> <li> <p>Lesinurad 400 mg added to febuxostat 80 mg monotherapy (CROSS) versus lesinurad 200 mg added to febuxostat 80 mg monotherapy (CROSS). Results for this comparison are shown in <a href="./full#CD010069-tbl-0006">summary of findings Table 6</a>. </p> </li> </ul> </p> <section id="CD010069-sec-0067"> <h5 class="title">Proportion with complete resolution of a target tophus</h5> <p>Lesinurad 400 mg in combination with febuxostat may be beneficial for resolution of tophi in gout. Low‐certainty evidence (downgraded for indirectness and imprecision) showed that 43/65 participants who continued on lesinurad 400 mg in combination with febuxostat showed complete resolution of target tophus compared to 38/64 of those who continued lesinurad 200 mg in combination with febuxostat (RR 1.11, 95% CI 0.85 to 1.46; <a href="./references#CD010069-fig-0013" title="">Analysis 6.1</a>), with an absolute improvement of 7% (10% less to 23% more) and a relative improvement of 12% (3% less to 19% more).   </p> </section> <section id="CD010069-sec-0068"> <h5 class="title">Proportion with adverse events</h5> <p>Lesinurad 400 mg in combination with febuxostat may result in little to no difference in adverse events. Low‐certainty evidence (downgraded for indirectness and imprecision) showed that 57/65 participants in the lesinurad 400 mg arm had one or more AE compared to 50/64 in the lesinurad 200 mg CONT arm (RR 1.12, 95% CI 0.96 to 1.32; <a href="./references#CD010069-fig-0014" title="">Analysis 6.2</a>). This corresponds to an absolute increase of 9% (3% less to 25% more) and a relative increase of 12% (8% less to 17% more). </p> </section> <section id="CD010069-sec-0069"> <h5 class="title">Withdrawal due to adverse events </h5> <p>Lesinurad 400 mg in combination with febuxostat may result in little to no difference in withdrawals due to adverse events. Low‐certainty evidence (downgraded for indirectness and imprecision) showed that 10/65 participants in the lesinurad 400 mg CONT arm withdrew from the study due to an adverse event, compared to 10/64 participants in the lesinurad 200 mg CONT arm (RR 0.98, 95% CI 0.44 to 2.20; <a href="./references#CD010069-fig-0015" title="">Analysis 6.3</a>). The absolute reduction was 0.3% (9% less to 188% more) and the relative reduction 1.92% (20% less to 20% more).  </p> </section> <section id="CD010069-sec-0070"> <h5 class="title">Mean sUA after 12 months</h5> <p>Lesinurad 400 mg in combination with febuxostat may result in little to no difference in mean sUA levels. Low‐certainty evidence (downgraded for indirectness and imprecision) showed that mean sUA was 3 mg/dl in the lesinurad 400 mg CONT arm and 3.9 mg/dl in the lesinurad 200 mg CONT arm (MD ‐0.90, 95% CI ‐1.51 to ‐0.29; <a href="./references#CD010069-fig-0016" title="">Analysis 6.4</a>). This corresponds to an absolute reduction of 0.9% (1.5% lower to 0.3% lower) and a relative reduction of 2.2% (3.75% lower to 0.7% lower).  </p> </section> </section> <section id="CD010069-sec-0071"> <h4 class="title">6. Lesinurad 400 mg plus Febuxostat CROSS versus Lesinurad 200 mg plus Febuxostat CROSS in participants with tophi </h4> <p>One study (129 participants) (<a href="./references#CD010069-bbs2-0003" title="Dalbeth, N, Jones, G, Terkeltaub, R, Khanna, D, Kopicko, J, Bhakta, N et al. Lesinurad, a Selective Uric Acid Reabsorption Inhibitor, in Combination With Febuxostat in Patients With Tophaceous Gout: Findings of a Phase III Clinical Trial. Arthritis &amp; Rheumatology2017;69:1903-13. DalbethN , JonesG , TerkeltaubR , KhannaD , FungM , BaumgartnerS , et al. Efficacy and safety during extended treatment of lesinurad in combination with febuxostat in patients with tophaceous gout: CRYSTAL extension study. Arthritis Research &amp; Therapy2019;21(1):8. [DOI: https://dx.doi.org/10.1186/s13075-018-1788-4]">Dalbeth 2019</a>) compared lesinurad 400 mg plus febuxostat CROSS versus lesinurad 200 mg plus febuxostat CROSS in participants with tophi. Results for this comparison are shown in <a href="./full#CD010069-tbl-0006">summary of findings Table 6</a>. </p> <section id="CD010069-sec-0072"> <h5 class="title">Proportion with complete resolution of a target tophus</h5> <p>Lesinurad 400 mg plus febuxostat may result in little to no difference in tophi resolution compared to lesinurad 200 mg plus febuxostat. Low‐certainty evidence (downgraded for indirectness and imprecision) showed that 17/34 participants in the lesinurad 400 mg plus febuxostat group probably had complete resolution of a target tophus compared to 14/33 in the lesinurad 200 mg plus febuxostat group (RR 1.18, 95% CI 0.70 to 1.98; <a href="./references#CD010069-fig-0017" title="">Analysis 7.1</a>), with an absolute improvement of 8% (16% less to 31% more) and a relative improvement of 19% (7% less to 30% more).  </p> </section> <section id="CD010069-sec-0073"> <h5 class="title">Proportion with adverse events</h5> <p>Lesinurad 400 mg in combination with febuxostat may result in no difference in adverse events. Low‐certainty evidence (downgraded for indirectness and imprecision) showed that 33/34 participants in the lesinurad CROSS arm probably had one or more adverse events compared to 27/33 in the lesinurad 200 mg CROSS arm (RR 1.19, 95% CI 1.00 to 1.41; <a href="./references#CD010069-fig-0018" title="">Analysis 7.2</a>). This corresponds to an absolute increase of 15% (2.9% less to 18% better) and a relative increase of 18.6% (15% less to 23% more). </p> </section> <section id="CD010069-sec-0074"> <h5 class="title">Withdrawal due to adverse events</h5> <p>Lesinurad 400 mg plus febuxostat may result in little to no difference in withdrawals due to adverse events. Low‐certainty evidence (downgraded for indirectness and imprecision) showed that 5/34 participants in the lesinurad 400 mg CROSS arm withdrew from the study due to an adverse event compared to 2/33 participants in the lesinurad 200 mg CROSS arm (RR 2.43, 95% CI 0.51 to 11.64; <a href="./references#CD010069-fig-0019" title="">Analysis 7.3</a>). The absolute increase was 8.6% (3% less to 43% more) and the relative increase 142% (81% less to 221% more).  </p> </section> <section id="CD010069-sec-0075"> <h5 class="title">Mean sUA after 12 months</h5> <p>Lesinurad 400 mg may result in no difference in sUA. Low‐certainty evidence (downgraded for indirectness and imprecision) showed that the mean sUA was 4.2 mg/dl in the lesinurad 400 mg CROSS arm and 3.8 mg/dl in the lesinurad 200 mg CROSS arm (MD 0.40, 95% CI ‐0.75 to 1.55; <a href="./references#CD010069-fig-0020" title="">Analysis 7.4</a>). The absolute difference was 0.4% higher (0.75% lower to 1.55% higher) and the relative difference 0.7% higher (1.4% lower to 2.9% higher).  </p> </section> </section> <section id="CD010069-sec-0076"> <h4 class="title">Febuxostat 80mg versus Allopurinol 300mg in participants with tophi</h4> <p>One study with 156 participants (<a href="./references#CD010069-bbs2-0002" title="BeckerMA , Schumacher HR Jr, WortmannRL , MacDonaldPA , EustaceD , PaloWA , StreitJ , Joseph-RidgeN . Febuxostat compared with allopurinol in patients with hyperuricemia and gout. New England Journal of Medicine December 8, 2005;353(23):2450-61. ">Becker 2005</a>) looked at febuxostat 80 mg and febuxostat 120 mg compared to 300 mg allopurinol. </p> <section id="CD010069-sec-0077"> <h5 class="title">Percentage reduction in tophus area at week 52</h5> <p>This was assessed in 156 participants who had tophi at baseline. Median percentage change in tophus area was 83% for participants on Febuxostat 80mg compared to 50% for participants on Allopurinol 300mg. There was no statistically significant difference between the groups according to the study. Number of participants within each intervention arm who had tophi at baseline was unclear.  </p> </section> <section id="CD010069-sec-0078"> <h5 class="title">Reduction in number of tophi at week 52</h5> <p>33 participants on Febuostat 80mg had change in number of tophi compared to 35 participants on Allopurinol 300mg. There was no statistically significant difference between the groups according to the study.  </p> </section> </section> <section id="CD010069-sec-0079"> <h4 class="title">Febuxostat 120mg versus Allopurinol 300mg in participants with tophi</h4> <section id="CD010069-sec-0080"> <h5 class="title">Percentage reduction in tophus area at week 52</h5> <p>Median percentage change in tophus area was 66% for participants on Febuxostat 120mg compared to 50% for participants on Allopurinol 300mg.  There was no statistically significant difference between the groups according to the study. </p> </section> <section id="CD010069-sec-0081"> <h5 class="title">Reduction in number of tophi at week 52</h5> <p>28 participants on Febuxostat 120mg had change in number of tophi compared to 35 participants on Allopurinol 300mg. There was no statistically significant difference between the groups according to the study.  </p> </section> </section> </section> </section> </section> <section class="discussion"> <div class="section-header section-collapse-header" id="CD010069-sec-0082" lang="en"> <h2 class="title section-collapse-title"> Discussion <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="discussion" lang="en"> <div class="section-header" id="CD010069-sec-0082"></div> <section id="CD010069-sec-0083"> <h3 class="title" id="CD010069-sec-0083">Summary of main results</h3> <p>Only one study met our inclusion criteria in the original review for interventions for tophi in gout, and this remains the only study of pegloticase in the current review. <a href="./references#CD010069-bbs2-0005" title="SundyJS , BarafHS , YoodRA , EdwardsNL , Gutierrez-UrenaSR , TreadwellEL , et al. Efficacy and tolerability of pegloticase for the treatment of chronic gout in patients refractory to conventional treatment; two randomized controlled trials. Journal of the American Medical Association2011;306:711-20. [ClinicalTrials.gov Identifier NCT00325195]">Sundy 2011</a> showed that pegloticase every two weeks (biweekly) at a dose of 8 mg was probably beneficial in the reduction of tophi compared with placebo. Adverse events and withdrawals due to adverse event were reported for all participants, with or without tophi at baseline. Monthly pegloticase was also probably beneficial in tophi reduction, but to a lesser degree. Relative risk of withdrawals due to adverse events appeared to be similar in the biweekly and monthly pegloticase groups. The evidence was of moderate certainty, being downgraded for imprecision for both biweekly and monthly doses of pegloticase. </p> <p>Although adverse events were similar in pegloticase arms compared to placebo, there was a higher proportion of withdrawals due to adverse events. This was likely due to infusion reactions. </p> <p>We included four more studies in our update; three which used lesinurad (<a href="./references#CD010069-bbs2-0001" title="BardinT , KeenanRT , KhannaPP , KopickoJ , FungM , BhaktaN , et al. Lesinurad in combination with allopurinol: a randomised, double-blind, placebo-controlled study in patients with gout with inadequate response to standard of care (the multinational CLEAR 2 study). Annals of the Rheumatic Diseases2017;76(5):811-20. [DOI: 10.1136/annrheumdis-2016-209213]">Bardin 2017</a>; <a href="./references#CD010069-bbs2-0003" title="Dalbeth, N, Jones, G, Terkeltaub, R, Khanna, D, Kopicko, J, Bhakta, N et al. Lesinurad, a Selective Uric Acid Reabsorption Inhibitor, in Combination With Febuxostat in Patients With Tophaceous Gout: Findings of a Phase III Clinical Trial. Arthritis &amp; Rheumatology2017;69:1903-13. DalbethN , JonesG , TerkeltaubR , KhannaD , FungM , BaumgartnerS , et al. Efficacy and safety during extended treatment of lesinurad in combination with febuxostat in patients with tophaceous gout: CRYSTAL extension study. Arthritis Research &amp; Therapy2019;21(1):8. [DOI: https://dx.doi.org/10.1186/s13075-018-1788-4]">Dalbeth 2019</a>; <a href="./references#CD010069-bbs2-0004" title="SaagKG , Fitz-PatrickD , KopickoJ , FungM , BhaktaN , AdlerS , et al. Lesinurad combined with allopurinol: a randomized, double-blind, placebo-controlled study in gout patients with an inadequate response to standard-of-care allopurinol (a US-based study). Arthritis &amp; Rheumatology2017;69(1):203-12. [DOI: 10.1002/art.39840]">Saag 2017</a>) and one which used febuxostat (<a href="./references#CD010069-bbs2-0002" title="BeckerMA , Schumacher HR Jr, WortmannRL , MacDonaldPA , EustaceD , PaloWA , StreitJ , Joseph-RidgeN . Febuxostat compared with allopurinol in patients with hyperuricemia and gout. New England Journal of Medicine December 8, 2005;353(23):2450-61. ">Becker 2005</a>). Moderate‐certainty evidence (downgraded for imprecision) from <a href="./references#CD010069-bbs2-0001" title="BardinT , KeenanRT , KhannaPP , KopickoJ , FungM , BhaktaN , et al. Lesinurad in combination with allopurinol: a randomised, double-blind, placebo-controlled study in patients with gout with inadequate response to standard of care (the multinational CLEAR 2 study). Annals of the Rheumatic Diseases2017;76(5):811-20. [DOI: 10.1136/annrheumdis-2016-209213]">Bardin 2017</a> and <a href="./references#CD010069-bbs2-0004" title="SaagKG , Fitz-PatrickD , KopickoJ , FungM , BhaktaN , AdlerS , et al. Lesinurad combined with allopurinol: a randomized, double-blind, placebo-controlled study in gout patients with an inadequate response to standard-of-care allopurinol (a US-based study). Arthritis &amp; Rheumatology2017;69(1):203-12. [DOI: 10.1002/art.39840]">Saag 2017</a> showed that lesinurad in combination with allopurinol was not superior for tophi resolution in comparison to allopurinol alone. <a href="./references#CD010069-bbs2-0003" title="Dalbeth, N, Jones, G, Terkeltaub, R, Khanna, D, Kopicko, J, Bhakta, N et al. Lesinurad, a Selective Uric Acid Reabsorption Inhibitor, in Combination With Febuxostat in Patients With Tophaceous Gout: Findings of a Phase III Clinical Trial. Arthritis &amp; Rheumatology2017;69:1903-13. DalbethN , JonesG , TerkeltaubR , KhannaD , FungM , BaumgartnerS , et al. Efficacy and safety during extended treatment of lesinurad in combination with febuxostat in patients with tophaceous gout: CRYSTAL extension study. Arthritis Research &amp; Therapy2019;21(1):8. [DOI: https://dx.doi.org/10.1186/s13075-018-1788-4]">Dalbeth 2019</a> included people who had completed the original study either on febuxostat alone or in combination with lesinurad. This study showed that lesinurad 400 mg in combination with febuxostat may be more effective for resolution of tophi compared to lesinurad 200 mg. There was no significant difference in adverse events or withdrawals due to adverse events between lesinurad 400 mg CROSS and lesinurad 200 mg CROSS. Evidence was of low certainty, downgraded for imprecision and indirectness. As there was no placebo arm in the <a href="./references#CD010069-bbs2-0003" title="Dalbeth, N, Jones, G, Terkeltaub, R, Khanna, D, Kopicko, J, Bhakta, N et al. Lesinurad, a Selective Uric Acid Reabsorption Inhibitor, in Combination With Febuxostat in Patients With Tophaceous Gout: Findings of a Phase III Clinical Trial. Arthritis &amp; Rheumatology2017;69:1903-13. DalbethN , JonesG , TerkeltaubR , KhannaD , FungM , BaumgartnerS , et al. Efficacy and safety during extended treatment of lesinurad in combination with febuxostat in patients with tophaceous gout: CRYSTAL extension study. Arthritis Research &amp; Therapy2019;21(1):8. [DOI: https://dx.doi.org/10.1186/s13075-018-1788-4]">Dalbeth 2019</a> study, we were unable to assess whether interventions were better than placebo. </p> <p><a href="./references#CD010069-bbs2-0002" title="BeckerMA , Schumacher HR Jr, WortmannRL , MacDonaldPA , EustaceD , PaloWA , StreitJ , Joseph-RidgeN . Febuxostat compared with allopurinol in patients with hyperuricemia and gout. New England Journal of Medicine December 8, 2005;353(23):2450-61. ">Becker 2005</a> stated that febuxostat 80mg or 120mg was not superior to allopurinol for reduction in tophus area or number of tophi. However, there was insufficient data to look at these outcomes in more detail.   </p> </section> <section id="CD010069-sec-0084"> <h3 class="title" id="CD010069-sec-0084">Overall completeness and applicability of evidence</h3> <p>We have included only RCT evidence for interventions for tophi that is published at present. We found no RCT data for other interventions or for non‐pharmacological interventions such as surgery. One study was an extension of an RCT studying the efficacy of lesinurad in combination with febuxostat (<a href="./references#CD010069-bbs2-0003" title="Dalbeth, N, Jones, G, Terkeltaub, R, Khanna, D, Kopicko, J, Bhakta, N et al. Lesinurad, a Selective Uric Acid Reabsorption Inhibitor, in Combination With Febuxostat in Patients With Tophaceous Gout: Findings of a Phase III Clinical Trial. Arthritis &amp; Rheumatology2017;69:1903-13. DalbethN , JonesG , TerkeltaubR , KhannaD , FungM , BaumgartnerS , et al. Efficacy and safety during extended treatment of lesinurad in combination with febuxostat in patients with tophaceous gout: CRYSTAL extension study. Arthritis Research &amp; Therapy2019;21(1):8. [DOI: https://dx.doi.org/10.1186/s13075-018-1788-4]">Dalbeth 2019</a>). Another one reported on the pooled results of two replicate randomised, double‐blind placebo‐controlled trials on pegloticase in chronic gout that was refractory to traditional urate‐lowering therapy (<a href="./references#CD010069-bbs2-0005" title="SundyJS , BarafHS , YoodRA , EdwardsNL , Gutierrez-UrenaSR , TreadwellEL , et al. Efficacy and tolerability of pegloticase for the treatment of chronic gout in patients refractory to conventional treatment; two randomized controlled trials. Journal of the American Medical Association2011;306:711-20. [ClinicalTrials.gov Identifier NCT00325195]">Sundy 2011</a>). Two studies trialled lesinurad in combination with allopurinol versus allopurinol alone, and data was pooled and analysed (<a href="./references#CD010069-bbs2-0001" title="BardinT , KeenanRT , KhannaPP , KopickoJ , FungM , BhaktaN , et al. Lesinurad in combination with allopurinol: a randomised, double-blind, placebo-controlled study in patients with gout with inadequate response to standard of care (the multinational CLEAR 2 study). Annals of the Rheumatic Diseases2017;76(5):811-20. [DOI: 10.1136/annrheumdis-2016-209213]">Bardin 2017</a>; <a href="./references#CD010069-bbs2-0004" title="SaagKG , Fitz-PatrickD , KopickoJ , FungM , BhaktaN , AdlerS , et al. Lesinurad combined with allopurinol: a randomized, double-blind, placebo-controlled study in gout patients with an inadequate response to standard-of-care allopurinol (a US-based study). Arthritis &amp; Rheumatology2017;69(1):203-12. [DOI: 10.1002/art.39840]">Saag 2017</a>). One study was an RCT which looked at febuxostat versus allopurinol ( <a href="./references#CD010069-bbs2-0002" title="BeckerMA , Schumacher HR Jr, WortmannRL , MacDonaldPA , EustaceD , PaloWA , StreitJ , Joseph-RidgeN . Febuxostat compared with allopurinol in patients with hyperuricemia and gout. New England Journal of Medicine December 8, 2005;353(23):2450-61. ">Becker 2005</a>). </p> <p>Participants were from a wide range of countries, including the USA, Canada, Mexico, South Africa, Australia, New Zealand, and locations in Europe. Trials were comparable in terms of participant age, symptom duration and presence of tophi at baseline. Two studies included participants who were currently on a stable dose of allopurinol, while one study included those on febuxostat alone or in combination with lesinurad. One study was conducted in people with chronic gout that was refractory to traditional urate‐lowering therapy. All trials were at low risk for detection bias due to blinding of a central reader for tophi outcomes except one where blinding of outcomes was unclear (<a href="./references#CD010069-bbs2-0002" title="BeckerMA , Schumacher HR Jr, WortmannRL , MacDonaldPA , EustaceD , PaloWA , StreitJ , Joseph-RidgeN . Febuxostat compared with allopurinol in patients with hyperuricemia and gout. New England Journal of Medicine December 8, 2005;353(23):2450-61. ">Becker 2005</a>). Although not part of the bias assessments in the review, we noted potential conflicts of interest for four of the included studies. <a href="./references#CD010069-bbs2-0001" title="BardinT , KeenanRT , KhannaPP , KopickoJ , FungM , BhaktaN , et al. Lesinurad in combination with allopurinol: a randomised, double-blind, placebo-controlled study in patients with gout with inadequate response to standard of care (the multinational CLEAR 2 study). Annals of the Rheumatic Diseases2017;76(5):811-20. [DOI: 10.1136/annrheumdis-2016-209213]">Bardin 2017</a> and <a href="./references#CD010069-bbs2-0004" title="SaagKG , Fitz-PatrickD , KopickoJ , FungM , BhaktaN , AdlerS , et al. Lesinurad combined with allopurinol: a randomized, double-blind, placebo-controlled study in gout patients with an inadequate response to standard-of-care allopurinol (a US-based study). Arthritis &amp; Rheumatology2017;69(1):203-12. [DOI: 10.1002/art.39840]">Saag 2017</a> were sponsored by Ardea Biosciences, who produce lesinurad. Ardea Biosciences played a role in design and conduct of study, collection, management, analysis and interpretation of the data, and the review. For <a href="./references#CD010069-bbs2-0003" title="Dalbeth, N, Jones, G, Terkeltaub, R, Khanna, D, Kopicko, J, Bhakta, N et al. Lesinurad, a Selective Uric Acid Reabsorption Inhibitor, in Combination With Febuxostat in Patients With Tophaceous Gout: Findings of a Phase III Clinical Trial. Arthritis &amp; Rheumatology2017;69:1903-13. DalbethN , JonesG , TerkeltaubR , KhannaD , FungM , BaumgartnerS , et al. Efficacy and safety during extended treatment of lesinurad in combination with febuxostat in patients with tophaceous gout: CRYSTAL extension study. Arthritis Research &amp; Therapy2019;21(1):8. [DOI: https://dx.doi.org/10.1186/s13075-018-1788-4]">Dalbeth 2019</a>, the core and extension studies were funded by Ardea Biosciences/AstraZeneca. The study sponsor had a role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; and review and approval of the manuscript.  <a href="./references#CD010069-bbs2-0002" title="BeckerMA , Schumacher HR Jr, WortmannRL , MacDonaldPA , EustaceD , PaloWA , StreitJ , Joseph-RidgeN . Febuxostat compared with allopurinol in patients with hyperuricemia and gout. New England Journal of Medicine December 8, 2005;353(23):2450-61. ">Becker 2005</a> was sponsored by TAP Pharmaceutical Products whose representatives were involved in data collection and statistical analyses. The implications of these potential conflicts on the interpretation of study findings should be considered. </p> <p>Most international guidelines advocate well‐established interventions such as allopurinol for the management of gout. However, this review revealed a paucity of RCT data specifically looking at the effects of such interventions on the management of tophi.  </p> </section> <section id="CD010069-sec-0085"> <h3 class="title" id="CD010069-sec-0085">Quality of the evidence</h3> <p>The overall certainty of evidence was moderate to low for resolution of tophi in all included studies. We assessed study limitations, indirectness, imprecision, inconsistency and publication bias. </p> <section id="CD010069-sec-0086"> <h4 class="title">Biweekly and monthly pegloticase compared to placebo</h4> <p>We downgraded evidence due to imprecision for complete resolution of tophi, adverse events and withdrawal due to adverse events. Studies did not measure important outcomes in participants with tophi: pain, quality of life, serum urate normalisation and function, thus we do not know the effect of treatment on these outcomes. The certainty of evidence is summarised in <a href="./full#CD010069-tbl-0001">summary of findings Table 1</a> and <a href="./full#CD010069-tbl-0002">summary of findings Table 2</a>. Savient Pharmaceuticals, as the manufacturer of pegloticase, sponsored the study. However, there was no evidence that this led to selective data reporting or publication bias, as all outcomes listed in the trial protocol were reported fully and the authors reported both positive and negative outcomes (i.e. adverse events), and how this could affect treatment. </p> </section> <section id="CD010069-sec-0087"> <h4 class="title">Lesinurad 200 mg and lesinurad 400 mg compared to allopurinol plus placebo</h4> <p>We downgraded the certainty of evidence due to imprecision for complete resolution of a target tophus; number of participants with tophi at baseline was low. These comparisons are described in <a href="./full#CD010069-tbl-0003">summary of findings Table 3</a> and <a href="./full#CD010069-tbl-0004">summary of findings Table 4</a>. </p> </section> <section id="CD010069-sec-0088"> <h4 class="title">Lesinurad 200 mg or 400 mg (continuation or cross‐over) in combination with febuxostat</h4> <p><a href="./references#CD010069-bbs2-0003" title="Dalbeth, N, Jones, G, Terkeltaub, R, Khanna, D, Kopicko, J, Bhakta, N et al. Lesinurad, a Selective Uric Acid Reabsorption Inhibitor, in Combination With Febuxostat in Patients With Tophaceous Gout: Findings of a Phase III Clinical Trial. Arthritis &amp; Rheumatology2017;69:1903-13. DalbethN , JonesG , TerkeltaubR , KhannaD , FungM , BaumgartnerS , et al. Efficacy and safety during extended treatment of lesinurad in combination with febuxostat in patients with tophaceous gout: CRYSTAL extension study. Arthritis Research &amp; Therapy2019;21(1):8. [DOI: https://dx.doi.org/10.1186/s13075-018-1788-4]">Dalbeth 2019</a> was an extension study and did not have a placebo arm, thus we were unable to determine whether lesinurad in combination with febuxostat (at either 200 mg or 400 mg doses, and either continued or as a treatment cross‐over) was effective when compared to placebo. In view of this, we downgraded the certainty of evidence in terms of indirectness and imprecision. <a href="./full#CD010069-tbl-0005">summary of findings Table 5</a> and <a href="./full#CD010069-tbl-0006">summary of findings Table 6</a> describe these comparisons. </p> <p>Ardea Biosciences produce lesinurad. However we did not find any evidence of selective data reporting or publication bias in the trials (<a href="./references#CD010069-bbs2-0001" title="BardinT , KeenanRT , KhannaPP , KopickoJ , FungM , BhaktaN , et al. Lesinurad in combination with allopurinol: a randomised, double-blind, placebo-controlled study in patients with gout with inadequate response to standard of care (the multinational CLEAR 2 study). Annals of the Rheumatic Diseases2017;76(5):811-20. [DOI: 10.1136/annrheumdis-2016-209213]">Bardin 2017</a> <a href="./references#CD010069-bbs2-0003" title="Dalbeth, N, Jones, G, Terkeltaub, R, Khanna, D, Kopicko, J, Bhakta, N et al. Lesinurad, a Selective Uric Acid Reabsorption Inhibitor, in Combination With Febuxostat in Patients With Tophaceous Gout: Findings of a Phase III Clinical Trial. Arthritis &amp; Rheumatology2017;69:1903-13. DalbethN , JonesG , TerkeltaubR , KhannaD , FungM , BaumgartnerS , et al. Efficacy and safety during extended treatment of lesinurad in combination with febuxostat in patients with tophaceous gout: CRYSTAL extension study. Arthritis Research &amp; Therapy2019;21(1):8. [DOI: https://dx.doi.org/10.1186/s13075-018-1788-4]">Dalbeth 2019</a>; <a href="./references#CD010069-bbs2-0004" title="SaagKG , Fitz-PatrickD , KopickoJ , FungM , BhaktaN , AdlerS , et al. Lesinurad combined with allopurinol: a randomized, double-blind, placebo-controlled study in gout patients with an inadequate response to standard-of-care allopurinol (a US-based study). Arthritis &amp; Rheumatology2017;69(1):203-12. [DOI: 10.1002/art.39840]">Saag 2017</a>). </p> </section> <section id="CD010069-sec-0089"> <h4 class="title">Febuxostat 80mg or 120mg compared to allopurinol</h4> <p><a href="./references#CD010069-bbs2-0002" title="BeckerMA , Schumacher HR Jr, WortmannRL , MacDonaldPA , EustaceD , PaloWA , StreitJ , Joseph-RidgeN . Febuxostat compared with allopurinol in patients with hyperuricemia and gout. New England Journal of Medicine December 8, 2005;353(23):2450-61. ">Becker 2005</a> did not have a placebo arm. A subset of patients had tophi at baseline. The study did not elucidate the number of patients with tophi at baseline in each intervention arm. Therefore we were unable to assess the results in more detail.   </p> </section> </section> <section id="CD010069-sec-0090"> <h3 class="title" id="CD010069-sec-0090">Potential biases in the review process</h3> <p>We used a sensitive search strategy and included searching of grey literature to identify as many studies as possible. However, we acknowledge that the time lag between the completion of the search and the publication of the review may be a potential source of bias. </p> <p>Two review authors independently extracted data, minimising errors and bias in the review process. </p> <p>We did not report data on pain, function and quality of life, as the included studies did not present these for participants with tophi. </p> </section> <section id="CD010069-sec-0091"> <h3 class="title" id="CD010069-sec-0091">Agreements and disagreements with other studies or reviews</h3> <p>To our knowledge, there have been no published systematic reviews examining interventions for tophi in gout in isolation, apart from our original review (<a href="./references#CD010069-bbs2-0031" title="Sriranganathan MK, VinikO , BombardierC , EdwardsCJ . Interventions for tophi in gout. Cochrane Database of Systematic Reviews2014, Issue 10. Art. No: CD010069. [DOI: 10.1002/14651858.CD010069.pub2]">Sriranganathan 2014</a>.) There is one previous Cochrane Review on pegloticase in chronic gout (<a href="./references#CD010069-bbs2-0018" title="AndersonA , SinghJA . Pegloticase for chronic gout. Cochrane Database of Systematic Reviews2010, Issue 3. Art. No: CD008335. [DOI: 10.1002/14651858.CD008335.pub2]">Anderson 2010</a>). However, the study did not report on tophi outcomes. </p> </section> </section> </section> <div class="figures-list"> <div class="figure" id="CD010069-fig-0001"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010069.pub3/media/CDSR/CD010069/urn:x-wiley:14651858:media:CD010069:CD010069-FIG-01" target="_blank"><b></b></a></p> </div><img alt="PRISMA Flow diagram for updated search 2020" data-id="CD010069-fig-0001" src="/cdsr/doi/10.1002/14651858.CD010069.pub3/media/CDSR/CD010069/image_n/nCD010069-FIG-01.png"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010069.pub3/media/CDSR/CD010069/image_t/tCD010069-FIG-01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 1</div> <div class="figure-caption"> <p>PRISMA Flow diagram for updated search 2020</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010069.pub3/full#CD010069-fig-0001">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010069.pub3/media/CDSR/CD010069/image_n/nCD010069-FIG-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010069-fig-0002"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010069.pub3/media/CDSR/CD010069/urn:x-wiley:14651858:media:CD010069:CD010069-FIG-02" target="_blank"><b></b></a></p> </div><img alt="Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies." data-id="CD010069-fig-0002" src="/cdsr/doi/10.1002/14651858.CD010069.pub3/media/CDSR/CD010069/image_n/nCD010069-FIG-02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010069.pub3/media/CDSR/CD010069/image_t/tCD010069-FIG-02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 2</div> <div class="figure-caption"> <p>Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010069.pub3/full#CD010069-fig-0002">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010069.pub3/media/CDSR/CD010069/image_n/nCD010069-FIG-02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010069-fig-0003"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010069.pub3/media/CDSR/CD010069/urn:x-wiley:14651858:media:CD010069:CD010069-FIG-03" target="_blank"><b></b></a></p> </div><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study." data-id="CD010069-fig-0003" src="/cdsr/doi/10.1002/14651858.CD010069.pub3/media/CDSR/CD010069/image_n/nCD010069-FIG-03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010069.pub3/media/CDSR/CD010069/image_t/tCD010069-FIG-03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 3</div> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010069.pub3/full#CD010069-fig-0003">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010069.pub3/media/CDSR/CD010069/image_n/nCD010069-FIG-03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010069-fig-0004"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010069.pub3/media/CDSR/CD010069/urn:x-wiley:14651858:media:CD010069:CD010069-CMP-001.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Pegloticase every two weeks (biweekly) versus placebo, Outcome 1: Proportion with tophi resolution" data-id="CD010069-fig-0004" src="/cdsr/doi/10.1002/14651858.CD010069.pub3/media/CDSR/CD010069/image_n/nCD010069-CMP-001.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010069.pub3/media/CDSR/CD010069/image_t/tCD010069-CMP-001.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.1</div> <div class="figure-caption"> <p>Comparison 1: Pegloticase every two weeks (biweekly) versus placebo, Outcome 1: Proportion with tophi resolution </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010069.pub3/references#CD010069-fig-0004">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010069.pub3/media/CDSR/CD010069/image_n/nCD010069-CMP-001.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010069-fig-0005"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010069.pub3/media/CDSR/CD010069/urn:x-wiley:14651858:media:CD010069:CD010069-CMP-001.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Pegloticase every two weeks (biweekly) versus placebo, Outcome 2: Withdrawal due to adverse events" data-id="CD010069-fig-0005" src="/cdsr/doi/10.1002/14651858.CD010069.pub3/media/CDSR/CD010069/image_n/nCD010069-CMP-001.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010069.pub3/media/CDSR/CD010069/image_t/tCD010069-CMP-001.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.2</div> <div class="figure-caption"> <p>Comparison 1: Pegloticase every two weeks (biweekly) versus placebo, Outcome 2: Withdrawal due to adverse events </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010069.pub3/references#CD010069-fig-0005">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010069.pub3/media/CDSR/CD010069/image_n/nCD010069-CMP-001.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010069-fig-0006"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010069.pub3/media/CDSR/CD010069/urn:x-wiley:14651858:media:CD010069:CD010069-CMP-001.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Pegloticase every two weeks (biweekly) versus placebo, Outcome 3: Total adverse events" data-id="CD010069-fig-0006" src="/cdsr/doi/10.1002/14651858.CD010069.pub3/media/CDSR/CD010069/image_n/nCD010069-CMP-001.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010069.pub3/media/CDSR/CD010069/image_t/tCD010069-CMP-001.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.3</div> <div class="figure-caption"> <p>Comparison 1: Pegloticase every two weeks (biweekly) versus placebo, Outcome 3: Total adverse events </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010069.pub3/references#CD010069-fig-0006">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010069.pub3/media/CDSR/CD010069/image_n/nCD010069-CMP-001.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010069-fig-0007"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010069.pub3/media/CDSR/CD010069/urn:x-wiley:14651858:media:CD010069:CD010069-CMP-002.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Pegloticase monthly versus placebo, Outcome 1: Proportion with tophi resolution" data-id="CD010069-fig-0007" src="/cdsr/doi/10.1002/14651858.CD010069.pub3/media/CDSR/CD010069/image_n/nCD010069-CMP-002.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010069.pub3/media/CDSR/CD010069/image_t/tCD010069-CMP-002.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.1</div> <div class="figure-caption"> <p>Comparison 2: Pegloticase monthly versus placebo, Outcome 1: Proportion with tophi resolution </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010069.pub3/references#CD010069-fig-0007">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010069.pub3/media/CDSR/CD010069/image_n/nCD010069-CMP-002.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010069-fig-0008"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010069.pub3/media/CDSR/CD010069/urn:x-wiley:14651858:media:CD010069:CD010069-CMP-002.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Pegloticase monthly versus placebo, Outcome 2: Withdrawal due to adverse events" data-id="CD010069-fig-0008" src="/cdsr/doi/10.1002/14651858.CD010069.pub3/media/CDSR/CD010069/image_n/nCD010069-CMP-002.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010069.pub3/media/CDSR/CD010069/image_t/tCD010069-CMP-002.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.2</div> <div class="figure-caption"> <p>Comparison 2: Pegloticase monthly versus placebo, Outcome 2: Withdrawal due to adverse events </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010069.pub3/references#CD010069-fig-0008">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010069.pub3/media/CDSR/CD010069/image_n/nCD010069-CMP-002.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010069-fig-0009"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010069.pub3/media/CDSR/CD010069/urn:x-wiley:14651858:media:CD010069:CD010069-CMP-002.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Pegloticase monthly versus placebo, Outcome 3: Total adverse events" data-id="CD010069-fig-0009" src="/cdsr/doi/10.1002/14651858.CD010069.pub3/media/CDSR/CD010069/image_n/nCD010069-CMP-002.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010069.pub3/media/CDSR/CD010069/image_t/tCD010069-CMP-002.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.3</div> <div class="figure-caption"> <p>Comparison 2: Pegloticase monthly versus placebo, Outcome 3: Total adverse events</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010069.pub3/references#CD010069-fig-0009">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010069.pub3/media/CDSR/CD010069/image_n/nCD010069-CMP-002.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010069-fig-0010"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010069.pub3/media/CDSR/CD010069/urn:x-wiley:14651858:media:CD010069:CD010069-CMP-003.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Pegloticase every two weeks (biweekly) versus pegloticase monthly, Outcome 1: Proportion with tophi resolution" data-id="CD010069-fig-0010" src="/cdsr/doi/10.1002/14651858.CD010069.pub3/media/CDSR/CD010069/image_n/nCD010069-CMP-003.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010069.pub3/media/CDSR/CD010069/image_t/tCD010069-CMP-003.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.1</div> <div class="figure-caption"> <p>Comparison 3: Pegloticase every two weeks (biweekly) versus pegloticase monthly, Outcome 1: Proportion with tophi resolution </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010069.pub3/references#CD010069-fig-0010">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010069.pub3/media/CDSR/CD010069/image_n/nCD010069-CMP-003.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010069-fig-0011"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010069.pub3/media/CDSR/CD010069/urn:x-wiley:14651858:media:CD010069:CD010069-CMP-004.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 4: Lesinurad 200 mg plus allopurinol versus placebo plus allopurinol , Outcome 1: Complete resolution of a target tophus" data-id="CD010069-fig-0011" src="/cdsr/doi/10.1002/14651858.CD010069.pub3/media/CDSR/CD010069/image_n/nCD010069-CMP-004.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010069.pub3/media/CDSR/CD010069/image_t/tCD010069-CMP-004.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.1</div> <div class="figure-caption"> <p>Comparison 4: Lesinurad 200 mg plus allopurinol versus placebo plus allopurinol , Outcome 1: Complete resolution of a target tophus </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010069.pub3/references#CD010069-fig-0011">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010069.pub3/media/CDSR/CD010069/image_n/nCD010069-CMP-004.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010069-fig-0012"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010069.pub3/media/CDSR/CD010069/urn:x-wiley:14651858:media:CD010069:CD010069-CMP-005.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 5: Lesinurad 400 mg plus allopurinol versus placebo plus allopurinol, Outcome 1: Complete resolution of a target tophus" data-id="CD010069-fig-0012" src="/cdsr/doi/10.1002/14651858.CD010069.pub3/media/CDSR/CD010069/image_n/nCD010069-CMP-005.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010069.pub3/media/CDSR/CD010069/image_t/tCD010069-CMP-005.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.1</div> <div class="figure-caption"> <p>Comparison 5: Lesinurad 400 mg plus allopurinol versus placebo plus allopurinol, Outcome 1: Complete resolution of a target tophus </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010069.pub3/references#CD010069-fig-0012">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010069.pub3/media/CDSR/CD010069/image_n/nCD010069-CMP-005.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010069-fig-0013"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010069.pub3/media/CDSR/CD010069/urn:x-wiley:14651858:media:CD010069:CD010069-CMP-006.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 6: Lesinurad 400 mg plus febuxostat CONTINUED versus lesinurad 200 mg plus febuxostat CONTINUED, Outcome 1: Complete resolution of a target tophus" data-id="CD010069-fig-0013" src="/cdsr/doi/10.1002/14651858.CD010069.pub3/media/CDSR/CD010069/image_n/nCD010069-CMP-006.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010069.pub3/media/CDSR/CD010069/image_t/tCD010069-CMP-006.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.1</div> <div class="figure-caption"> <p>Comparison 6: Lesinurad 400 mg plus febuxostat CONTINUED versus lesinurad 200 mg plus febuxostat CONTINUED, Outcome 1: Complete resolution of a target tophus </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010069.pub3/references#CD010069-fig-0013">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010069.pub3/media/CDSR/CD010069/image_n/nCD010069-CMP-006.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010069-fig-0014"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010069.pub3/media/CDSR/CD010069/urn:x-wiley:14651858:media:CD010069:CD010069-CMP-006.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 6: Lesinurad 400 mg plus febuxostat CONTINUED versus lesinurad 200 mg plus febuxostat CONTINUED, Outcome 2: Total adverse events" data-id="CD010069-fig-0014" src="/cdsr/doi/10.1002/14651858.CD010069.pub3/media/CDSR/CD010069/image_n/nCD010069-CMP-006.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010069.pub3/media/CDSR/CD010069/image_t/tCD010069-CMP-006.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.2</div> <div class="figure-caption"> <p>Comparison 6: Lesinurad 400 mg plus febuxostat CONTINUED versus lesinurad 200 mg plus febuxostat CONTINUED, Outcome 2: Total adverse events </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010069.pub3/references#CD010069-fig-0014">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010069.pub3/media/CDSR/CD010069/image_n/nCD010069-CMP-006.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010069-fig-0015"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010069.pub3/media/CDSR/CD010069/urn:x-wiley:14651858:media:CD010069:CD010069-CMP-006.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 6: Lesinurad 400 mg plus febuxostat CONTINUED versus lesinurad 200 mg plus febuxostat CONTINUED, Outcome 3: Withdrawal due to adverse event" data-id="CD010069-fig-0015" src="/cdsr/doi/10.1002/14651858.CD010069.pub3/media/CDSR/CD010069/image_n/nCD010069-CMP-006.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010069.pub3/media/CDSR/CD010069/image_t/tCD010069-CMP-006.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.3</div> <div class="figure-caption"> <p>Comparison 6: Lesinurad 400 mg plus febuxostat CONTINUED versus lesinurad 200 mg plus febuxostat CONTINUED, Outcome 3: Withdrawal due to adverse event </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010069.pub3/references#CD010069-fig-0015">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010069.pub3/media/CDSR/CD010069/image_n/nCD010069-CMP-006.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010069-fig-0016"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010069.pub3/media/CDSR/CD010069/urn:x-wiley:14651858:media:CD010069:CD010069-CMP-006.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 6: Lesinurad 400 mg plus febuxostat CONTINUED versus lesinurad 200 mg plus febuxostat CONTINUED, Outcome 4: Mean serum uric acid (sUA) at end of 12 months" data-id="CD010069-fig-0016" src="/cdsr/doi/10.1002/14651858.CD010069.pub3/media/CDSR/CD010069/image_n/nCD010069-CMP-006.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010069.pub3/media/CDSR/CD010069/image_t/tCD010069-CMP-006.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.4</div> <div class="figure-caption"> <p>Comparison 6: Lesinurad 400 mg plus febuxostat CONTINUED versus lesinurad 200 mg plus febuxostat CONTINUED, Outcome 4: Mean serum uric acid (sUA) at end of 12 months </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010069.pub3/references#CD010069-fig-0016">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010069.pub3/media/CDSR/CD010069/image_n/nCD010069-CMP-006.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010069-fig-0017"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010069.pub3/media/CDSR/CD010069/urn:x-wiley:14651858:media:CD010069:CD010069-CMP-007.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 7: Lesinurad 400 mg plus febuxostat CROSS versus lesinurad 200 mg plus febuxostat CROSS, Outcome 1: Complete resolution of a target tophus" data-id="CD010069-fig-0017" src="/cdsr/doi/10.1002/14651858.CD010069.pub3/media/CDSR/CD010069/image_n/nCD010069-CMP-007.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010069.pub3/media/CDSR/CD010069/image_t/tCD010069-CMP-007.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.1</div> <div class="figure-caption"> <p>Comparison 7: Lesinurad 400 mg plus febuxostat CROSS versus lesinurad 200 mg plus febuxostat CROSS, Outcome 1: Complete resolution of a target tophus </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010069.pub3/references#CD010069-fig-0017">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010069.pub3/media/CDSR/CD010069/image_n/nCD010069-CMP-007.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010069-fig-0018"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010069.pub3/media/CDSR/CD010069/urn:x-wiley:14651858:media:CD010069:CD010069-CMP-007.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 7: Lesinurad 400 mg plus febuxostat CROSS versus lesinurad 200 mg plus febuxostat CROSS, Outcome 2: Total adverse events" data-id="CD010069-fig-0018" src="/cdsr/doi/10.1002/14651858.CD010069.pub3/media/CDSR/CD010069/image_n/nCD010069-CMP-007.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010069.pub3/media/CDSR/CD010069/image_t/tCD010069-CMP-007.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.2</div> <div class="figure-caption"> <p>Comparison 7: Lesinurad 400 mg plus febuxostat CROSS versus lesinurad 200 mg plus febuxostat CROSS, Outcome 2: Total adverse events </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010069.pub3/references#CD010069-fig-0018">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010069.pub3/media/CDSR/CD010069/image_n/nCD010069-CMP-007.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010069-fig-0019"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010069.pub3/media/CDSR/CD010069/urn:x-wiley:14651858:media:CD010069:CD010069-CMP-007.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 7: Lesinurad 400 mg plus febuxostat CROSS versus lesinurad 200 mg plus febuxostat CROSS, Outcome 3: Withdrawal due to adverse event" data-id="CD010069-fig-0019" src="/cdsr/doi/10.1002/14651858.CD010069.pub3/media/CDSR/CD010069/image_n/nCD010069-CMP-007.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010069.pub3/media/CDSR/CD010069/image_t/tCD010069-CMP-007.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.3</div> <div class="figure-caption"> <p>Comparison 7: Lesinurad 400 mg plus febuxostat CROSS versus lesinurad 200 mg plus febuxostat CROSS, Outcome 3: Withdrawal due to adverse event </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010069.pub3/references#CD010069-fig-0019">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010069.pub3/media/CDSR/CD010069/image_n/nCD010069-CMP-007.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010069-fig-0020"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010069.pub3/media/CDSR/CD010069/urn:x-wiley:14651858:media:CD010069:CD010069-CMP-007.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 7: Lesinurad 400 mg plus febuxostat CROSS versus lesinurad 200 mg plus febuxostat CROSS, Outcome 4: Mean serum uric acid (sUA) at end of 12 months" data-id="CD010069-fig-0020" src="/cdsr/doi/10.1002/14651858.CD010069.pub3/media/CDSR/CD010069/image_n/nCD010069-CMP-007.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010069.pub3/media/CDSR/CD010069/image_t/tCD010069-CMP-007.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.4</div> <div class="figure-caption"> <p>Comparison 7: Lesinurad 400 mg plus febuxostat CROSS versus lesinurad 200 mg plus febuxostat CROSS, Outcome 4: Mean serum uric acid (sUA) at end of 12 months </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010069.pub3/references#CD010069-fig-0020">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010069.pub3/media/CDSR/CD010069/image_n/nCD010069-CMP-007.04.svg" target="_blank">Open in new tab</a></div> </div> </div> <div class="tables-list"> <div class="table"> <table class="summary-of-findings framed" data-id="CD010069-tbl-0001"> <div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Pegloticase every two weeks (biweekly) compared with placebo for tophi in gout</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Pegloticase every two weeks (biweekly) compared with placebo for tophi in gout</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> participants with tophi in gout<br/><b>Settings:</b> clinic<br/><b>Intervention:</b> pegloticase every two weeks (biweekly)<br/><b>Comparison:</b> placebo </p> </td> </tr> <tr class="separated"> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="center" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>No of participants<br/>(studies)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with placebo</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p>Risk difference with b<b>iweekly pegloticase</b> </p> </th> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Proportion with complete resolution of tophi<br/>Follow‐up: median 6 months </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>74 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>404 per 1000<br/>(104 to 1000) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 5.45<br/>(1.38 to 21.54) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>79<br/>(1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/>MODERATE<sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Biweekly pegloticase probably improves resolution of tophi.</p> <p>Absolute improvement with pegloticase 33% (16% better to 50% better)</p> <p>Relative change 445% (40% better to 2060% better)</p> <p>NNTB 3 (2 to 6)</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Joint pain reduction ‐ not reported</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Reported for all participants but not separately for people with tophi</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Quality of life ‐ not reported</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Reported for all participants but not separately for people with tophi</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Serum urate normalisation ‐ not reported</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Reported for all participants but not separately for people with tophi</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Function ‐ not reported</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Reported for all participants but not separately for people with tophi</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Number of participant withdrawals due to adverse events</p> <p>Follow‐up: median 6 months</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>23 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>177 per 1000<br/>(24 to 1000) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 7.59<br/>(1.04 to 55.55) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>128<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/>MODERATE<sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Biweekly pegloticase probably increases withdrawals due to adverse events.</p> <p>Absolute increase in withdrawals with pegloticase 16% (8% more to 28% more)</p> <p>Relative increase in withdrawals 660% (4% more to 5455% more)</p> <p>NNTH 7 (4 to 16)</p> <p>(Reported for all participants but not separately for those with tophi)</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Total adverse events</p> <p>Follow‐up: 25 weeks</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>953 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>941 per 1000</p> <p>(851 to 1000)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.99 (0.91</p> <p>to 1.07)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>128 (1 RCT)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/>MODERATE<sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Biweekly pegloticase probably results in little or no difference in adverse events.</p> <p>Absolute decrease in adverse events with pegloticase 1% (9% decrease to 7% increase)</p> <p>Relative decrease 1% (10% decrease to 7% increase)</p> <p>NNTH ‐ not applicable</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><b>CI:</b> confidence interval; <b>NNTB:</b> number needed to treat for an additional beneficial outcome; <b>NNTH:</b> number needed to treat for an additional harmful outcome; <b>RR:</b> risk ratio. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/><b>High certainty:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/><b>Moderate certainty:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/><b>Low certainty:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/><b>Very low certainty:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Estimates are from a single study, and wide confidence intervals indicate imprecision. Downgraded by one level. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Pegloticase every two weeks (biweekly) compared with placebo for tophi in gout</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD010069.pub3/full#CD010069-tbl-0001">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD010069-tbl-0002"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Monthly pegloticase compared with placebo for tophi in gout</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Monthly pegloticase compared with placebo for tophi in gout</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> participants with tophi in gout<br/><b>Settings:</b> clinic<br/><b>Intervention:</b> monthly pegloticase<br/><b>Comparison:</b> placebo </p> </td> </tr> <tr class="separated"> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="center" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>No of participants<br/>(studies)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with placebo</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p>Risk difference with m<b>onthly pegloticase</b> </p> </th> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Proportion with complete resolution of tophi<br/>Follow‐up: mean 6 months </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>74 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>212 per 1000<br/>(52 to 889) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 2.86<br/>(0.68, 11.97) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>79<br/>(1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/>MODERATE<sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Monthly pegloticase probably improves resolution of tophi. Absolute improvement with pegloticase: 14% (1% worse to 29% better) </p> <p>Relative change: 190% improvement (30% worse to 1100% better)</p> <p>NNTB 8 (95% CI 4 to 91)</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Joint pain reduction ‐ not reported</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Reported for all participants but not separately for people with tophi</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Quality of life ‐ not reported</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not estimable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Reported for all participants but not separately for people with tophi</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Serum urate normalisation ‐ not reported</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Reported for all participants but not separately for people with tophi</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Function ‐ not reported</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not estimable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Reported for all participants but not separately for people with tophi</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Number of participant withdrawals due to adverse events</p> <p>Follow‐up: mean 6 months</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>23 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>190 per 1000<br/>(166 to 1000) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RR 8.19 <br/>(1.12 to 59.71) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>127<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊕⊝<br/>MODERATE<sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Monthly pegloticase probably increases withdrawals due to adverse events. Absolute increase in withdrawals with pegloticase: 17% (7% to 26%), which was clinically significant. </p> <p>Relative change: 719% more withdrawals (12% more to 5870% more)</p> <p>NNTH 6 (4 to 14)</p> <p>(Reported for all participants but not separately for people with tophi)</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Total adverse events</p> <p>Follow‐up: mean 6 months</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>953 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>1000 per 1000</p> <p>(980 to 1000)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 1.05</p> <p>(0.98 to 1.14)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>127 (1 RCT)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/>MODERATE<sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Monthly pegloticase probably results in little or no difference in adverse events. Absolute increase with pegloticase: 5% (20% decrease to 12% increase) </p> <p>Relative increase 5% (2% decrease to 14% increase)</p> <p>NNTH ‐ not applicable</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><b>CI:</b> confidence interval; <b>NNTB:</b> number needed to treat for an additional beneficial outcome; <b>NNTH:</b> number needed to treat for an additional harmful outcome; <b>RR:</b> risk ratio. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/><b>High certainty:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/><b>Moderate certainty:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/><b>Low certainty:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/><b>Very low certainty:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Estimates are from a single study, and wide confidence intervals indicate imprecision. Downgraded by one level. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Monthly pegloticase compared with placebo for tophi in gout</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD010069.pub3/full#CD010069-tbl-0002">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD010069-tbl-0003"> <div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">Lesinurad 200 mg plus allopurinol compared to placebo plus allopurinol for tophi in gout</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Lesinurad 200 mg plus allopurinol compared to placebo plus allopurinol for tophi in gout</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> participants with tophi in gout<br/><b>Setting:</b> clinic<br/><b>Intervention:</b> lesinurad 200 mg plus allopurinol<br/><b>Comparison:</b> placebo plus allopurinol </p> </td> </tr> <tr class="separated"> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="center" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect</b> <br/><b>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>No of participants</b> <br/><b>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence</b> <br/><b>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with allopurinol alone</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk difference with lesinurad 200 mg plus allopurinol</b> </p> </th> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Proportion with complete resolution of a target tophus</p> <p>Follow up: 12 months</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>320 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>128 fewer per 1000<br/>(13 fewer to 1000 more) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RR 0.40 (0.04, 4.57)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>103<br/>(2 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊕⊝<br/>MODERATE<sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Lesinurad 200 mg plus allopurinol is probably not beneficial for the resolution of tophi in gout. Absolute reduction 19% (31% less to 114% more) </p> <p>Relative reduction 60% (96% less to 357% more)</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><br/><b>CI:</b> Confidence interval; <b>RR:</b> Risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> We are very confident that the true effect lies close to that of the estimate of the effect<br/><b>Moderate certainty:</b> We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/><b>Low certainty:</b> Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect<br/><b>Very low certainty:</b> We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Downgraded for imprecision as low number of participants. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">Lesinurad 200 mg plus allopurinol compared to placebo plus allopurinol for tophi in gout</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD010069.pub3/full#CD010069-tbl-0003">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD010069-tbl-0004"> <div class="table-heading"><span class="table-label">Summary of findings 4.</span> <span class="table-title">Lesinurad 400 mg plus allopurinol compared to placebo plus allopurinol for tophi in gout</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Lesinurad 400 mg plus allopurinol compared to placebo plus allopurinol for tophi in gout</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> participants with tophi in gout<br/><b>Setting:</b> clinic<br/><b>Intervention:</b> lesinurad 400 mg plus allopurinol<br/><b>Comparison:</b> placebo plus allopurinol </p> </td> </tr> <tr class="separated"> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="center" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect</b> <br/><b>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>№ of participants</b> <br/><b>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence</b> <br/><b>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with allopurinol alone</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk difference with lesinurad 400 mg plus allopurinol</b> </p> </th> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Proportion with complete resolution of a target tophus</p> <p>Follow up:12 months</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>320 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>253 per 1000<br/>(134 fewer to 477 more) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.79<br/>(0.42 to 1.49) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>98<br/>(2 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/>MODERATE<sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Lesinurad 400 mg plus allopurinol is probably not beneficial for the resolution of tophi in gout. Absolute reduction 6.7% fewer (18.6% fewer to 15.7% more) </p> <p>Relative reduction 21% fewer (58% fewer to 49% more)</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><br/><b>CI:</b> Confidence interval; <b>RR:</b> Risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> We are very confident that the true effect lies close to that of the estimate of the effect<br/><b>Moderate certainty:</b> We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/><b>Low certainty:</b> Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect<br/><b>Very low certainty:</b> We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>The number of participants with tophi from both studies was small; downgraded by one level for imprecision. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 4.</span> <span class="table-title">Lesinurad 400 mg plus allopurinol compared to placebo plus allopurinol for tophi in gout</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD010069.pub3/full#CD010069-tbl-0004">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD010069-tbl-0005"> <div class="table-heading"><span class="table-label">Summary of findings 5.</span> <span class="table-title">Lesinurad 400 mg plus febuxostat CONTINUED compared to lesinurad 200 mg plus febuxostat CONTINUED for tophi in gout</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Lesinurad 400 mg plus febuxostat CONTINUED compared to lesinurad 200 mg plus febuxostat CONTINUED for tophi in gout</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> participants with tophi in gout<br/><b>Setting:</b> clinic<br/><b>Intervention:</b> lesinurad 400 mg plus febuxostat CONTINUED<br/><b>Comparison:</b> lesinurad 200 mg plus febuxostat CONTINUED </p> </td> </tr> <tr class="separated"> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="center" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect</b> <br/><b>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>№ of participants</b> <br/><b>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence</b> <br/><b>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with lesinurad 200 mg plus febuxostat CONTINUED</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk difference with lesinurad 400 mg plus febuxostat CONTINUED</b> </p> </th> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Proportion with complete resolution of a target tophus</p> <p>Follow up: 12 months</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>594 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>65 more per 1000<br/>(89 fewer to 273 more) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RR 1.11<br/>(0.85 to 1.46) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>129<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊝⊝<br/>LOW<sup>a,b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Lesinurad 400 mg in combination with febuxostat may be beneficial for resolution of tophi in gout. Absolute improvement 7% (10% less to 23% more) </p> <p>Relative improvement 12% (3% less to 19% more)</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Total adverse events</p> <p>Follow up: 12 months</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>781 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>94 more per 1000<br/>(31 fewer to 250 more) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 1.12<br/>(0.96 to 1.32) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>129<br/>(1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/>LOW<sup>a,b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Lesinurad 400 mg in combination with febuxostat may result in little to no difference in adverse events. Absolute increase 9% (3% less to 25% more) </p> <p>Relative increase 12% (8% less to 17% more)</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Number of participant withdrawals due to adverse events</p> <p>Follow up: 12 months</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>156 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>3 fewer per 1000<br/>(88 fewer to 188 more) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.98<br/>(0.44 to 2.20) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>129<br/>(1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/>LOW<sup>a,b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Lesinurad 400 mg in combination with febuxostat may result in little to no difference in withdrawals due to adverse events. Absolute reduction 0.3% (9% less to 188% more) </p> <p>Relative reduction 1.92% (20% less to 20% more)</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean sUA at end of 12 months</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean sUA at end of 12 months was 3.9 mg/dl</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>MD 0.9 mg/dl lower<br/>(1.51 lower to 0.29 lower) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>129<br/>(1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/>LOW<sup>a,b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Lesinurad 400 mg in combination with febuxostat may result in little to no difference in mean serum uric acid. Absolute reduction 0.9% (1.5% lower to 0.3% lower) relative reduction 2.2% (3.75% lower to 0.7% lower)<sup>c</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><br/><b>CI:</b> Confidence interval; <b>RR:</b> Risk ratio;<b>sUA</b>: serum uric acid </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> We are very confident that the true effect lies close to that of the estimate of the effect<br/><b>Moderate certainty:</b> We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/><b>Low certainty:</b> Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect<br/><b>Very low certainty:</b> We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Downgraded for indirectness. Study is an extension trial. There is no placebo arm. Thus unable to assess if interventions are better than placebo.<br/><sup>b</sup>Downgraded for imprecision as low number of participants.<br/><sup>c</sup>Relative change calculated based on mean (SD) sUA in control group (lesinurad 200 mg CONT) at baseline 4 mg/dl (2.2) (<a href="./references#CD010069-bbs2-0003" title="Dalbeth, N, Jones, G, Terkeltaub, R, Khanna, D, Kopicko, J, Bhakta, N et al. Lesinurad, a Selective Uric Acid Reabsorption Inhibitor, in Combination With Febuxostat in Patients With Tophaceous Gout: Findings of a Phase III Clinical Trial. Arthritis &amp; Rheumatology2017;69:1903-13. DalbethN , JonesG , TerkeltaubR , KhannaD , FungM , BaumgartnerS , et al. Efficacy and safety during extended treatment of lesinurad in combination with febuxostat in patients with tophaceous gout: CRYSTAL extension study. Arthritis Research &amp; Therapy2019;21(1):8. [DOI: https://dx.doi.org/10.1186/s13075-018-1788-4]">Dalbeth 2019</a>). ‘CONT’ = patients who continued with the same treatment as given during original CRYSTAL study i.e. febuxostat plus lesinurad or placebo </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 5.</span> <span class="table-title">Lesinurad 400 mg plus febuxostat CONTINUED compared to lesinurad 200 mg plus febuxostat CONTINUED for tophi in gout</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD010069.pub3/full#CD010069-tbl-0005">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD010069-tbl-0006"> <div class="table-heading"><span class="table-label">Summary of findings 6.</span> <span class="table-title">Lesinurad 400 mg plus febuxostat CROSS compared to lesinurad 200 mg plus febuxostat CROSS for tophi in gout</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Lesinurad 400 mg plus febuxostat CROSS compared to lesinurad 200 mg plus febuxostat CROSS for tophi in gout</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> participants with tophi in gout<br/><b>Setting:</b> clinic<br/><b>Intervention:</b> lesinurad 400 mg plus febuxostat CROSS<br/><b>Comparison:</b> lesinurad 200 mg plus febuxostat CROSS </p> </td> </tr> <tr class="separated"> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="center" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect</b> <br/><b>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>№ of participants</b> <br/><b>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence</b> <br/><b>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with lesinurad 200 mg plus febuxostat CROSS</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk difference with lesinurad 400 mg plus febuxostat CROSS</b> </p> </th> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Proportion with complete resolution of a target tophus</p> <p>Follow up: 12 months</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>424 per 1,000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>76 more per 1,000<br/>(127 fewer to 416 more) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 1.18<br/>(0.70 to 1.98) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>67<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/>LOW<sup>a,b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Lesinurad 400 mg plus febuxostat may be beneficial for resolution of tophi in gout. Absolute improvement 8% (16% less to 31% more) </p> <p>Relative improvement 19% (7% less to 30% more)</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Total adverse events</p> <p>Follow up: 12 months</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>818 per 1,000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>152 more per 1,000<br/>(29 fewer to 178 more) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 1.19 (1.00 to 1.41)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>67<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/>LOW<sup>a,b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Lesinurad 400 mg in combination with febuxostat may result in no difference in adverse events. Absolute increase 15% (2.9% less to 18% better) </p> <p>Relative increase 18.6% (15% less to 23% more)</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Number of participant withdrawals due to adverse events</p> <p>Follow up: 12 months</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>61 per 1,000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>86 more per 1,000<br/>(31 fewer to 429 more)  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 2.43 (0.51 to 11.64)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>67<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/>LOW<sup>a,b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Lesinurad 400 mg plus febuxostat may result in little to no difference in withdrawals due to adverse events. Absolute increase 8.6% (3% less to 43% more) </p> <p>Relative increase 142% (81% less to 221% more)</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean sUA at end of 12 months</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean sUA at end of 12 months was 3.8 mg/dl</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>MD 0.4 mg/dl higher<br/>(0.75 lower to 1.55 higher) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>67<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/>LOW<sup>a,b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Lesinurad 400 mg plus febuxostat may result in no difference in serum uric acid. Absolute difference 0.4% higher (0.75% lower to 1.55% higher) relative difference 0.7% higher (1.4% lower to 2.9% higher)<sup>c</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><br/><b>CI:</b> Confidence interval; <b>RR:</b> Risk ratio; <b>sUA</b>: serum uric acid </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> We are very confident that the true effect lies close to that of the estimate of the effect<br/><b>Moderate certainty:</b> We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/><b>Low certainty:</b> Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect<br/><b>Very low certainty:</b> We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Downgraded for indirectness. This is an extension study with no placebo arm. Therefore we have only been able to compare different interventions against each other.<br/><sup>b</sup>Downgraded for imprecision; number of participants/events was small<br/><sup>c</sup>Relative change calculated based on mean (SD) sUA in control group (lesinurad 200 mg CROSS) at baseline 5.2 mg/dl (1.7) <a href="./references#CD010069-bbs2-0003" title="Dalbeth, N, Jones, G, Terkeltaub, R, Khanna, D, Kopicko, J, Bhakta, N et al. Lesinurad, a Selective Uric Acid Reabsorption Inhibitor, in Combination With Febuxostat in Patients With Tophaceous Gout: Findings of a Phase III Clinical Trial. Arthritis &amp; Rheumatology2017;69:1903-13. DalbethN , JonesG , TerkeltaubR , KhannaD , FungM , BaumgartnerS , et al. Efficacy and safety during extended treatment of lesinurad in combination with febuxostat in patients with tophaceous gout: CRYSTAL extension study. Arthritis Research &amp; Therapy2019;21(1):8. [DOI: https://dx.doi.org/10.1186/s13075-018-1788-4]">Dalbeth 2019</a>. ‘CROSS’ = patients who crossed into different treatment arm, i.e. randomised to receive lesinurad instead of placebo in combination with febuxostat </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 6.</span> <span class="table-title">Lesinurad 400 mg plus febuxostat CROSS compared to lesinurad 200 mg plus febuxostat CROSS for tophi in gout</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD010069.pub3/full#CD010069-tbl-0006">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD010069-tbl-0007"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Pegloticase every two weeks (biweekly) versus placebo</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.1 Proportion with tophi resolution <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.2 Withdrawal due to adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.3 Total adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Pegloticase every two weeks (biweekly) versus placebo</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD010069.pub3/references#CD010069-tbl-0007">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD010069-tbl-0008"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Pegloticase monthly versus placebo</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.1 Proportion with tophi resolution <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.2 Withdrawal due to adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.3 Total adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Pegloticase monthly versus placebo</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD010069.pub3/references#CD010069-tbl-0008">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD010069-tbl-0009"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">Pegloticase every two weeks (biweekly) versus pegloticase monthly</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.1 Proportion with tophi resolution <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">Pegloticase every two weeks (biweekly) versus pegloticase monthly</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD010069.pub3/references#CD010069-tbl-0009">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD010069-tbl-0010"> <div class="table-heading"><span class="table-label">Comparison 4.</span> <span class="table-title">Lesinurad 200 mg plus allopurinol versus placebo plus allopurinol </span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4.1 Complete resolution of a target tophus <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>103</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.40 [0.04, 4.57]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 4.</span> <span class="table-title">Lesinurad 200 mg plus allopurinol versus placebo plus allopurinol </span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD010069.pub3/references#CD010069-tbl-0010">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD010069-tbl-0011"> <div class="table-heading"><span class="table-label">Comparison 5.</span> <span class="table-title">Lesinurad 400 mg plus allopurinol versus placebo plus allopurinol</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5.1 Complete resolution of a target tophus <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>98</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.79 [0.42, 1.49]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 5.</span> <span class="table-title">Lesinurad 400 mg plus allopurinol versus placebo plus allopurinol</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD010069.pub3/references#CD010069-tbl-0011">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD010069-tbl-0012"> <div class="table-heading"><span class="table-label">Comparison 6.</span> <span class="table-title">Lesinurad 400 mg plus febuxostat CONTINUED versus lesinurad 200 mg plus febuxostat CONTINUED</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6.1 Complete resolution of a target tophus <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6.2 Total adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6.3 Withdrawal due to adverse event <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6.4 Mean serum uric acid (sUA) at end of 12 months <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 6.</span> <span class="table-title">Lesinurad 400 mg plus febuxostat CONTINUED versus lesinurad 200 mg plus febuxostat CONTINUED</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD010069.pub3/references#CD010069-tbl-0012">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD010069-tbl-0013"> <div class="table-heading"><span class="table-label">Comparison 7.</span> <span class="table-title">Lesinurad 400 mg plus febuxostat CROSS versus lesinurad 200 mg plus febuxostat CROSS</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7.1 Complete resolution of a target tophus <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7.2 Total adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7.3 Withdrawal due to adverse event <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7.4 Mean serum uric acid (sUA) at end of 12 months <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 7.</span> <span class="table-title">Lesinurad 400 mg plus febuxostat CROSS versus lesinurad 200 mg plus febuxostat CROSS</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD010069.pub3/references#CD010069-tbl-0013">Navigate to table in review</a></div> </div> </div> <noscript> <img height="1" src="/scolaris-auth/report/nonjs/fulltexthtmlreg?doi=10.1002%2F14651858.CD010069.pub3&amp;rf=&amp;articleType=CDSR" style="display:none" width="1"> </img></noscript> <section class="translation-notes-modal" data-modal-class="translation-notes" data-modal-title="Translation notes" data-ok-btn-selector=".ok-btn" style="display: none"> <div class="translation-notes"> <div class="section-language-toggles"> <nav class="section-languages"> <ul> <li class="section-languages-legend">Available in</li> <li class="section-language"> <a class="" href="es#CD010069-note-0014">Español</a> </li> <li class="section-language"> <a class="" href="fa#CD010069-note-0013">فارسی</a> </li> <li class="section-language"> <a class="" href="hr#CD010069-note-0012">Hrvatski</a> </li> <li class="section-language"> <a class="" href="ms#CD010069-note-0011">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="ru#CD010069-note-0010">Русский</a> </li> <li class="section-language"> <a class="" href="zh_HANS#CD010069-note-0008">简体中文</a> </li> <li class="section-language"> <a class="" href="zh_HANT#CD010069-note-0009">繁體中文</a> </li> </ul> </nav> </div> <section class="translation-notes-content"> </section> <button class="btn primary ok-btn pull-right" type="button">Close</button> </div> </section></article> </div> <div class="citation-modal" style="display: none"> <div class="export-citation-header"> <p class="inset-message" data-load-error="Unable to load citation data" id="citeProcText"></p> </div> <div class="export-citation-body row-fluid"> <div class="span12"> <div class="addthis_toolbox addthis_default_style addthis_16x16_style"> <nav class="inline-nav-list is-bordered"> <li> <h4 class="heading">Save citation to:</h4> </li> <li><a class="citation-btn-refworks at300b btn btn-link" href="#" id="refWorksCitationBtn"><span class="citation-icon refworks"></span>RefWorks</a></li> <li><a class="citation-btn-sciwheel at300b btn btn-link disabled" href="#" id="sciWheelCitationBtn" target="_blank"><span class="citation-icon sciwheel"></span>SciWheel</a></li> </nav> </div> </div> </div> <div class="row-fluid"> <div class="span12"> <div class="citation-format"> <h4>Copy or download citation</h4> <a href="/en/help/exporting-search-results" rel="noopener noreferrer" target="_blank">Export help</a> </div> <nav class="inline-nav-list has-dividers"> <li class="citation-option" data-option="plain"><button class="btn btn-link" type="button">Plain text</button></li> <li class="citation-option" data-option="endnote"><button class="btn btn-link" type="button">EndNote</button></li> <li class="citation-option" data-option="refmanager"><button class="btn btn-link" type="button">Reference Manager</button></li> <li class="citation-option" data-option="procite"><button class="btn btn-link" type="button">ProCite</button></li> <li class="citation-option" data-option="bibtex"><button class="btn btn-link" type="button">BibteX</button></li> <li class="citation-option" data-option="csv"><button class="btn btn-link" type="button">CSV (Excel)</button></li> </nav> <div class="citation-content"> <pre data-load-error="Unable to load citation data" id="citationContent" tabindex="0"></pre> </div> <div class="clearfix"> <form class="download-citation-form" data-citation-citeproc-url="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=citation-citeproc&amp;p_p_cacheability=cacheLevelPage&amp;p_p_col_id=column-1&amp;p_p_col_count=1" method="GET" target="citation-download-iframe"> <input id="siteId" name="siteId" type="hidden" value=""> <input id="downloadType" name="downloadType" type="hidden" value=""> <input id="style" name="style" type="hidden" value=""> <input id="articleId" name="articleId" type="hidden" value=""> <input name="p_p_id" type="hidden" value="scolariscontentdisplay_WAR_scolariscontentdisplay"><input name="p_p_lifecycle" type="hidden" value="2"><input name="p_p_state" type="hidden" value="normal"><input name="p_p_mode" type="hidden" value="view"/><input name="p_p_resource_id" type="hidden" value="citation-download"/><input name="p_p_cacheability" type="hidden" value="cacheLevelPage"/><input name="p_p_col_id" type="hidden" value="column-1"/><input name="p_p_col_count" type="hidden" value="1"/> <button class="btn primary wide pull-right" type="submit">Download</button> <div class="inline-checkbox pull-right"> <label title=" for=" withabstract"=""> <input checked="" class="checkbox" name="withAbstract" type="checkbox"/> <span class="checkbox-label">Include abstract</span> </label> </div> </input></input></input></input></input></input></input></form> <iframe aria-hidden="true" name="citation-download-iframe" src="" style="display: none; visibility: hidden" title="Citation download frame"></iframe> </div> </div> </div> </div> <div class="print-modal" data-modal-title="Print this review" style="display: none;"> <div class="print-options-wrapper"> <p><strong>All sections are selected by default</strong>, please select the sections you do not wish to print or use the select or deselect all button to add or remove sections.</p> <div class="print-options-controls"> <input checked="checked" class="print-options-select-all" title="Select/deselect all" type="checkbox"/> <span class="checkbox-label">Select/deselect all</span> </div> <ul class="print-options checkbox-list"> </ul> <button class="btn primary print-article pull-right"><i aria-hidden="true" class="fa fa-print"></i> Print</button> </div> </div> <div class="download-stats-data-modal" data-modal-title="Download data package" style="display: none;"> <div> <p> The data available are protected by copyright and may only be used in accordance with the <a class="external" href="/about/data-download" target="_blank">Terms and Conditions.</a> </p> <div class="hide-for-zip"> <p> <a class="external" href="https://revman.cochrane.org/#/rm5Converter" target="_blank">RevMan 5 files</a> can be converted to a <a class="external" href="https://links.cochrane.org/review-datapack-userguide" target="_blank">data package.</a> </p> </div> <p> Files in the data package can be imported to <a class="external" href="https://revman.cochrane.org/info" target="_blank">Review Manager software</a> or opened in other tools that support CSV and RIS. </p> <form class="download-stats-data-form" method="GET" target="_blank"> <input name="content-disposition" type="hidden" value="attachment"/> <input name="mime-type" type="hidden" value="application/octet-stream"/> <p class="print-options-controls"> <input aria-label="I agree to these terms and conditions" class="download-stats-data-toc-check-box" type="checkbox"/> <span aria-hidden="true" class="checkbox-label">I agree to these terms and conditions</span> <button class="btn primary download-stats-data pull-right" disabled=""><i aria-hidden="true" class="fa fa-download"></i> Download data</button> </p> </form> </div> </div> <div class="share-modal" data-modal-title="Share this review" style="display:none;"> </div> <div class="viewer-thumbnail-pane-html" style="display:none;"> <div class="figure-viewer-options"> <nav class="inline-nav-list"> <li class="figure-options-btn-container"><button class="btn btn-link" id="figureOptionBtn" type="button">Figures</button></li> <li class="table-options-btn-container"><button class="btn btn-link" id="tableOptionBtn" type="button">Tables</button></li> </nav> </div> <div class="figure-viewer-thumbnails"> <div class="figure-thumbnails is-visible" id="figureThumbnails"></div> <div class="table-thumbnails" id="tableThumbnails"></div> </div> </div> <div class="utilities-html" style="display:none;"> <div class="figure-viewer-utilities"> <a class="figure-viewer-menu-toggle" href="#"> <i class="fa fa-chevron-left"></i><span class="toggle-label" data-figure-hide-text="Hide thumbnails" data-figure-show-text="Show thumbnails" data-table-hide-text="Hide table list" data-table-show-text="Show table list">Hide thumbnails</span> </a> <a class="figure-viewer-navigateback" href="#"> <i class="fa fa-chevron-left"></i> </a> <a class="figure-viewer-rotate" href="#"> <i class="fa fa-undo"></i> </a> <a class="figure-viewer-download" href="#"> <i class="fa fa-download"></i> </a> <a class="figure-viewer-share" href="#"> <i class="fa fa-share-alt"></i> </a> <a class="figure-viewer-zoomin" href="#"> <i class="fa fa-plus"></i><span>zoom in</span> </a> <a class="figure-viewer-zoomout" href="#"> <i class="fa fa-minus"></i><span>zoom out</span> </a> </div> </div> <div class="controls-html" style="display:none;"> <div class="figure-viewer-navigation"> <a class="figure-viewer-nav previous" href="#"> <i class="fa fa-chevron-left"></i><span>left</span> </a> <a class="figure-viewer-nav next" href="#"> <i class="fa fa-chevron-right"></i><span>right</span> </a> </div> </div> <div class="mobile-thumbnail-selector-html" style="display:none;"> <div class="figure-viewer-mobile-thumbnails"> <select class="figure-selection"> <option>Figures</option> </select> <select class="table-selection"> <option>Tables</option> </select> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div>
<div class="portlet-boundary portlet-boundary_1_WAR_kaleodesignerportlet_ portlet-static portlet-static-end kaleo-designer-portlet" id="p_p_id_1_WAR_kaleodesignerportlet_">
<span id="p_1_WAR_kaleodesignerportlet"></span>
</div>
<form action="#" id="hrefFm" method="post" name="hrefFm">
<span></span>
</form>
</div>
<footer class="footer">
<div class="main-footer">
<div class="main-footer-wrapper container">
<div class="brand">
<p class="brand-name">Cochrane</p>
<a href="http://www.cochrane.org/" title="Cochrane logo">
<img alt="Cochrane logo" class="footer-logo logo-part-1" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-1.png"> <img alt="" class="footer-logo logo-part-2" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-2.png"> </img></img></a> </div> </div> </div> <div class="aux-footer"> <div class="aux-footer-nav-container container"> <nav class="aux-footer-nav"> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse Publications</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse by Subject</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/advertisers">Advertisers &amp; Agents</a></li> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Contact Us</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Help &amp; Support</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/terms-and-conditions">Terms &amp; Conditions</a></li> </ul> </nav> </div> <div class="brand"> <div class="brand-container container"> <p class="copyright"> Copyright © 2000 - 2025 by <a class="" href="http://www.wiley.com">John Wiley &amp; Sons, Inc.</a> All Rights Reserved <br> Review our <a href="https://www.wiley.com/privacy"><strong>Privacy Policy</strong></a> <a href="https://www.wiley.com/cookies"><strong>Cookie Policy</strong></a> <a href="#" onclick="Osano.cm.showDrawer('osano-cm-dom-info-dialog-open')"><strong>Cookie Preferences</strong></a> </br></p> <a href="http://eu.wiley.com/"><img alt="Wiley logo" class="logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_wiley-footer-logo.png"/></a> </div> </div> <span class="wiley-semi-circle"></span> </div> <!--BEGIN QUALTRICS WEBSITE FEEDBACK SNIPPET--> <script type="text/javascript"> (function(){var g=function(e,h,f,g){ this.get=function(a){for(var a=a+"=",c=document.cookie.split(";"),b=0,e=c.length;b<e;b++){for(var d=c[b];" "==d.charAt(0);)d=d.substring(1,d.length);if(0==d.indexOf(a))return d.substring(a.length,d.length)}return null}; this.set=function(a,c){var b="",b=new Date;b.setTime(b.getTime()+6048E5);b="; expires="+b.toGMTString();document.cookie=a+"="+c+b+"; path=/; "}; this.check=function(){var a=this.get(f);if(a)a=a.split(":");else if(100!=e)"v"==h&&(e=Math.random()>=e/100?0:100),a=[h,e,0],this.set(f,a.join(":"));else return!0;var c=a[1];if(100==c)return!0;switch(a[0]){case "v":return!1;case "r":return c=a[2]%Math.floor(100/c),a[2]++,this.set(f,a.join(":")),!c}return!0}; this.go=function(){if(this.check()){var a=document.createElement("script");a.type="text/javascript";a.src=g;document.body&&document.body.appendChild(a)}}; this.start=function(){var t=this;"complete"!==document.readyState?window.addEventListener?window.addEventListener("load",function(){t.go()},!1):window.attachEvent&&window.attachEvent("onload",function(){t.go()}):t.go()};}; try{(new g(100,"r","QSI_S_ZN_cGCHHvWNpnJb1zf","https://zncgchhvwnpnjb1zf-wiley.siteintercept.qualtrics.com/SIE/?Q_ZID=ZN_cGCHHvWNpnJb1zf")).start()}catch(i){}})(); </script><div id="ZN_cGCHHvWNpnJb1zf"><!--DO NOT REMOVE-CONTENTS PLACED HERE--></div> <!--END WEBSITE FEEDBACK SNIPPET--> </footer> <div class="scolaris-modal-overlay"></div> <div class="scolaris-modal"> <div class="scolaris-modal-titlebar clearfix"> <p class="scolaris-modal-title"></p> <a class="scolaris-modal-close" href="#"><span>close</span><span class="icon fa fa-times"></span></a> <div class="scolaris-modal-ui"></div> </div> <!-- Static injection of addtoAny as dynamic injection not working properly--> <div class="scolaris-share-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"> <div class="a2a_kit a2a_kit_size_32 a2a_default_style"> <a class="a2a_button_facebook share-button">  Facebook</a> <a class="a2a_button_x share-button">  X(Twitter)</a> <a class="a2a_button_whatsapp share-button">  WhatsApp</a> <a class="a2a_dd share-button">  View more</a> </div> </div> </div> <div class="scolaris-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="english-only-modal-wrapper" data-modal-class="english-only-modal" data-modal-title="Feature in English only" style="display: none"> <div class="english-only-modal"> <p class="message"></p> <button class="btn primary ok-btn pull-right" type="button">OK</button> <button class="btn primary border-only cancel-btn pull-right" type="button">Cancel</button> </div> </div> <!--[if gte IE 9]><!--> <script src="/cochrane-theme/vendor/ie9.js?t=1738734739000" type="text/javascript"></script> <!--<![endif]--> <script src="https://www.cochranelibrary.com/cochrane-theme/js/theme.js?t=1738734739000" type="text/javascript"></script> <script src="https://content.readcube.com/cochrane/checkout.js"></script> <script src="https://content.readcube.com/cochrane/epdf_linker.js" type="text/javascript"></script> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" type="text/javascript"></script> <script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/hit-highlighting.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/topics-lookup.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/institution.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/api-manager.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/pico.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/reference-linking.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/rightsLink.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.submit.failed.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.comment.form.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/safety-alerts.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.translation-notes-modal.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/notifications-portlet/notifications/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-search/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773542000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-topics/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-language-portlet/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773471000" type="text/javascript"></script> <script type="text/javascript">Liferay.Util.addInputFocus();</script> <script type="text/javascript">Liferay.Portlet.register("scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_",portletId:"scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD010069\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD010069\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD010069\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD010069\x2epub3"});Liferay.Portlet.register("scolariscontentdisplay_WAR_scolariscontentdisplay");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_",portletId:"scolariscontentdisplay_WAR_scolariscontentdisplay",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentdisplay_WAR_scolariscontentdisplay\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dcolumn-1\x26p_p_col_pos\x3d0\x26p_p_col_count\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD010069\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD010069\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D"});Liferay.provide(Liferay.Util,"openKaleoDesignerPortlet",function(c){var b=AUI();var e=Liferay.PortletURL.createURL("https://www.cochranelibrary.com/en/content?p_p_id=2_WAR_kaleodesignerportlet&p_p_lifecycle=0");e.setParameter("mvcPath","/designer/edit_kaleo_draft_definition.jsp");e.setParameter("availableFields",c.availableFields);e.setParameter("availablePropertyModels",c.availablePropertyModels);e.setParameter("ddmStructureId",c.ddmStructureId);e.setParameter("draftVersion",c.draftVersion);e.setParameter("kaleoProcessId",c.kaleoProcessId);e.setParameter("name",c.name);e.setParameter("openerWindowName",c.openerWindowName);e.setParameter("portletResourceNamespace",c.portletResourceNamespace);e.setParameter("propertiesSaveCallback",c.propertiesSaveCallback);e.setParameter("refreshOpenerOnClose",c.refreshOpenerOnClose);e.setParameter("saveCallback",c.saveCallback);e.setParameter("version",c.version);e.setWindowState("pop_up");c.uri=e.toString();var d=c.dialog;if(!d){var f=b.one(Liferay.Util.getOpener()).get("region");d={destroyOnHide:true};c.dialog=d}if(!("align" in d)){d.align=Liferay.Util.Window.ALIGN_CENTER}var a=c.dialogIframe;if(!a){a={closeOnEscape:false};c.dialogIframe=a}Liferay.Util.openWindow(c)},["liferay-portlet-url"]);Liferay.Portlet.register("1_WAR_kaleodesignerportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_1_WAR_kaleodesignerportlet_",portletId:"1_WAR_kaleodesignerportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3d1_WAR_kaleodesignerportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD010069\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD010069\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD010069\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD010069\x2epub3"});Liferay.Portlet.register("scolarissearchportlet_WAR_scolarissearch");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarissearchportlet_WAR_scolarissearch_",portletId:"scolarissearchportlet_WAR_scolarissearch",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarissearchportlet_WAR_scolarissearch\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD010069\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD010069\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD010069\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD010069\x2epub3"});Liferay.Portlet.register("scolariscontentlanguagebanner_WAR_scolarislanguageportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_",portletId:"scolariscontentlanguagebanner_WAR_scolarislanguageportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentlanguagebanner_WAR_scolarislanguageportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD010069\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD010069\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD010069\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD010069\x2epub3"});AUI().use("aui-base","liferay-menu","liferay-notice","liferay-poller","liferay-session",function(a){(function(){Liferay.Util.addInputType();Liferay.Portlet.ready(function(b,c){Liferay.Util.addInputType(c)});if(a.UA.mobile){Liferay.Util.addInputCancel()}})();(function(){new Liferay.Menu();var b=Liferay.Data.notices;for(var c=1;c<b.length;c++){new Liferay.Notice(b[c])}})();(function(){Liferay.Session=new Liferay.SessionBase({autoExtend:true,sessionLength:1800,redirectOnExpire:false,redirectUrl:"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane",warningLength:0})})()});</script> <script src="https://www.cochranelibrary.com/cochrane-theme/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" type="text/javascript"></script> <script type="text/javascript"></script> <div class="mobile-righthand-nav"> <a class="rh-nav-close-btn" href="#"> <span>Close</span> <span class="fa fa-chevron-down"></span> </a> <div class="wrapper"> </div> <a class="rh-nav-open-btn" href="#"> <span>Review tools &amp; navigation</span> </a> </div> <iframe aria-hidden="true" id="printframe" name="printframe" style="position: absolute; left: -2000px; top: 0;" title="Print frame"></iframe> <iframe aria-hidden="true" id="citationExportFrame" name="citationExportFrame" style="position: absolute; left: -2000px; top: 0;" title="scolaris.citation.export.frame"></iframe> <nav> <div class="mobile-navigation"> <div class="close-container"> <a aria-label="Navigate back" class="main-nav-back-btn" href="#"><i class="fa fa-chevron-left"></i></a> <a class="main-nav-close-btn" href="#" title="Close menu">Close menu <i class="fa fa-times"></i></a> </div> <div class="mobile-search basic-search-container"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="ymag__null__null" src="/scolaris-search/icon.png"> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </img></span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=9mpoajSI&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"> <input name="facetDisplayName" type="hidden" value=""> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</input></input></form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD010069.pub3&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD010069.pub3';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<a class="btn secondary" href="/en/browse-by-topic">Browse </a>
<a class="btn secondary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
<div class="menu-items parent">
<div>
<div class="nav-root-item parent">
<a class="language-selection-title-link" href="#" title="Select language">
<span class="mobile-nav-language-title">Select your preferred language </span></a> <span class="icon fa fa-caret-down"></span>
<div class="mob-child">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="fdkn__null__null" src="/scolaris-language-portlet/icon.png"> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </img></span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> English </a> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> English </a> </div> <div class="form-content language-selector-modal child"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> <div class="dropdown-trigger" id="active-content-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="content-language-selector" data-languagecode="de" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de">Deutsch</a> <a class="content-language-selector is-active" data-languagecode="en" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en">English</a> <a class="content-language-selector" data-languagecode="es" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es">Español</a> <a class="content-language-selector" data-languagecode="fa" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa">فارسی</a> <a class="content-language-selector" data-languagecode="fr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr">Français</a> <a class="content-language-selector" data-languagecode="hi" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hi">हिन्दी</a> <a class="content-language-selector" data-languagecode="hr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr">Hrvatski</a> <a class="content-language-selector" data-languagecode="id" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=id">Bahasa Indonesia</a> <a class="content-language-selector" data-languagecode="ja" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja">日本語</a> <a class="content-language-selector" data-languagecode="ko" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko">한국어</a> <a class="content-language-selector" data-languagecode="hu" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hu">Magyar</a> <a class="content-language-selector" data-languagecode="ms" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms">Bahasa Malaysia</a> <a class="content-language-selector" data-languagecode="nl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=nl">Nederlands</a> <a class="content-language-selector" data-languagecode="pl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl">Polski</a> <a class="content-language-selector" data-languagecode="pt" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt">Português</a> <a class="content-language-selector" data-languagecode="ru" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru">Русский</a> <a class="content-language-selector" data-languagecode="ro" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ro">Română</a> <a class="content-language-selector" data-languagecode="ta" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta">தமிழ்</a> <a class="content-language-selector" data-languagecode="th" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th">ภาษาไทย</a> <a class="content-language-selector" data-languagecode="zh_HANT" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANT">繁體中文</a> <a class="content-language-selector" data-languagecode="zh_HANS" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANS">简体中文</a> </div> </div> <div class="row-fluid"> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div class="dropdown-trigger" id="active-portal-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="portal-language-selector is-active" data-portallanguage="en" href="/en/cdsr/doi/10.1002/14651858.CD010069.pub3/full/en">English</a> <a class="portal-language-selector" data-portallanguage="es" href="/es/cdsr/doi/10.1002/14651858.CD010069.pub3/full/es">Español</a> </div> </div> <a class="btn secondary ok-btn pull-right" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
<div class="parent">
<a class="mobile-link signin" data-redirect="false" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD010069.pub3%2Ffull" rel="nofollow">
                        Sign In
                    </a>
</div>
</div>
<div class="menu-items-footer">
<div class="utility-links">
<a class="cochrane-link" href="http://www.cochrane.org/" target="_blank">Visit Cochrane.org</a>
</div>
</div>
</div>
<div class="menu-items child"></div>
</div>
</nav><div class="basic-login-form-content" data-modal-title="Sign in" style="display: none;">
<div class="form-content">
<div class="row-fluid">
<div class="span12">
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_MODAL_">
<span id="p_58_INSTANCE_MODAL"></span>
<section class="portlet" id="portlet_58_INSTANCE_MODAL">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="dbam__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_MODAL" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_MODAL&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_MODAL_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_MODAL_fm" method="post" name="_58_INSTANCE_MODAL_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_MODAL_formDate" type="hidden" value="1740728280072"> <input class="field" id="_58_INSTANCE_MODAL_saveLastPath" name="_58_INSTANCE_MODAL_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_MODAL_redirect" name="_58_INSTANCE_MODAL_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD010069.pub3/full"> <input class="field" id="_58_INSTANCE_MODAL_doActionAfterLogin" name="_58_INSTANCE_MODAL_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_login"> Email Address </label> <input class="field clearable" id="_58_INSTANCE_MODAL_login" name="_58_INSTANCE_MODAL_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_password"> Password </label> <input class="field" id="_58_INSTANCE_MODAL_password" name="_58_INSTANCE_MODAL_password" type="password" value=""/> </div> <span id="_58_INSTANCE_MODAL_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="clearfix"> <div class="checkbox-list pull-left"> <div class="checkbox-list-item"> <div class="control-group form-inline input-checkbox-wrapper"> <label for="_58_INSTANCE_MODAL_rememberMeCheckbox"> <input id="_58_INSTANCE_MODAL_rememberMe" name="_58_INSTANCE_MODAL_rememberMe" type="hidden" value="true"/> <input checked="" class="field" id="_58_INSTANCE_MODAL_rememberMeCheckbox" name="_58_INSTANCE_MODAL_rememberMeCheckbox" onclick="Liferay.Util.updateCheckboxValue(this); " type="checkbox" value="true"/> Remember Me </label> </div> </div> </div> <div class="pull-right"> <a href="https://onlinelibrary.wiley.com/user/forgottenpassword" target="_blank">Forgotten password?</a> </div> </div> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> <a class="btn secondary" href="https://onlinelibrary.wiley.com/user-registration" target="_blank">Register</a> </div> <div class="pull-right"> <a class="institutional-login-form-button" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=0&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolariscontentdisplay_WAR_scolariscontentdisplay_action=institution-access">Institutional login</a> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div></div>
<div class="institution-login-form-content" data-modal-title="Institutional login" style="display: none;">
<div class="form-content">
<div class="row-fluid access-content-wrapper">
<div class="span12">
<div class="section">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="obft__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="access-content-section"> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/>
</div>
<button class="btn primary" name="button" type="submit">Go</button>
</div>
<div class="message error" id="institutionLookupErrorDiv" style="display:none">
                        '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access.
                    </div>
</div>
<input id="entityId" name="entityId" type="hidden" value=""/>
</form>
<h4>Previously accessed institutions</h4>
<ul class="plain" id="previousInstitutions">
<li>(none)</li>
</ul>
</div>
<div class="section-content">
<div class="open-athens-login">
                Login using <a href="/openathens">OpenAthens</a>
</div>
</div>
</div>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_4_">
<span id="p_58_INSTANCE_4"></span>
<section class="portlet" id="portlet_58_INSTANCE_4">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="joiu__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_4" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <p>If you have a <strong>Wiley Online Library</strong> institutional username and password, enter them here.</p> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_4&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_4_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_4_fm" method="post" name="_58_INSTANCE_4_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_4_formDate" type="hidden" value="1740728280076"> <input class="field" id="_58_INSTANCE_4_saveLastPath" name="_58_INSTANCE_4_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_4_redirect" name="_58_INSTANCE_4_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD010069.pub3/full"> <input class="field" id="_58_INSTANCE_4_doActionAfterLogin" name="_58_INSTANCE_4_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_login"> Username </label> <input class="field clearable" id="_58_INSTANCE_4_login" name="_58_INSTANCE_4_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_password"> Password </label> <input class="field" id="_58_INSTANCE_4_password" name="_58_INSTANCE_4_password" type="password" value=""> </input></div> <input class="field" id="_58_INSTANCE_4_institutionalLogin" name="_58_INSTANCE_4_institutionalLogin" type="hidden" value="true"/> <span id="_58_INSTANCE_4_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div></div>
<div class="get-access-form-content" data-modal-title="Unlock gold-standard Cochrane evidence" style="display: none;">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="wpdq__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="readcube-checkout-container-outer"> <div class="row-fluid access-content-wrapper"> <div class="span6 access-left-content"> <div class="section"> <div class="section-content"> <p>Improve your health decisions with access to trusted, independent evidence from the Cochrane Library. Unlock this review for uninterrupted access.</p> <p>Still deciding? <a href="https://m.info.wiley.com/webApp/cochranenewsletter"> Sign up to our newsletter to learn more </a> </p> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title">Institutional users</h3> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/> </div> <button class="btn primary" name="button" type="submit">Go</button> </div> <div class="message error" id="institutionLookupErrorDiv" style="display:none"> '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access. </div> </div> <input id="entityId" name="entityId" type="hidden" value=""/> </form> <h4>Previously accessed institutions</h4> <ul class="plain" id="previousInstitutions"> <li>(none)</li> </ul> </div> <div class="section-content"> <div class="open-athens-login"> Login using <a href="/openathens">OpenAthens</a> </div> </div> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title"> Other access options </h3> <div class="section-content"> <ul class="plain"> <li> <a class="get-access-individual-login-button" href="/c/portal/login"> Individual access - via Wiley Online Library </a> </li> </ul> </div> </div> </div> </div> <div class="span6 access-right-content readcube-checkout-container"> <div class="section"> </div> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/> <input id="openlabel" name="openlabel" type="hidden" value="Open access"/> </div> </section> </div> </div> <!-- Scolaris Version: --> <script type="text/javascript">if(window._satellite){_satellite.pageBottom()};</script> </div> <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'918ec09cdc00f46e',t:'MTc0MDcyODI4MC4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script></body> </html> 